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Abstract
Burkholderia cenocepacia is an opportunistic pathogen causing life-threatening
infections in cystic fibrosis and other immunocompromised patients. The
bacterium survives within macrophages by interfering with typical endocytic
trafficking, resulting in delayed maturation of a B. cenocepacia-containing
phagosome. We hypothesize that B. cenocepacia alters gene expression after
internalization by macrophages, inducing genes involved in intracellular survival
and host adaptation. Furthermore, we hypothesize that specialized bacterial
secretion systems are involved in the interactions between intracellular bacteria
and macrophages. In this work, we characterize later-stage infection of
macrophages by B. cenocepacia, showing replication within an acidified
endosomal compartment suggestive of a phagolysosome. We examine
differential gene expression by intracellular B. cenocepacia using selective
capture of transcribed sequences (SCOTS) with both competitive enrichment and
microarray analysis. We identified 766 genes differentially regulated in
intracellular bacteria, of which 329 were induced and 437 repressed. Affected
genes are involved in all aspects of cellular life, including information storage and
processing, cellular processes and signalling, and metabolism; in general,
intracellular gene expression demonstrates a pattern of environmental sensing,
bacterial response, and metabolic adaptation to the phagosomal environment.
Deletion of various SCOTS-identified genes affects B. cenocepacia entry into
macrophages and intracellular replication, as well as host-directed cytotoxicity
and spread to neighbouring cells. Expression of secretion system genes is
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differentially-regulated by intracellular B. cenocepacia. Although none of the five
major secretion systems are essential for growth in culture, we show that
bacterial secretion systems are involved in macrophage entry, intracellular
replication, and host-directed cytotoxicity. Type IV secretion systems play a role
in early interactions with macrophages, while type II and VI secretion systems
contribute to post-internalization intracellular replication and host-directed
cytotoxicity. As a whole, secretion systems appear to increase pathogenicity in
macrophages while limiting the spread of B. cenocepacia infection.
Together, these studies advance our understanding of the intracellular behaviour
of B. cenocepacia in macrophages. Further investigation into the remaining
SCOTS-identified genes, as well as putative secreted effectors, will provide a
better understanding of the adaptive responses of intracellular B. cenocepacia,
leading to life in a phagosomal niche and host cell cytotoxicity.

Keywords
Burkholderia cenocepacia, macrophage, intracellular gene expression,
microarray, SCOTS, secretion systems
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Chapter 1 – Introduction

1.1 Burkholderia cenocepacia and the Burkholderia cepacia
complex

1.1.1

The Burkholderia cepacia complex

The Burkholderia cepacia complex, or Bcc, is a group of at least 17 closely
related organisms which are phenotypically similar but genetically distinct (493,
495). Originally identified in the 1940’s as the causative agent of soft onion rot,
or “sour skin”, discoverer Walter Burkholder designated the organism
Pseudomonas cepacia, from the Latin cepia for onion (63). Later studies showed
P. multivorans, a metabolically diverse environmental isolate, and P. kingii,
isolated from both clinical specimens and disinfectants, to be synonymous strains
(442). In 1992, the genus Burkholderia was created, and seven Pseudomonas
spp., including P. cepacia were transferred into the new genus (529). Two of the
original seven species were later reclassified as Ralstonia spp. (530), and over
sixty new species have since been described in the Burkholderia genus
(http://www.bacterio.cict.fr). Marked heterogeneity among species designated as
B. cepacia led to division into genomovars, genetically distinct organisms
awaiting official species designation based on phenotypic distinction (493).
Eventually, as the sensitivity and specificity of tests improved, each genomovar
received a binomial species designation. Biochemical differentiation among
members of the Bcc is difficult, thus genetic techniques are most often used for
species determination (287). Sequence polymorphisms in the recA gene,
encoding a protein essential for DNA recombination and repair, are discriminatory
for most species (288), but members of the Bcc are best distinguished based on
multilocus sequence typing (MLST). This strategy utilizes sequence
polymorphisms in seven housekeeping genes located on the first two
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chromosomes (atpD, gltB, gyrB, recA, lepA, phaC, and trpB); amplification of
300-400 base pair (bp) fragments of each gene creates an allelic profile which
can be used to assign a clonal sequence type (ST) (31). Currently, the complex
consists of B. cepacia, B. multivorans, B. cenocepacia, B. stabilis, B.
vietnamiensis, B. dolosa, B. ambifaria, B. anthina, B. pyrrocinia, B. ubonensis, B.
latens, B. diffusa, B. arboris, B. seminalis, B. metallica, B. contaminans, and B.
lata (495). Isolates of all 17 species have been found in a clinical setting, with all
but B. ubonensis isolated from cystic fibrosis patients; additionally, with the
exception of B. latens and B. metallica, all species have also been isolated from
the natural environment (505). Pre-classification literature from 1950 through
mid-1990 refers to only P. cepacia or B. cepacia; current re-analysis has
demonstrated that Burkholder’s original onion pathogens were true B. cepacia
species, P. kingii clinical isolates were B. cenocepacia, and P. multivorans
environmental isolates were mainly B. lata and B. cepacia (491). Due to the
complexity of taxonomic classification within the B. cepacia complex, many
studies, particularly environmental surveys, in which Bcc bacteria are a
serendipitous identification choose to identify the bacteria only as B. cepacia-like.
Thus, current species designations will be utilized where possible, but when
referring to literature where members of the Bcc were not distinguished,
designations “P. cepacia”, or “B. cepacia” will be used.

1.1.2

Burkholderia cenocepacia

Burkholderia cenocepacia, literally meaning “new cepacia”, is an aerobic, Gram
negative, non-spore-forming, motile, bacillus-shaped, β-proteobacterium (178,
492). The bacterium ranges in size from 1.0 to 2.0 µm long and from 0.6 to 0.9
µm wide, and grows at 37oC and room temperature but not at 5oC; growth at
42oC is strain-dependent (492). B. cenocepacia is metabolically diverse; many
functions are strain-specific (492), as are the production of pigment (231, 492),
and lipopolysaccharide O antigen (356). The species B. cenocepacia may be
further subdivided into four phylogenetic clusters based on recA gene sequence,
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IIIA to IIID, with most clinically relevant isolates represented in the first two
groups (134). B. cenocepacia is an opportunistic pathogen of cystic fibrosis (CF)
patients (380) - the type strain for the species, LMG 16656, or J2315, was
isolated from the sputum of a cystic fibrosis patient in Edinburgh in 1989 (492) but B. cenocepacia infections are also found in non-CF patients (380). The
bacterium is also frequently isolated from environmental reservoirs; in some
instances, the same strain can be found in both clinical and environmental niches
(30).

1.1.3

B. cenocepacia in the environment

B. cenocepacia and other members of the Bcc have been isolated from many
different environmental sources, ranging from urban (327), woodland (495), and
agricultural (268) soils, to European rivers (503), Chinese lakes (146), and the
sediments of American streams (353), to Mexican radishes (30), Indian sugar
cane (496), Brazilian flowers (495), and raw milk (346). B. cenocepacia engages
in both pathogenic and beneficial interactions with plants, and can act as an
endosymbiont for both fungi and insects. Though non-Bcc Burkholderia spp. are
able to cause serious disease in higher mammals - most notably equine glanders
resulting from B. mallei infection – there is only a single example of natural Bcc
infection in animals, where B. cenocepacia caused an outbreak of subclinical
mastitis in sheep (49).

1.1.3.1

Phytopathogens

“B. cepacia” was first discovered as a phytopathogen in onion crops (63).
Though recent classification of Burkholder’s original strains has identified true B.
cepacia species, B. cenocepacia has also been isolated directly from the lesions
of field-grown onion bulbs which naturally developed bacterial rot (452). In a
field study in Michigan, B. cenocepacia was isolated from both the bulk soil and
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the onion rhizosphere, with presence in the rhizosphere increasing with onion
root development; 90% of the 480 B. cenocepacia isolates were highly virulent
when assayed for pathogenicity on detached onion bulb scales (213).
In a natural setting, bacteria present in the surrounding soil and rhizosphere can
be transferred to plant leaves and bulbs by splashing water from irrigation or rain
(213). Pathogenicity in onion tissue requires an existent tissue wound for
bacterial ingress, and moisture for effective spreading (228). Plant damage
occurs by two separate mechanisms. Plant tissue watersoaking (ptw) is an
accumulation of fluids in the intracellular spaces of plant tissues caused by a loss
of cell membrane integrity (141); accumulation of fluids contributes to the spread
of the bacteria through the tissues. Early studies in “P. cepacia” showed
production of a pectic enzyme called polygalacturonase (486).
Polygalacturonase is a secreted enzyme that hydrolyzes pectin, one of the
principal macromolecular components in primary plant cell walls (313, 314).
Bacterial infection lowered the pH of onion tissue from 5.5 to 4.0, conducive to
polygalacturonase activity, and resulted in tissue maceration (486). “B. cepacia”
has also been shown to cause disease in tomatoes, mushrooms, and orchids
(399); B. cenocepacia, specifically, is the causal agent of banana finger-tip rot
(262).

1.1.3.2

Beneficial interactions with plants

Although B. cenocepacia is pathogenic in several types of plant, many bacteriaplant interactions exist which are neutral or mutually beneficial. Early research in
“B. cepacia” showed antagonism and repression of soil-borne plant pathogens,
including the fungi Alternaria which affects canola and ginseng (200),
Aphanomyces in peas, alfalfa, and snap beans (57), Sclerotinia in sunflowers
(323), and Pythium in cucumbers and peas (57, 200). “B. cepacia” can also
suppress damaging fungal growth in nursery seedlings (200). Field studies
showed presence of “P. cepacia” in the rhizosphere – soil on root surfaces – of
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maize; through production of pyrrolnitrin and a second unidentified antifungal
agent, “P. cepacia” was antagonistic to five major fungal pathogens of maize
(249). Paradoxically, endosymbiotic bacteria and fungi within the rhizosphere are
able to promote plant resistance to stress and disease; “B. cepacia” is an
endosymbiont of several species of the fungus Glomus, which establishes an
endophytic relationship with sorghum (20). Plant-associated Bcc bacteria also
promote growth by the fixation of N 2 . B. vietnamiensis, shown to promote growth
of sugar cane, is the only currently identified diazotroph in the complex (179),
though an unclassified member of the Bcc is able to induce nitrogen-fixing root
nodules in the wild rose wood tree legume Dalbergia spp. (375).
B. cenocepacia has been identified in the rhizosphere of onions (213) and maize
(113). From the rhizosphere, bacteria may enter the root tissue and establish an
endophytic relationship with a plant. B. cenocepacia has been isolated from the
stem and roots of sugar cane (324), as well as wheat and lupine shoots (29). In
sugarcane, endophytic B. cenocepacia produces the plant growth hormone IAA,
and strongly inhibits hyphal growth of Fusarium moniliforme, causative agent of
Pokkah boeng disease (324).

1.1.3.3

Endosymbiosis with insects

Unidentified Burkholderia spp. have been found as endosymbiotic gut bacteria in
plant-associated insects, including Japanese broad-headed bugs Leptocorisa
chinensis and Riptortus clavatus (235), and the ant Tetraponera binghami (488);
no purpose for this relationship has been experimentally established. B.
cenocepacia participates in a tri-symbiotic relationship with the leaf-cutting ant
Atta sexdens rubropilosa and the fungus Leucoagaricus gongylophorus (96).
Leaf-cutting ants maintain a fungus garden, protecting and providing leaf
substrates to the obligate mutualistic fungus, which in turn supplies the ant with
nutrients (416). Bcc bacteria isolated from ant nests inhibit several species of
entomopathogenic and general saprophytic fungi, as well as the specialized
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garden parasite Escovopsis weberi, but not the mutualist L. gongylophorus (416);
thus, in such a complex relationship, Bcc bacteria maintain the integrity of the
fungus garden while protecting the ant from fungal infection.

1.1.3.4

Bioremediation

Bcc bacteria possess extraordinary metabolic diversity, to the extent that the
bacteria can survive in simple tap water (279) and can utilize antibiotics such as
penicillin as a sole carbon source (41). As a consequence of this metabolic
diversity, Bcc bacteria have shown promise in bioremedial applications. 2,4,5trichlorophenoxyacetic acid (2,4,5-T) is a herbicide to defoliate broad-leaf plants
which is persistent in the environment, poorly biodegradable, and a major
component of Agent Orange; 2,4,5-T can be broken down by “P. cepacia” (74).
Insecticide and anti-parasitic abamectin, an environmental pollutant affecting
non-target soil vertebrates and aquatic systems, can be used as a carbon source
by “B. cepacia” (12). Bcc bacteria are also able to degrade the fungicide
carbendazim (223), insect repellent and plasticizer dimethyl phthalate (511),
solvent trichloroethylene (158), and pesticide endosulfan (208), among others.
Endophytic and rhizospheric strains of Bcc bacteria have shown degradation of
phenol (510). In a biofilm with cyanobacteria, Bcc bacteria were able to degrade
diesel in hydrocarbon-rich industrial wastewater (75); indeed, a strain of B.
cenocepacia isolated from oil-contaminated soil produces a biosurfactant that
enhances the solubilization of multiple pesticides (514).

1.1.3.5

Commercial potential

Bcc bacteria have the ability to degrade serious environmental pollutants,
antagonize soil-borne pathogens, and promote plant growth, and as such, could
be of great benefit to agriculture and industry. As a biocontrol agent, Bcc
bacteria have the potential to replace, at least in part, such common chemical
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biocides as captan, thiram, benomyl, and chloropicrin, all of which have toxicity or
carcinogenic issues (360). Several strains of B. ambifaria and a strain of B.
cenocepacia were registered as biopesticides in the mid-1990s and used
commercially until withdrawn from use a decade later (79). Field trials with B.
vietnamiensis efficiently removed trichloroethylene, one of the most abundant
organic aquifer contaminants, from groundwater (244), and a US patent was
obtained (79). Industrial applications continue to be explored, with development
of a Bcc-containing microalgae-bacteria consortium to degrade crude oil (474),
and a bioreactor utilizing Bcc to remove petroleum hydrocarbons from refinery
wastewater (75). An engineered endophytic strain of B. cepacia was used to
improve lupine phytoremediation of soil co-contaminated with the organic
pollutant trichloroethylene and toxic nickel (520). However, commercial
applications must be weighed against capacity for opportunistic infection, as
identical strains have been isolated from both clinical and environmental sources
(30); until Bcc infections can be successfully addressed, the biotechnological
potential present among members of the complex cannot ethically be developed.

1.1.4

B. cenocepacia as an industrial contaminant

Outside the natural environmental, Bcc bacteria are also able to survive in a wide
variety of man-made products. “P. cepacia” contamination was found in serum
albumin (461), the anaesthetic fentanyl (53, 439), and commercial iodine and
benzalkonium chloride antiseptics (18, 161); in one study, “P. cepacia” survived
for 14 years in an inorganic salt solution containing benzalkonium chloride as an
antimicrobial (173). “B. cepacia” contamination of oxymetazoline nasal spray
resulted in an infection outbreak in the United States and recall of the product
(132). Bcc bacterial contamination has also been identified in prefabricated moist
washcloths (310), ultrasound echocardiographic gel (304), multiple catheter
disinfectants (183, 190), the antiemetic bromopride (312), trypan blue ophthalmic
solution (470), heparin (531), alcohol-free mouthwash (245), Albuterol
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nebulization solution (34), and moisturizing body milk (14), among others.
Product contamination can be compounded, as “B. cepacia” contamination of
trypan blue, a dye used to examine tissues, led to contamination of a cornea
tissue bank, though no post-graft infection was reported for any of the 169
contaminated grafts (331).
In an 8 year study of 327 US Food and Drug Administration (FDA) non-sterile and
sterile product recalls, “B. cepacia” was the most frequently isolated microbe in
22% and 2.5% of the recalls, respectively (216). Among Bcc bacteria, B.
cenocepacia is one of the most common industrial contaminants (287). However,
Bcc contamination may arise from other sources, including water. An outbreak in
a haemodialysis unit in Brazil was linked to “B. cepacia” contamination of reverse
osmosis tubing in the water reservoir (454). Hospital tap water has also been
linked to multiple infection outbreaks (279, 391). Bcc-contaminated water is not
unique to a hospital environment, as “B. cepacia” is also the primary contaminant
of the Space Shuttle water system both pre- and post-flight (237). The presence
of B. cenocepacia within a hospital setting may contribute to opportunistic
infection. While recall of contaminated products is fairly straightforward,
eradication of B. cenocepacia from an infected hospital unit water source is more
complex (243).

1.1.5

B. cenocepacia as an opportunistic human pathogen

The first clinical isolate of “P. cepacia” was found in urine in 1951; over the next
14 years, isolates were identified in a vast number of clinical sources, including
blood, eye, stool, throat, myocardial abscess, spinal fluid, sputum, knee joint, and
many others (220). Contaminated medical products led to frequent nosocomial
infection outbreaks, including endocarditis, respiratory infection, and septicemia
(39, 325, 420, 459). Infections were seen in patients with conditions including
cancer, congenital heart disease, fistulae, quadriplegia, diabetes, and surgicallyrepaired major trauma (138). Today, Bcc bacteria are generally considered
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opportunistic pathogens, or bacteria which do not typically cause disease in a
healthy host, but exploit a niche created in the absence of a functional immune
system. Bcc infection is most commonly seen in individuals with cystic fibrosis,
although infections are also seen in immunocompromised patients, including
those with chronic granulomatous disease, and, more rarely, in
immunocompetent individuals (described in detail below). With the exception of
contaminated medical products and direct patient-to-patient transmission, the
source of an infection is not always clear. Unlike P. aeruginosa, which is carried
by approximately 10% of the population, B. cenocepacia is not typically
recovered from human sources other than sites of infection, and is thus likely
acquired from the environment (287).

1.1.5.1

Cystic fibrosis

Cystic fibrosis is one of the most common genetic diseases in Caucasians,
affecting approximately 1 in 3000 live births (301). The disease is caused by
mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene
encoding a cyclic adenosine 5'- monophosphate (cAMP) regulated chloride
channel (77, 384). Although the disease affects many organs, the most important
site for morbidity and mortality is the lungs. In the lungs, CFTR defect results in
thick mucus secretions which impair mucociliary clearance (81, 316), as well as
an accumulation of salt in the airway surface liquid covering the epithelia,
interfering with the bactericidal activity of defensins and lysozyme (175, 301).
Bacteria like P. aeruginosa, the eventual predominant pathogen in CF patients,
easily and sequentially colonize the CF lung causing chronic infection leading to
bronchiectasis, respiratory failure, and death (116).
“P. cepacia” was recognized as an important pathogen in CF patients in 1984;
throughout a ten year study, though the prevalence of P. aeruginosa remained
stable at 70-80%, carriage of “P. cepacia” increased from 10% to 18%, with the
latter infections associated with greater impairment in lung function (212).
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Currently, approximately 3.5% of CF patients are infected with Bcc by age 18
(171), though regions of significantly higher prevalence exist (342); such patients
exhibit a more rapid decline in lung function compared to those infected with
other CF-related pathogens (100), with mean survival decreasing by between 12
and 25 years following Bcc infection (79, 455). Though many Bcc-infected
individuals show asymptomatic carriage or chronic lung infection, one in five
develop a condition known as ‘cepacia syndrome’, a generally fatal condition
characterized by high fever, severe progressive respiratory failure, acute
necrotizing pneumonia, and septicaemia (212). Resistance to almost all clinically
relevant antibiotics (264) complicates treatment and creates great difficulties in
eradicating infection. Though nosocomial acquisition is possible, patient-topatient transmission has been demonstrated (177, 457), resulting in segregation
of the CF community and discouragement of CF social opportunities such as
summer camps; such isolation negatively affects psychological well-being (137).
Although nearly all species of the Bcc have been identified in the sputum of CF
patients, B. cenocepacia and B. multivorans are the most prevalent species,
accounting for 85-97% of all Bcc-CF infections (380, 495, 496). However, B.
cenocepacia infection has far more severe clinical consequences than B.
multivorans. B. cenocepacia is highly transmissible, containing the majority of
epidemic strains identified thus far (134); indeed, two distinct sequence types of
B. cenocepacia have shown intercontinental spread among CF patients (134,
218). B. cenocepacia is also associated with more severe infection, reduced
survival, and increased risk of developing cepacia syndrome (102, 219, 292,
457), and can replace other Bcc species in the CF lung (293). Though lung
transplantation is the only viable treatment for end-stage CF patients, infection
with B. cenocepacia is a relative or absolute contraindication to transplantation in
almost every centre outside of Toronto, where the prevalence of infection is over
15% (22, 342). Patients infected pre-operation with B. cenocepacia have
significantly increased morbidity and mortality post-transplant, while those
infected with other Bcc species fare no differently than P. aeruginosa-infected CF
patients (22, 120). B. cenocepacia post-transplant death is generally due to
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development of sepsis, or cepacia syndrome (120); there are only five reported
cases in the literature of survival in septic patients with cepacia syndrome, all
after extremely aggressive antibiotic therapy (342).
Aggressive CF management has increased the life expectancy of CF patients to
mid-forties, revealing CF-related non-pulmonary conditions, including
osteoporosis, diabetes, and liver disease (87, 137). Chronic colonization with
Bcc, but not with P. aeruginosa, is associated with risk of developing CF liver
disease, which itself is associated with requirement for lung transplantation, and
death (87).

1.1.5.2

Chronic granulomatous disease

Chronic granulomatous disease (CGD) is a much less common genetic disease,
conferring immunodeficiency in approximately one in 250 000 individuals with
presentation varying from fatal septicaemia in infancy to mild symptoms late in
life (489). CGD is genetically heterogeneous, caused by mutation to any of the
five structural elements of the nicotinamide dinucleotide phosphate (NADPH)
oxidase complex: membrane-bound cytochrome components gp91phox and
p22phox, and cytoplasmic components p47phox , p40phox and p67phox (433). Defect
to the NADPH oxidase leaves phagocytes unable to generate an oxidative burst,
causing susceptibility to recurrent infection; CGD patients also suffer from a
dysregulated Th-17-lymphocyte-controlled inflammatory response resulting in
granuloma formation, and poor wound healing and dehiscence (387, 431). In a
normally functioning oxidative burst, the NADPH oxidase generates superoxide
anion, which is metabolized by superoxide dismutase to hydrogen peroxide,
which is further metabolized by myeloperoxidase to hypohalous acid and
hydroxyl anion; such reactive oxygen species (ROS) can function directly as
antimicrobials (371). Activation of the NADPH oxidase is also necessary for the
activation of microbicidal granule proteases and formation of neutrophil
extracellular traps (NETs) (433). In the absence of a fully functional immune
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response, CGD patients suffer from recurrent infections, most commonly with
Nocardia and Aspergillus spp., Staphylococcus aureus, Serratia marcescens,
and Bcc (433, 489, 523). Large cohort studies in Europe and North America
have shown Aspergillus spp. to be the most common infectious agents and cause
of death in CGD patients; however, the latter is a function of the former, as
Aspergillus-mediated death occurs in only 8% (15/181) and 19% (23/120) of
European and North American infections, respectively (489, 523). Less common,
but far more serious, Bcc infections caused death in at least 43% (3/7) and 50%
(12/24) of European and North American Bcc-infected CGD patients (489, 523).
Serious “P. cepacia” infection in CGD patients has frequently been linked with
pneumonia, septicaemia and death in smaller studies (9, 56, 247, 456). It has
been shown that CGD neutrophils, which can kill P. aeruginosa effectively, are
unable to kill “P. cepacia” (456). B. cenocepacia is able to promote apoptosis in
both normal and CGD human neutrophils; however, engulfed B. cenocepacia is
also able to induce necrosis in CGD neutrophils lacking ROS (67). Among Bcc
species, B. cenocepacia is most virulent in a gp91phox -/- murine model of CGD,
causing septic death 3 days post-infection (p.i.) (453). In a p47phox -/- murine
model of CGD, restoration of p47phox through ex vivo gene transfer lowered “B.
cepacia” bacteremia levels and conferred a survival advantage to the mouse
(302), again linking the NADPH oxidase and Bcc infection. Interestingly, B.
cenocepacia is also able to delay assembly of the NADPH oxidase complex in
murine macrophages (230).

1.1.5.3

Nosocomial infection

Hospitalized patients are susceptible to nosocomial “B. cepacia” infection,
especially in light of contaminated medical products. Nosocomial infections most
commonly arise in the intensive care unit (ICU), and can result in pneumonia,
bacteremia, surgical site infection, urinary tract infection, and skin-soft tissue
infection (131). Typically, non-CF-related “B. cepacia” bacteremia occurs in
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severely ill patients who require frequent health care interventions and invasive
procedures, and thus have multiple exposures to antibiotic resistant nosocomial
pathogens; specific risk factors include greater than two bronchoscopic
procedures, tracheostomy, abdominal surgery, dialysis-requiring renal failure,
and the presence of an indwelling vascular catheter (60). B. cenocepacia
bacteremia has been seen in oncology patients (300, 311), haemodialysis
patients (222, 271), and intensive care neonates (260), generally related to
central venous catheter use. In patients who have undergone mitral valve
replacement, “B. cepacia” infections lead to endocarditis, or inflammation of the
inside lining of the heart chambers or valves; such infections can be fatal (8). “P.
cepacia”-induced endocarditis has also been seen in heroin addicts both with and
without histories of heart disease (345); in rare cases, these infections can
exacerbate into skin and soft tissue involvement via ecthyma gangrenosum
(299). “B. cepacia” has also caused postoperative bacterial endophthalmitis and
keratitis leading to poor visual outcome (354, 398, 470). Bcc bacteria can also be
transmitted between CF and non-CF patients, as seen in a large hospital
outbreak where a single strain of “B. cepacia” infected 23 CF patients and 245
non-CF ICU patients; non-CF patients that survived the infection generally
cleared the bacteria following discharge from the ICU, while CF patients
remained persistently infected (201).

1.1.5.4

Immunocompetent individuals

Bcc infections in immunocompetent patients are rare. Community-acquired “P.
cepacia” pneumonia and bacteremia have been reported on several occasions in
previously-healthy adults (42, 111, 512), and children (368, 524). Hospitalacquired bacteremia has also been seen in immunocompetent children (174,
524). An individual with chronic suppurative otitis media developed intracranial
infection and brain abscesses requiring multiple surgeries and resulting in loss of
inner ear function in one ear (194). Less serious infection has presented in
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individuals with sinonasal polyposis (59, 305), while “B. cepacia” infection in an
immunocompetent individual resulted in infective endocarditis with subsequent
cerebral involvement (234). “P. cepacia” was also found to cause ‘trench foot’, or
macerated hyperkeratotic lesions of the feet, in soldiers working in swamp
conditions (475). A single case showed evidence of Bcc transmission from an
infected CF child to a healthy, non-CF mother, resulting in chronic colonization
and acquired bronchiectasis (257).

1.1.6

Model systems to study B. cenocepacia pathogenesis

Various in vivo and in vitro systems have been developed to study B.
cenocepacia pathogenesis. Though traditional murine models arguably provide
the most relevant context for investigation relative to human disease, researchers
have sought simpler, swifter, more economical models better suited to genetic
manipulation (347). Several different models have since been developed,
including plants, animals, and in vitro cell culture, which fit some or all of the
criteria, allowing investigation into virulence factors, host response, and treatment
options.

1.1.6.1

Murine models

CF patients infected with Bcc have three potential clinical presentations, including
asymptomatic carriage, chronic infection with slow lung function decline, and
acute infection leading to bacteremia and death. The latter two situations may be
investigated by means of murine models. A chronic, nonlethal, pulmonary
infection in rats established for CF pathogen P. aeruginosa (72) can also be
applied to Bcc (446, 450). In this model, chronic infection is initiated by
intratracheal insertion of agar beads containing the bacteria of interest; at 7 and
28 days p.i., the lungs are removed for bacterial enumeration and
histopathological analysis (446). Lung inflammation in the model approximates
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that seen in non-bacteremic pneumonia with mixed inflammatory cell infiltrate and
foci of necrosis (72). An agar bead model of Bcc lung infection has also been
utilized to examine systemic infection in C57/BL6 mice (91, 458). A second
murine model of acute infection approximating bacteremia involves aerosol
inoculation of neutropenic mice (106, 446). On days 0, 3, and 7 p.i., the mice are
sacrificed and bacterial load in the lungs enumerated; though the bacteria are
generally cleared, factors involved in colonization and short-term infection can be
explored (446). Disease-specific murine models have been used with Bcc,
including a cystic fibrosis Cftr-/- murine model of chronic pneumonia (407), and
two murine models of chronic granulomatous disease: gp91phox -/- (453), and
p47phox -/- (302). Aside from investigating pathogen virulence factors and host
response, murine models are also useful in the development of B. cenocepacia
vaccines (50, 294).

1.1.6.2

Other animal models

Simpler, less expensive animal models applied to Bcc infection include the
zebrafish Danio rerio (502), the nematode Caenorhabditis elegans (241), the fruit
fly Drosophila melanogaster (73), and larvae of the wax moth Galleria mellonella,
or wax worms (429). For each of the models, members of the Bcc, as well as
strains of the same species, often have different outcomes; however, the results
do not always agree between models (485).
C. elegans is a simple, genetically-tractable model in which bacterial virulence in
worms often parallels clinical data; C. elegans lacks adaptive immunity, but
mounts an innate immune response to bacterial pathogens (347). B.
cenocepacia is able to effectively kill C. elegans via two separate killing modes,
termed slow killing and fast killing (241). In fast killing, B. cenocepacia grown on
a high-osmolarity medium produces an extracellular toxin which paralyzes, then
kills the nematodes within 24 h (241). When B. cenocepacia is grown on
nematode growth medium, slow killing of C. elegans occurs over 2-3 days as the
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bacteria accumulate in the intestinal lumen; the more pathogenic the bacteria, the
more rapid the killing (241). To facilitate large scale analyses, a rapid screening
method called the 48-well plate mortality assay was developed which correlates
well with the standard slow killing assay (69). Additionally, lumenal infection can
be visualized microscopically (241).
The innate immune system of D. melanogaster is similar to the mammalian
version (152), and the genome has been fully sequenced (6), enabling a
dissection of host-pathogen interactions. Infection can be induced naturally by
feeding, or artificially by nicking; ingested Bcc colonize the fly without injury, while
nicked flies are killed by internally-replicating Bcc, at strain-specific rates, with
results comparable to those seen in murine models (73).
Virulence assays with B. cenocepacia have used zebrafish at different stages of
the life cycle. Mortality assays and quantitation of bacterial survival have utilized
6-month-old zebrafish following intraperitoneal inoculation of bacteria (122).
However, at the embryonic stage (28-32 h post-fertilization), zebrafish have a
developed innate immune system resembling the mammalian equivalent, but are
transparent, allowing infection to be visualized in real-time (502). Infection is
more complicated than the previous models, requiring dechorionation – removal
of the membrane surrounding the developing embryo – and anaesthetization of
the embryo prior to microinjection of bacteria into blood circulation (502). B.
cenocepacia are taken up by macrophages, replicate intracellularly, then
disseminate throughout the embryo, leading to systemic infection and embryo
death; however, virulence is species and strain dependent (502). While the
ability to visualize infection in real-time is of great interest, D. rerio is temperature
sensitive, a limitation common to D. melanogaster and C. elegans; none survive
long at optimal temperatures for bacterial growth (73, 502).
G. mellonella possesses a fairly complex innate immune system (429), but differs
from the three previous models in two key ways: Although it survives at 30oC –
amenable to bacterial growth – it lacks genetic tractability thus far (73). Similar to
D. melanogaster and C. elegans, the model can be predictive of mammalian

17

response to pathogens; Bcc infection in G. mellonella corresponds well with
results in murine models (429). The model itself is exceedingly simple, scoring
larvae as alive or dead up to 72 h post-Bcc injection; dead larvae turn black as a
result of melanization (429).

1.1.6.3

Plant models

Research with P. aeruginosa has demonstrated a conservation of virulence
factors in the infection of plant and animal hosts (374), meaning preliminary work
can be done in a simple, inexpensive model with no ethical considerations.
Because “B. cepacia” was first identified as a phytopathogen in onions, Allium
cepa remains a useful model for investigation of pathogenicity; tissue maceration,
water soaking, and necrosis are quantified in wounded onion scales inoculated
with Bcc (213). Alfalfa, or Medicago sativa, was the first non-murine model
proposed for Bcc. Seedling leaves are wounded and inoculated with Bcc, then
maintained at 37oC under normal light/dark conditions; 7 days p.i., disease
symptoms – yellow leaves, stunted roots, and brown necrotic regions – are
assessed (48). Common plant model Arabidopsis thaliana has been little applied
to Bcc work, though Bcc lipopolysaccharide (LPS) activates the innate immune
response of the plant (286), and Bcc-produced volatiles promote its growth (504).

1.1.6.4

In vitro cell culture models

Although Bcc are predominantly extracellular bacteria, they have been isolated
from intracellular environments in infected patients and in vivo models (80). “B.
cepacia” has been isolated from the tracheal epithelial cells of a septicaemic CF
patient (80). B. cenocepacia has also been found in the respiratory epithelium,
alveolar septae, inflammatory cell infiltrates, and luminal and parenchymal
macrophages of CF patients (406). “B. cepacia” invades respiratory epithelial

18

cells and macrophages in a murine model of infection (80), while B. cenocepacia
is preferentially taken up by macrophages in a zebrafish embryo model (502).
Numerous cells and cell lines have been used to investigate interactions between
Bcc and host cells (412). In vitro, B. cenocepacia has been shown to survive
within free-living amoebae (253, 308), phagocytes (252), and epithelial cells
(409). In Acanthamoeba polyphaga, B. cenocepacia survives without replication
in an acidic vacuole distinct from the lysosomal compartment (253). The
interactions between B. cenocepacia, and macrophages and epithelial cells have
been much more closely studied.
It is not known whether B. cenocepacia is able to actively invade macrophages or
whether the bacteria are taken up by phagocytosis, though internalization at a
higher rate than P. aeruginosa or S. aureus has been demonstrated (321). Once
internalized, B. cenocepacia is able to delay phagosomal maturation (252) and
assembly of the NADPH oxidase complex (230), and induce interleukin (IL)-1β
production (242); each of these phenotypes requires viable bacteria, and is
exacerbated in the absence of a functional CFTR (230, 242, 254). B.
cenocepacia is able to inactivate the Rab7 GTPase, a marker found on the
cytosolic face of the phagosome which is important for phagolysosomal fusion
(210). B. cenocepacia is also able to alter the actin cytoskeleton of the
macrophage in a process requiring a functional Type VI secretion system (T6SS)
(25, 390). Despite the delay in phagosomal maturation, the bacteria-containing
vacuole (BCV) has been shown to fuse with lysosomes and become acidified by
6h p.i. (252), and replication of intracellular bacteria by 24h p.i. has been
demonstrated (185), suggesting B. cenocepacia may be able to replicate within
an acidic environment.
B. cenocepacia invasion of pulmonary epithelial cells is mediated by binding to
glycosphingolipid receptors (335), and involves bacterial lipase (336), and host
microfilaments and microtubules, but not CFTR (477). In CF-derived epithelial
cells, F-actin polymerization into stress fibres is seen upon bacterial uptake into
the endocytic pathway; live bacteria escape the classical endocytic pathway to
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non-acidified autophagosomes and eventual replication in the endoplasmic
reticulum (ER) (409). Infection of epithelial cells with B. cenocepacia upregulates
expression of matrix metalloprotease-9, which inhibits wound repair (525), and
proinflammatory cytokine IL-8, which enhances growth of intracellular bacteria
(229). B. cenocepacia is able to access lung capillaries to initiate septicaemia by
traversing the respiratory epithelium via disruption of tight junctions (236) or
induction of epithelial cell death (107).
The sputum of Bcc-infected CF patients has less viable granulocytes, and a
higher proportion of secondary necrotic granulocytes, typically seen when
phagocytic clearance of apoptotic cells is ineffective (513). In cell culture models,
B. cenocepacia interacts with neutrophils, promoting apoptosis postinternalization (67). B. cenocepacia is also able to interfere with normal
maturation and induce necrosis in dendritic cells (285).

1.1.7

Genetics of B. cenocepacia

B. cenocepacia is a remarkably adaptable bacterium exhibiting nutritional
versatility and inhabiting a wide variety of niches ranging from the CF lung to
agricultural soil; the same sequence type has been isolated from clinical,
industrial & natural sources (287). It is thought that the adaptability of Bcc
bacteria is due to both larger than average coding potential arranged in a
multireplicon structure, and the presence of many insertion sequences yielding
genomic plasticity & adaptability (265).

1.1.7.1

Genetic organization

The genome of the type strain of B. cenocepacia, J2315, encodes 7261 putative
coding sequences (CDS) in 8 Mbp of genetic material with an average G+C
content of 66.9% (195). The genome is divided into three circular chromosomes
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and a plasmid, with sizes of approximately 3.9 Mbp, 3.2 Mbp, 0.9 Mbp, and 92
kbp, respectively; genes are designated with a replicon-specific prefix – BCAL,
BCAM, BCAS, or pBCA – and a number. The genome contains a perfect gene
duplication of 57 putative CDSs on chromosome 1, as well as 79 insertion
sequences, and 126 partial or pseudogenes; fourteen putative genomic islands –
likely a result of horizontal gene transfer – account for 9.3% of chromosomal DNA
and may contain mobile genetic elements including bacteriophage and
transposons (195).

1.1.7.2

Genetic manipulation

B. cenocepacia is not readily tractable genetically, and until recently, genetic
manipulation was greatly hindered by few tools and limited selection markers,
mainly trimethoprim and tetracycline; while the latter has not changed,
development of the homing endonuclease pGPI-SceI system enables sequential,
non-polar, unmarked gene deletions in B. cenocepacia (156). The system uses
two separate plasmids, suicide plasmid pGPI-SceI, and replicative but unstable
plasmid pDAI-SceI, each sequentially transferred via tri-parental mating. Two
small – 200 bp is sufficient – regions of homology flanking the sequence to be
deleted are cloned into mutagenesis plasmid pGPI-SceI, which contains a unique
I-SceI recognition site in the plasmid backbone. Because B. cenocepacia does
not produce Pir, required for maintenance of pGP plasmids with a Pir-dependent
ori R6K (154), the mutagenesis plasmid is incorporated into the genome by
homologous recombination, producing an intermediate mutant. Introduction of
the second plasmid, pDAI-SceI, constitutively expressing the I-SceI nuclease,
creates a double strand break in the integrated plasmid backbone, which must be
repaired for survival of the bacterium. Recombination within the first region of
homology restores the wild-type chromosome, but recombination within the
second region of homology results in a deletion of all chromosomal DNA between
the two regions of homology (156). Deletion mutants are confirmed by
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polymerase chain reaction (PCR) with primers external to the deletion, and/or
Southern blot hybridization. The plasmid expressing the I-SceI nuclease also
contains a sacB site, allowing it to be cured by growth on sucrose (185).
Because the resultant deletion is unmarked, application of the pGPI-SceI strategy
allows continued re-use of the same two antibiotic selection markers to create
sequential deletions in the same strain.

1.1.7.3

Strain differences

B. cenocepacia as a species designation takes in four different recA lineages, IIIA
to D; thus far, all IIIC are environmental, while there are no environmental strains
of IIID and few for IIIA, suggesting possible niche-specific adaptations (287).
Though most CF epidemic strains in the United States, including PHDC – so
designated based on the two American cities in which the strain was first isolated
from CF patients (92) – and Midwest, belong to the IIIB group, Canada and
Europe are dominated by IIIA strains; sequenced strain J2315 belongs to a
recIIIA lineage known as Edinburgh Toronto (ET )-12, or ST-28 (134). There are
significant genetic differences between lineages, as comparison of the IIIA J2315
sequence with IIIB lineage PHDC strains AU1054 and HI2424 showed regions of
difference encompassing 21% of the total genome, including lack of all fourteen
genomic islands in PHDC (195). There are also genetic differences within the
same lineage: ST-28 and ST-32 are closely related IIIA strains with
intercontinental distribution, but differing pathogenicity; the less-virulent ST-32
undergoes extensive genomic rearrangement and transposition events when
exposed to ROS, while the genome of the more-virulent ST-28 appears stable
under the same conditions (134).
The work described in this thesis uses B. cenocepacia K56-2, or ST-30, isolated
from the lungs of a Canadian CF patient. K56-2 belongs to the ET-12 lineage,
and is assigned to the same clonal complex as J2315 (290). Because K56-2 has
yet to be sequenced, the published sequence of J2315 was applied to K56-2 for
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the purposes of this work. However, there are differences between K56-2 and
J2315 both genetically (195), and phenotypically, including LPS structure (356),
ability to infect macrophages (411), and virulence in G. mellonella (429), D.
melanogaster (73), C. elegans (69), and D. rerio (502). Because K56-2 has
lower resistance to useful antimicrobial selection agents than does J2315, the
former is more amenable to genetic manipulation, and was thus the strain of
choice for this work.
Recently, MH1K, an aminoglycoside-sensitive strain of K56-2, was developed;
though sensitive to concentrations of gentamicin as low as 10 µg/mL, MH1K
behaves as wild-type when internalized by murine macrophages (185). This
strain is a very useful tool for in vitro studies of B. cenocepacia. Prior to MH1K,
classical studies of the interaction between bacteria and eukaryotic cells were
hampered by the extreme resistance of B. cenocepacia to antibiotics, requiring
researchers to use high concentrations of gentamicin and ceftazidime to kill
extracellular bacteria; the presence of such high levels of aminoglycosides had
the potential to affect intracellular bacteria, as well as the eukaryotic cells. With
the use of MH1K, extracellular bacteria can now be killed, facilitating more
accurate and longer-term investigation of the internalization and intracellular
behaviour of B. cenocepacia.

1.1.8

Virulence factors in B. cenocepacia

B. cenocepacia possesses a wide range of virulence factors putatively involved in
the ability of the bacterium to cause disease [reviewed in (278)]. Previous work
employed a signature-tagged transposon mutagenesis (STM) to identify 84
unique genes essential for in vivo survival in a rat model of chronic lung infection;
these genes were spread across all four genetic elements of B. cenocepacia and
included metabolic, regulatory, transport, cell surface-associated, and information
processing genes, as well as conserved genes of unknown function (207).
Transposon mutation screens have also been done in a C. elegans model,
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identifying several genes involved in virulence (451). Recently, the metabolic
network was modelled for J2315, demonstrating biosynthesis pathways for
virulence factors including lipopolysaccharide, quorum sensing molecules, and
putatively, rhamnolipids (145). Comparative transcriptomics has also been
applied to the identification of virulence factors; global expression studies have
examined the response of clinical and environmental isolates of B. cenocepacia,
to synthetic CF sputum (133, 535, 536), although only four genes are common to
all three studies. Many putative virulence factors have been specifically targeted
for investigation through a mutation-based approach; other studies have utilized
these mutants to test the contribution of putative virulence factors in multiple
models of infection.

1.1.8.1

Genomic islands

B. cenocepacia IIIA strain J2315 contains fourteen genomic islands, comprising
9.3% of the total genome, which are not found in sequenced IIIB strains; because
most IIIA strains are clinical isolates, it is possible that the genomic islands
contain genes promoting adaptation to the CF lung (195). Many of the islands
are prophages, or are of phage or plasmid origin, while others contain metabolic
genes; genomic island 11, formerly referred to as the B. cenocepacia island (cci),
encodes 43 CDS involved in a wide variety of functions, including quorum
sensing, stress response, antibiotic and arsenic resistance, and ion and amino
acid transport (195). The cci also includes the “B. cepacia epidemic strain
marker” (BCESM), unique to strains capable of epidemic spread among CF
patients (291); genes within the cci are linked with persistence and virulence in a
murine model of chronic lung infection (32).
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1.1.8.2

Antimicrobial resistance

Pan-resistant B. cenocepacia strains – that is, resistant to most, if not all,
clinically useful antibiotics – are common; where treatment is possible, it often
requires the concurrent use of multiple antibiotics (1). Isolates from CF patients
suffering from pulmonary exacerbation are generally more resistant to antibiotics
than those isolated from stable, chronically-infected patients (460). Antibiotic
resistance in B. cenocepacia is undoubtedly multifactorial, as the bacteria
possess mechanisms for alteration of cell wall permeability, alteration of drug
targets, enzymatic inactivation, and active efflux (134). Transcriptomic studies
have suggested a role for efflux pumps in antimicrobial resistance (417), which
has been borne out in the increased antibiotic susceptibility of deletion mutants
(40, 64, 185). Surface structure lipopolysaccharide also plays a role in resistance
to antimicrobial peptides (277). Genomic analysis has also demonstrated the
presence of beta-lactamases, fosmidomycin resistance protein, and trimethoprim
resistance factor dihydrofolate reductase, among others (195).

1.1.8.3

Quorum sensing

Quorum sensing (QS) is a form of interbacterial communication that regulates
gene expression relative to cell density; a signalling molecule – typically N-acylhomoserine-lactone (AHL) – is produced by a synthase and detected by a
transcriptional regulator (167). B. cenocepacia is able to synthesize at least three
different types of signalling molecules, including putative intergenus signal 2heptyl-4(1H)-quinolone (HHQ), which can be processed into a QS signal by P.
aeruginosa (129). Epidemic strains of B. cenocepacia carry two copies of the
AHL-mediated quorum sensing system: The first, with AHL-synthase CepI and
regulator CepR, is common to all B. cenocepacia strains and produces primarily
N-octanoyl-L-homoserine lactone (C8-HSL) (266); the second, designated CciIR,
is located within the cci and synthesizes mainly N-hexanoyl-L-homoserine
lactone (C6-HSL) (32, 297). Though both systems function as global regulators

25

of quorum sensing gene expression, the two participate in reciprocal regulation of
many genes, including motility- and iron transport-associated genes, synthesis of
exoenzymes, and the nematocidal protein AidA (349). Accordingly, mutation of
cepI reduces virulence in C. elegans, but mutation to cciI has no effect (485).
CepIR QS-deficient mutants were less virulent in both the rat agar bead model of
chronic lung infection, and intranasal infections in wild-type and Cftr-/- mice (449);
CciIR mutants were also attenuated for virulence in the rat model (32). A third
CepR homolog exists in B. cenocepacia which lacks an associated AHL
synthase; CepR2 participates in QS regulation, but can function in the absence of
AHL signals (298).
A third quorum sensing system in B. cenocepacia uses cis-2-dodecenoic acid
(BDSF), a non-homoserine lactone diffusible signal factor detected by a histidine
kinase encoded by BCAM0227; mutation of the sensor decreases virulence in
both G. mellonella larvae and the mouse agar-bead model of chronic lung
infection (318). Mutation of a gene involved in the synthesis of BDSF results in
decreased virulence in a D. rerio model of infection (122).

1.1.8.4

Iron acquisition

Though an essential nutrient, free iron is limited in a host environment, and must
thus be scavenged by the infecting pathogen. B. cenocepacia produces ironchelating siderophores salicylic acid (SA), ornibactin, and pyochelin (446, 506).
In a survey of “P. cepacia” isolates from CF patients, pyochelin-producing strains
were associated with more severe pulmonary disease and death, while
pyochelin-negative strains were associated with more mild infections (444).
Though the pyochelin biosynthesis genes in J2315 contain a frameshift mutation,
the transport and utilization genes are intact (195); in a rat model of chronic lung
infection, exogenously supplied pyochelin increased the virulence of pyochelinnegative “B. cepacia” strains (450), though pyochelin alone is insufficient for iron
acquisition in vivo (506). SA, originally referred to as azurechelin, is also
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produced by clinical isolates of “P. cepacia”; similar to pyochelin, SA is able to
promote growth of “B. cepacia” under iron-limiting conditions, and compete with
transferrin for iron in vitro (444, 447). Though SA and ornibactin are the
predominant siderophores produced by clinical isolates of “B. cepacia” (114), SA
does not appear to be able to compete with host iron binding proteins and
promote iron acquisition in vivo (445), but may instead play a role in inducing
antibiotic resistance (339). Ornibactin contributes to colonization, bacterial
persistence, and lung pathology in murine models of acute and chronic lung
infection (446); ornibactin-deficient mutants also display decreased virulence in
C. elegans, and are avirulent in G. mellonella (485). B. cenocepacia is also able
to utilize some xenosiderophores, including ferrichrome and ferrioxamine B (478).
Iron sequestration in the lung typically involves molecules of transferrin,
lactoferrin, and ferritin (484). Compared to a normal lung, the CF lung contains
elevated levels of ferritin, which are elevated further in the presence of an
inflammatory response (379, 465). B. cenocepacia is able to acquire iron from
ferritin in a serine-protease-dependent manner (521), and also capable of utilizing
oxidized haem as an iron source (478, 521).

1.1.8.5

Secretion systems

Many pathogens interfere with eukaryotic host cell processes by employing large,
specialized secretion systems to translocate effector molecules into the host
(168). In particular, types III, IV, and VI secretion systems – all of which are
present in B. cenocepacia – have been implicated in interactions between
prokaryotic and eukaryotic cells. The pathogenic potential of the type III secretion
system (T3SS) of B. cenocepacia has been examined in several models:
Previous studies have shown that a mutant bearing a polar insertion in the T3SS
gene cluster delays phagosomal maturation similar to wild type (252), but an
insertionally-activated T3SS mutant was cleared more rapidly from the lungs of
infected mice (480), and displayed reduced virulence in C. elegans (306, 485).
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B. cenocepacia encodes two type IV secretion systems (T4SS), the first a
chimera of VirB/D4 and F-specific subunits on the plasmid (T4SS-1), and the
second a VirB/D4 homolog on chromosome two (T4SS-2) (86, 195). B.
cenocepacia T4SS-1 has been previously examined for in vivo relevance;
insertional inactivation of a putative T4SS coupling protein affected intracellular
persistence in macrophages (403). T4SS-1 is also required to induce plant tissue
water soaking (141). The only known role for T4SS-2 is in plasmid mobilization
(539). Mutations in the type VI secretion system (T6SS) of B. cenocepacia render
the bacteria deficient in survival in a murine model of chronic lung infection (207)
and susceptible to predation by the amoeba Dictyostelium discoideum (25). An
active T6SS mediates actin rearrangement in B. cenocepacia-infected
macrophages (25).
B. cenocepacia also encodes a type II secretion system (T2SS) (195), generally
responsible for movement of toxins, proteases, cellulases and lipases across the
bacterial membrane [reviewed in (217)]. A type II secretion pseudopilin was
found to be involved in the pathogenesis of B. cenocepacia in C. elegans (451).
Finally, B. cenocepacia possesses four type V secretion systems (T5SS); all four
autotransporters appear to be involved in adhesion, two containing pertactin
domains and two containing hemagglutinin repeat domains (195).

1.1.8.6

Exoenzymes

B. cenocepacia produces various exoenzymes which may be involved in hostpathogen interactions. Early studies of “P. cepacia” clinical isolates revealed
production of lipase, protease, lecithinase, phospholipase C, and, in a small
proportion of isolates, hemolysin (340, 497). More recent genomic studies have
shown that the B. cenocepacia J2315 genome encodes five phospholipase C
homologs with putative functional specificity, and a phosphatidylinositol-specific
phospholipase C, which, in gram-positive pathogens, is involved in virulence;
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J2315 also encodes pectin degradation enzymes, involved in the breakdown of
plant tissue (195).
Functional studies with B. cenocepacia have revealed a wide variety of
exoenzymes. B. cenocepacia J2315 produces a haemolytic protein with strong
biosurfactant properties that is able to induce apoptosis and degranulation in
phagocytic cells; the toxin is capable of inhibiting S. aureus and, at high
concentrations, P. aeruginosa, but does not inhibit B. cenocepacia (209). B.
cenocepacia also secretes a homologue of the redox enzyme azurin which is
capable of inducing caspase-dependent apoptosis in macrophages (370), and a
purple alkaline phosphatase highly active against phosphorylated proteins, and,
to a lesser extent, phosphoenolpyruvate and ATP (533). The invasion of
epithelial cells by B. cenocepacia involves a secreted lipase that does not affect
the eukaryotic plasma membrane or tight junction integrity (336). The best
studied exoenzymes of B. cenocepacia are the QS-regulated ZmpA and ZmpB
zinc metalloproteases (99, 240). Both enzymes can degrade casein, gelatin,
tissue components type IV collagen and human fibronectin, protease inhibitors
 2 -microglobulin and -1 proteinase inhibitor, and a variety of antimicrobial
peptides, though the manner of cleavage is generally enzyme-specific (238-240,
322); ZmpA also cleaves gamma interferon (238), and ZmpB degrades
lactoferrin, transferrin, and immunoglobulins IgA, IgG, and IgM (240). Though
both enzymes contribute to lung pathology in a murine model of chronic lung
infection (99, 240), ZmpA also contributes to persistence in the lung (99) and,
when instilled in a purified form, induces bronchopneumonia in rats (322).

1.1.8.7

Cell surface structures

Structures present on the bacterial cell envelope are frequently involved in the
interactions between the bacterium and host cells, modulating adherence,
invasion, and cytotoxicity, as well as bacterial motility. Alterations to the cell
surface can affect persistence in murine models of infection (89). B. cenocepacia
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possesses polar flagella, which have been implicated in pathogenesis. Nonmotile flagellar mutants are deficient in invasion of, but not in adherence to,
respiratory epithelial cells, a phenotype dependent on flagellar-mediated motility
(481). Flagellar mutants are also non-lethal in a murine model of chronic lung
infection, and do not stimulate a strong immune response, whereas wild type B.
cenocepacia elicits a strong immune response, partially by initiating a signalling
cascade through the interaction of bacterial flagellin with Toll-like receptor (TLR)
5 (487). There has been speculation that the flagella are important in
establishment of an infection, while adaptation to chronic lung infection involves a
loss of motility (417), as is seen for P. aeruginosa isolates from chronicallyinfected CF patients (289).
One of the two hallmarks of the highly transmissible ET-12 lineage of B.
cenocepacia is the presence of the cblA gene encoding the major subunit of
surface cable (Cbl) pili (469). A 22-kDa Cbl pilin-associated adhesin mediates
bacterial binding to cytokeratin 13 (CK13) and mucin, both of which are abundant
in the CF airway epithelia (404, 408); binding of B. cenocepacia to CK13
promotes bacterial invasion into epithelial cells and cell damage (405). Cbl pili
are cytotoxic, able to activate caspases and induce apoptosis in epithelial cells
(78). J2315 also encodes components of a type IVa pilus, and two clusters of
Flp-type pili (195).
Other proteins are also involved in mediating bacterial adherence to host cells. A
trimeric autotransporter adhesin is involved in in vitro adherence to extracellular
matrix proteins and virulence against G. mellonella larvae (326). Genomic
studies have shown that J2315 encodes eight BuHA family proteins,
autotransporting membrane proteins with homology to hemagglutinin and invasin
proteins (195).
In contrast, bacterial adherence to epithelial cells is inhibited by the presence of
O-antigen, the outermost portion of lipopolysaccharide (LPS) (411). LPS, which
forms the major surface component of gram negative bacteria, is a complex
glycolipid composed of lipid A, a core oligosaccharide, and, in some strains, O-
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antigen (373). Unlike other bacteria, B. cenocepacia constitutively incorporates
4-amino-4-deoxy-L-arabinose (Ara4N) residues into the lipid A and core
oligosaccharide, resulting in a reduction in the net negative charge of the LPS
molecule (358). Lipid A anchors the LPS molecule in the membrane, maintaining
membrane integrity while serving as an endotoxin (373). B. cenocepacia LPS
induces cytokine production by human monocytes in a TLR4- and CD-14dependent manner (35, 119); the immune response to “B. cepacia” LPS is over
nine-fold greater than that elicited by P. aeruginosa LPS (434). The O-antigen
also prevents phagocytosis by macrophages (411) and serum-mediated killing
(356). Mutations to the O-antigen synthesis cluster result in attenuated survival
in a rat model of chronic lung infection (207), as do mutant strains unable to
synthesize the complete LPS core oligosaccharide (277). The latter also show
impaired virulence in C. elegans and G. mellonella models, fail to traffic properly
in murine macrophages, and are more sensitive to antimicrobial peptides (357,
485).
The production of exopolysaccharide (EPS), leading to a mucoid phenotype, has
been noted in some strains of B. cenocepacia; typically, EPS production appears
more common in environmental isolates and strains belonging to the recA IIIB
lineage (541). In clinical isolates, there is speculation that EPS masks bacterial
surface ligands, reducing the virulence of mucoid isolates and increasing
bacterial persistence in the murine lung (97); however, EPS-deficient mutants
show reduced virulence in a CGD mouse model of infection (453). The most
common EPS produced by Bcc species is designated cepacian (443). Though
the ET-12 lineage cannot produce cepacian due to a deletion in the biosynthesis
cluster, other B. cenocepacia strains can produce EPS in response to
carbohydrates in onion tissue and alcohol sugars (38).

B. cenocepacia is

capable of producing mucoid material consisting of multiple polysaccharides,
including polysaccharide-1 (PS-1), cepacian (formerly PS-2), and dextran; EPS
produced by B. cenocepacia can inhibit neutrophil chemotaxis and the production
of reactive oxygen species (66).
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1.1.8.8

Resistance to oxidative stress

In the course of a respiratory infection, B. cenocepacia is exposed to a toxic array
of reactive oxygen species; intracellular bacteria are subject to the oxidative burst
of phagocytic cells, while extracellular bacteria are exposed to the highly
oxidative environment of the CF lung, characterized by persistent neutrophil
infiltration and a sustained inflammatory response. B. cenocepacia possesses
numerous mechanisms to resist damage due to ROS. Two separate
catalase/peroxidase enzymes have been identified in B. cenocepacia, the first a
classical enzyme participating in global resistance to oxidative stress, and the
second a specialized enzyme employed in the metabolism of carbon sources
through the tricarboxylic acid cycle, and in hydrogen peroxide resistance under
conditions of iron limitation (263). Intracellular B. cenocepacia is able to delay
assembly of the NADPH oxidase complex, responsible for producing ROS (230);
a periplasmic superoxide dismutase SodC is required for resistance to
extracellular superoxide, mutations to which result in rapid NADPH oxidasedependent killing by murine macrophages (232).
Some strains of B. cenocepacia produce a melanin-like pigment which also
contributes to resistance to oxidative stress in vitro and intracellular survival
within murine macrophages (231), while EPS produced by B. cenocepacia is able
to scavenge ROS from activated phagocytes (66). Genes involved in resistance
to oxidative stress are upregulated when B. cenocepacia is grown in cystic
fibrosis sputum (133). Transcriptomic analysis of the response of sessile B.
cenocepacia to ROS shows upregulation of pathways involved in scavenging and
neutralizing ROS, and repair of cellular damage resulting from ROS exposure
(363).
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1.1.8.9

Biofilm

B. cenocepacia is capable of forming biofilms – complex multicellular
communities protected from antibiotics and host defences – on both abiotic (98)
and biotic (425) surfaces. The invasion of the airway epithelium by B.
cenocepacia is mediated by biofilm formation; biofilm-associated bacteria are
able to degrade the glycocalyx barrier, rearrange the actin cytoskeleton of the
underlying epithelial cells, and induce necrosis of the luminal cells (425). Biofilmassociated B. cenocepacia produces cyanide, which may participate in
destruction of host tissue (397); accumulation of cyanide in the sputum of P.
aeruginosa-infected CF patients is associated with a decline in lung function
(396).
Reported regulators of B. cenocepacia biofilm formation, structure, and stability
include all three quorum sensing systems (123, 206, 482), RpoN (410), ShvR
(47), and AtsR, a hybrid sensor kinase-response regulator that also regulates the
T6SS (25); formation and structure are also affected by iron availability (46), and
EPS production (108).
During co-infection of the CF lung, B. cenocepacia and P. aeruginosa can form
mixed-species biofilms, where interspecies communication occurs (383). P.
aeruginosa is able to enhance the binding of “P. cepacia” to epithelial cells (401),
and produces QS molecules that can upregulate the production of virulence
factors in B. cenocepacia (320, 383).
Biofilm-associated bacteria are more resistant to disinfectants (362), and
antibiotics, including double antibiotic combinations (112). However, treating
biofilms with a combination of antibiotic and quorum-sensing inhibitors (QSI) has
proven effective in killing biofilm-associated B. cenocepacia; compared to
treatment with antibiotic alone, the combination with QSI also increases survival
of infected C. elegans and G. mellonella, and decreases bacterial burden in a
murine model of lung infection (58).
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1.1.8.10 Other virulence determinants
Degradation of many aromatic compounds converges at the catabolic pathway
for phenylacetic acid (PA) prior to entering the Krebs cycle (280). The PA
pathway is upregulated when B. cenocepacia is grown in synthetic CF medium
(186); transposon mutants in the PA pathway are attenuated for survival in C.
elegans (256), as well as a rat model of chronic lung infection (207), suggesting
aromatic compounds may be an important nutrient source in host-pathogen
interactions.
MgtC is a protein of unknown function which is required for growth under
magnesium-limiting conditions and for intramacrophage survival in intracellular
pathogens such as Salmonella enterica (381) and Brucella suis (255). MgtC
fulfills the same role in B. cenocepacia (296), where it is also necessary for
virulence in a rat model of chronic lung infection (207). There are two additional
homologs of MgtC in the B. cenocepacia genome that have not yet been
investigated; since the original mutant was not susceptible to in vitro
intramacrophage-like conditions such as reactive oxygen and nitrogen species,
cationic antimicrobial peptides, or low pH (296), it is possible the two additional
MgtC proteins can complement certain phenotypes or under certain conditions.
ShvR, a LysR-type transcriptional regulator, is necessary for virulence in an
alfalfa model, as well as full lung histopathology in a murine model of chronic lung
infection (47). ShvR also regulates colony morphotype, biofilm formation,
exoenzyme production, type II secretion, and production of an anti-fungal agent
(348).
HtrA is a periplasmic protein involved in the extracytoplasmic stress response;
necessary for growth under thermal and osmotic stress, HtrA is also essential for
in vivo survival in a murine model of chronic lung infection (154). HtrA-like
proteases are regulated by the alternative sigma factor RpoE, which in B.
cenocepacia, is also necessary for growth under thermal and osmotic stress, as
well as proper trafficking in murine macropahges (157). A second alternative
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sigma factor, RpoN, also plays a role in intra-macrophage trafficking, as well as
motility and biofilm formation (410).
Rhamnolipids are amphiphilic molecules which can act as biosurfactants; in P.
aeruginosa, rhamnolipids are involved in biofilm development (115) and
swarming motility (483), and can inhibit macrophage phagocytosis (319), disrupt
the respiratory epithelium (543), and interfere with normal functioning of the
tracheal cilia (378). Rhamnolipid production has been seen in non-Bcc
Burkholderia spp. (19, 136, 187), where it functions as an endotoxin in
pathogenic strains. Orthologs to the rhamnolipid biosynthetic genes of B.
thailandensis and P. aeruginosa have been identified in B. cenocepacia,
suggesting a capacity to generate rhamnolipids (145).

1.2 Secretion systems
Secretion in gram-negative bacteria requires transport across two hydrophobic
membranes separated by a peptidoglycan-containing aqueous periplasm. The
movement of large macromolecules across this cellular envelope poses
challenges in terms of maintaining the integrity of the membrane, as well as
regulation of cross-membrane movement. Estimates place at least 25-30% of
the typical gram-negative total protein content in the cell envelope or secretome;
as such, gram negative bacteria have developed six known large multi-gene
secretion systems – types I through VI – including both one-step “tunnels” and
two-step processes separated by a periplasmic stage (198). A type VII secretion
system has also been identified in gram-positive bacteria (2). Secretion is
particularly important in intercellular signalling for cooperation or competition, and
in virulence effector delivery to eukaryotic cells, and thus some secretion systems
are contact-dependent (188).
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1.2.1

The Sec and Tat systems

The general secretory (Sec) pathway and the twin-arginine translocation (Tat)
pathway both function to move proteins across the inner membrane (IM); the
former transports unfolded proteins, while the latter translocates folded proteins
(261). Protein substrates are targeted for export via an amino (N)-terminal signal
sequence called a signal peptide (SP), which is cleaved when the protein
reaches the periplasm. The composition of the Tat sytem is varied, minimally
consisting of a TatABC substrate-binding receptor complex which associates with
a separate TatA complex to form an active translocon, through which tranport is
driven by the proton motive force (385). Proteins targeted to the Sec system bind
to cytosolic motor protein SecA, an ATPase that drives translocation through a
SecYEG channel; in the periplasm, the SP is cleaved by signal peptidase,
allowing folding of the mature protein (135).

1.2.2

Type I

The type I secretion system (T1SS) is a simple trimeric complex spanning the
entire cell envelope (199). The translocon consists of an IM ATP-binding
cassette (ABC) transporter, with a nucleotide binding domain (NBD) fused to a
transmembrane domain, and an outer membrane (OM) pore linked by an adaptor
protein, or membrane fusion protein. Unfolded substrates are targeted to the
T1SS, where a non-cleavable carboxy (C)-terminal signal sequence binds to the
NBD of the ABC transporter to induce translocation.

1.2.3

Type II

The type II secretion system (T2SS), often referred to as the general secretory
pathway, mediates a two-step process. First, exoproteins with an N-terminal SP
are transported to the periplasm by either the Sec or Tat systems; following
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cleavage of the SP, fully folded proteins are translocated across the OM by the
secreton (217). The secreton is a large complex composed of an OM pore called
a secretin, and an IM pilus-like structure postulated to act as a piston to force
substrates through the secretin (90). The T2SS is closely related to the type IV
pili (217), and secretes a wide variety of exoenzymes (90).

1.2.4

Type III

The type III secretion system (T3SS) is a generally contact-dependent system
found in pathogenic bacteria for the delivery of effectors to the cytosol of
eukaryotic cells. It is characterized by an injectisome, or needle-like structure
capable of injecting substrates directly into a eukaryotic cell through a cellenvelope-spanning channel; outside the bacterial OM, the T3SS is capped with a
needle, a tip complex, and a translocation pore forming a channel in the
eukaryotic membrane (188). In structure and assembly, the T3SS is homologous
to the flagellar export system (143), though secreted effectors are varied.

1.2.5

Type IV

The type IV secretion system (T4SS) is a mostly contact-dependent system able
to transport substrates directly into both prokaryotic and eukaryotic cells.
Homologous to bacterial conjugation machinery, T4SSs are able to translocate
both DNA and protein substrates; the former contribute to rapid inter-bacterial
spread of resistance genes and fitness traits, while the latter contribute to
virulence against eukaryotic cells (86). The main structures of the T4SS
comprise a cell surface adhesin or pili for intercellular contact, a transenvelope
channel, and a Type IV coupling protein (T4CP), which mediates substrate
entrance into the channel (188). There are two general lineages of T4SS, one
homologous to the VirB/D4 system of Agrobacterium tumefaciens, and one
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homologous to the Dot/Icm system of L. pneumophila, although there are T4SSs
that fit well into neither lineage (86).

1.2.6

Type V

The simplest of the secretion systems, Type V secretion systems (T5SS) also
use a two-step secretion mechanism with a periplasmic intermediate for the
secretion of very large proteins. Unfolded proteins are transported to the
periplasm through the Sec system, where a -barrel translocator domain is
needed for transport across the OM (189). T5SS can be divided into
autotransporters (AT) and two-partner secretion systems (TPS). ATs consist of a
signal domain and a -barrel domain linked by a passenger domain; the signal
domain directs the protein to the periplasm where the -barrel domain forms a
pore in the OM for secretion of the passenger domain. The passenger domain
may remain associated with the OM or be released into the extracellular milieu by
proteolysis. AT proteins often contribute to cellular adhesion, aggregation, biofilm
formation, invasion, and toxicity (519). TPSs are very similar to ATs, but the
passenger domain, or exoprotein, and the pore-forming -barrel domain, or
transporter, are translated as two separate proteins (189). TPSs are implicated
in contact-dependent growth inhibition (188).

1.2.7

Type VI

The type VI secretion system (T6SS) is the most recently discovered of the large
multi-gene secretion systems, and as such, has not been as well characterized.
Some proteins of the T6SS are homologous to bacteriophage proteins, including
tube-like hexameric ring protein Hcp, and tailspike-like protein VgrG, and the
T6SS can participate in contact-dependent effector delivery (215). However, the
purpose of the T6SS is a hotly debated topic, with phenotypes ranging from
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restriction of H. hepaticus colonization and downregulation of the host immune
response in infected epithelial cells (83), to P. aeruginosa toxin-mediated killing of
neighbouring prokaryotic cells (204), B. thailandensis resistance to cell contactinduced growth inhibition (427), B. mallei virulence in hamsters (421), and
translocation of an actin cross-linking effector into host cells by intracellular Vibrio
cholerae (284).

1.3 Prokaryotic interactions with macrophages
As professional phagocytic cells, macrophages are key elements of the innate
immune response uniquely suited to engulf large particles, including
microorganisms. Particles are generally taken up by a receptor-mediated
process into plasma-membrane derived vacuoles; these phagosomes mature
through successive interactions with the endosomal pathway, a series of
membrane bound organelles responsible for the degradation, recycling, and
sorting of molecules from both the cellular membrane and the extracellular milieu.
As the phagosome matures, both the membrane composition and the internal
contents are altered through interaction with a multitude of cellular and
membrane proteins, changing the phagosome from a relatively innocuous
environment to a highly acidic and oxidative environment rich in degradative
enzymes suitable for microbe destruction (55). While most bacteria are
successfully eliminated by the macrophage, some pathogens have developed
strategies for preventing internalization or interfering with normal host cell
processes. Still others have adapted to the intracellular environment, which has
advantages for pathogens able to overcome host defenses. Macrophages are
fairly long-lived cells, and thus provide a competition-free, nutrient-rich niche
protected from extracellular host defenses for microbes able to subvert normal
macrophage degradative processes.
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1.3.1

Bacterial internalization

The most common means of bacterial uptake into macrophages is via receptormediated, actin-driven, zipper-like phagocytosis. Macrophages express a wide
range of receptors recognizing both pathogen-associated molecules and host
serum opsonins coating the bacterial surface. Opsonins such as complement
protein C3b and immunoglobulin G (IgG) are recognized by complement receptor
3 and Fc receptors, respectively; because Fc receptors are relatively low
affinity, activation of phagocytosis requires simultaneous binding of multiple
receptor-ligand complexes (55). While opsonization is a non-specific process
enabling detection of a vast array of microbes (490), phagocytes also express a
wide variety of pattern recognition receptors (PRRs) which recognize pathogenassociated molecular patterns (PAMPs) (479). Plasma membrane-localized
PRRs, including those belonging to the scavenger receptor, C-type lectin, and
Toll-like receptor (TLR) families, are able to recognize diverse bacterial PAMPs,
including simple and complex lipids, carbohydrates, proteins and peptides, and
nucleic acids (364). There is evidence of synergy between both opsonic and
non-opsonic receptors. Binding of microbial ligands to phagocytic receptors
activates complex signalling cascades, cytoskeletal remodelling, and membrane
delivery from intracellular compartments, leading to engulfment of the pathogen
into a vacuole composed of the plasma membrane (55). Receptor ligation and
actin polymerization are linked by the action of Rho family small G proteins,
including Rac1, RhoA, and Cdc42, which function as molecular switches (71).
Inactive Rho proteins are bounding to guanine dissociation inhibitors (GDIs);
guanine nucleotide exchange factors (GEFs) activate Rho proteins by
exchanging GDP for GTP, while GTPase-activating proteins (GAPs) mediate
GTP hydrolysis and inactivation (71). Rho-family GTPases recruit and activate
downstream effectors, which in turn activate the actin-nucleating Arp2/3 complex
to mediate actin remodelling (181).
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1.3.1.1

Preventing bacterial internalization

Bacteria unequipped to survive within phagocytic cells have developed methods
to avoid internalization. S. aureus, E. coli, and P. aeruginosa can all prevent
opsonic phagocytosis; S. aureus interferes with the activation of complement via
a secreted inhibitor (389), E. coli produces an outer membrane protein which
binds to a regulator of complement (367), and P. aeruginosa secretes enzymes
able to directly degrade complement proteins (203). Group B streptococci
prevent scavenger receptor-mediated non-opsonic phagocytosis by producing a
polysaccharide capsule which masks a surface lipoprotein ligand (21).
Pathogenic Yersinia spp. employ a T3SS to translocate multiple Yop effector
proteins into phagocytic cells; YopO acts as a GDI, while YopE functions as a
GAP, both of which modulate the activity of Rho GTPases to prevent bacterial
uptake (7). Other bacteria, including Clostridium spp., produce binary toxins
capable of self-mediated delivery to the cytosol and ADP-ribosylation of actin,
which inhibits actin polymerization and destroys the actin cytoskeleton,
preventing uptake of bacteria (11). Clostridium spp. also produce toxins capable
of covalent modification and inactivation of Rho (37). P. aeruginosa and
Aeromonas salmonicida produce bifunctional T3-secreted effectors with both
RhoGAP and ADP-ribosyltransferase activity (269, 303), while the T6SS effector
VgrG1 from Aeromonas hydrophila is also able to ADP-ribosylate actin, leading to
depolymerization of actin and apoptosis (467).

1.3.1.2

Promoting bacterial internalization

Bacteria have also developed methods to enter non-phagocytic cells, either by
direct invasion – the zipper mechanism – or by promoting phagocytosis through
manipulation of host signalling – the trigger mechanism. Listeria monocytogenes
employs the zipper mechanism, mimicking natural phagocytosis through the
binding of bacterial surface proteins to cell-adhesion-associated receptors; the
clustering of ligand-receptor complexes induces actin polymerization and
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membrane extension, leading to engulfment of the pathogen (101). While the
zipper mechanism is dependent on adhesion, bacteria utilizing the trigger
mechanism rely on translocation of effectors which directly activate the actin
cytoskeleton remodelling necessary for phagocytic uptake. Salmonella mediates
internalization into non-professional phagocytes via T3-secreted effector SopB,
which mediates actin remodelling by activating SGEF, an exchange factor for
RhoG (361). Similarly, B. pseudomallei, Shigella flexneri, and E. coli (both EHEC
and EPEC) secrete effectors capable of acting as GEFs for the Rho family
GTPases, while Bordetella spp., E. coli, and Y. pseudotuberculosis produce
toxins that covalently modify Rho proteins such that they are constitutively active
(10).

1.3.2

Phagosomal maturation

Following internalization of a bacterium into a plasma-membrane-derived
vacuole, the nascent phagosome matures from early phagosome to late
phagosome to phagolysosome; the progression is mediated by sequential
interactions with subcompartments of the endosomal pathway (155). Interaction
between the nascent phagosome and the early, or sorting, endosome creates the
early phagosome, characterized by a mildly acidic pH (6.1 – 6.5) and an active
form of the Rab5 GTPase. Rab5 recruits effector proteins, including tethering
protein early endosome antigen 1 (EEA1), which facilitates the fusion of
phagosome and early endosome, and Vps34, a kinase that generates
phosphatidylinositol-3-phosphate (PI(3)P); PI(3)P anchors EEA1 to the cytosolic
face of the phagosomal membrane (155). Active Rab5 also recruits Mon1, which
in turn recruits Ccz1; the Mon1-Ccz1 complex displaces the Rab7 GDI, recruiting
Rab7 to the phagosomal membrane and marking the transition to the late
phagosome. As markers of the early phagosome are lost, the late phagosome
becomes characterized by a lower pH (5.5 - 6.0) due to the acquisition of VATPases, as well as enrichment in hydrolytic enzymes, lysobisphosphatidic acid
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(LBPA), mannose-6-phosphate receptors (M6PR), and lysosomal-associated
membrane proteins (LAMPs). Active Rab7 recruits Rab-interacting lysosomal
protein (RILP), an adaptor for microtubule-associated motor protein dynein, which
can bring together late phagosomes and lysosomes. Late endosomal markers
such as LBPA and M6PR are removed during the transition to a fully formed
phagolysosome, a highly acidic (pH < 5.5) vacuole characterized by LAMPs and
V-ATPases which employs both oxidative and non-oxidative killing mechanisms.
The phagolysosome is rich in antimicrobial peptides and active hydrolases,
including lipases, proteases, nucleases, and glycosidases; recruited NADPH
oxidase and inducible nitric oxide synthase generate reactive oxygen and
nitrogen species, and nutrients are scavenged by molecules such as lactoferrin,
creating an environment hostile to continued microbial presence (55).

1.3.3

Bacterial strategies for intracellular survival

Pathogens have developed unique strategies for surviving within phagocytic
cells. True intracellular pathogens survive and replicate either in the cytosol or
within a membrane-bound organelle, in most cases attempting to avoid the harsh
lysosomal environment. Bacteria remaining within a membrane-bound vacuole
utilize several different survival strategies to evade or adapt to the lysosome.

1.3.3.1

Escape to the cytosol

Bacteria such as B. pseudomallei (464), S. flexneri (359), L. monocytogenes
(372), and Rickettsia prowazekii (509) rapidly escape the nascent phagosome
and invade the cytosol, where the pH is relatively neutral, nutrients are plenteous,
and host cell defenses are less effective (428). Generally, this exit strategy is
environmentally triggered, but bacterially driven, caused by destabilization of the
phagosome membrane by bacterial gene products and/or permeabilization via
pores and enzymes (377). Once in the cytosol, these bacteria can replicate, and,
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by polymerizing eukaryotic actin, form comet tails to aid in intracellular and
intercellular locomotion (377). Bacterial actin-based motility (ABM) can force
membrane protrusions into neighbouring cells, leading to the engulfment of the
bacteria into a double-membrane vacuole in a process termed paracytophagy;
rapid ABM facilitates evasion of host immune responses within the cell, as well as
facilitating intercellular spread without exposure to the extracellular milieu (463).

1.3.3.2

Arrest of phagosomal maturation

Some bacteria, such as Mycobacterium tuberculosis (162), and S. enterica
serovar Typhimurium (28), arrest the maturation of the phagosome, rendering the
environment more hospitable for bacterial growth. M. tuberculosis-containing
vacuoles maintain an early-endosome-like environment, preventing the transition
to late phagosome by retaining the Rab5 GTPase while excluding EEA1 and
Rab7 (162). The lipoglycan mannose-capped lipoarabinomannan can also affect
vacuole dynamics (438). In contrast, S. Typhimurium halts phagosome
maturation at a later stage through the action of T3-secreted effectors; though the
lumen acidifies and acquires late endosomal markers Rab7 and LAMP1, the
Salmonella-containing vacuole (SCV) does not accumulate mature hydrolases,
nor does it fuse with lysosomes (27). Although a multiplicity of effectors are likely
involved in SCV trafficking, a T3-secreted phosphoinositide phosphatase reduces
the negative charge on the phagosomal membrane, which affects the trafficking
of endocytic proteins and prevents lysosomal fusion (28). Thus, by arresting
phagosomal maturation, Mycobacterium spp. and Salmonella spp. are spared
the full microbicidal effects of the lysosome.

1.3.3.3

Diversion from the endosomal pathway

While some bacteria modify the phagocytic vacuole such that it is no longer
recognized as part of the endosomal pathway, others manipulate the host cell
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and take up residence in an existing organelle such as the endoplasmic reticulum
(ER). Following phagocytosis, Legionella pneumophila persists within a vacuole
that transiently recruits mitochondria, followed by ER exit vesicles; eventually, the
Legionella-containing vacuole (LCV) takes on the character of the rough ER,
suitable for bacterial replication (211). Successful remodeling of the LCV
requires T4-mediated secretion of a multitude of effectors affecting host signaling,
membrane trafficking, and protein synthesis (182). The Brucella abortuscontaining vacuole (BCV) acquires early endosomal markers EEA1 and Rab5,
acidifies, and acquires LAMP1, but not Rab7, thus avoiding lysosomal fusion;
similar to the LCV, the BCV interacts with ER exit vesicles in a T4SS-dependent
manner, acquiring characteristics of the ER permissive to bacterial replication
(364). Chlamydia trachomatis produces proteins that insert into the nascent
phagosomal membrane, interacting with Rab proteins to direct intracellular
trafficking (68); C. trachomatis induces Golgi fragmentation, forming Golgi
ministacks that accumulate around the vacuole to promote sphingolipid
acquisition and bacterial replication (192).

1.3.3.4 Delay of phagosomal maturation for adaptation to the
phagolysosome
Finally, some organisms, including Coxiella burnetti (507) and Leishmania
donovani (273), delay the maturation of the phagosome while evolving to a form
suitable for survival and replication within an acidic environment. Previous work
in our laboratory has examined the maturation of the B. cenocepacia-containing
vacuole (BcCV) in the presence of metabolically-active bacteria, demonstrating
rapid association with the early endosome, followed by prolonged absence of
phagosomal markers, then eventual fusion with the late endosome and lysosome
(252); bacterial replication has been noted 24h p.i. (185). In other organisms,
mechanisms of delay are thought to include regulation of surface
glycoconjugants, release of effectors through a secretion system, and blebbing of
outer membrane vesicles (OMV). Though not a bacterium, L. donovani delay of
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phagosomal maturation has been well characterized. L. donovani employs
lipophosphoglycan (LPG) to alter lipid microdomains in the phagosomal
membrane, inhibiting fusion with late endocytic organelles (124, 125); LPG also
prevents assembly of a functional NADPH oxidase complex on the phagosomal
surface (274). In the presence of LPG, the L. donovani-containing vacuole retains
RhoGTPase Cdc42, causing an accumulation of periphagosomal F-actin (272).
Assembly of an F-actin coat delays phagosomal maturation by physically
preventing vesicle docking; this association is transient, as F-actin is not found on
mature phagolysosomes (267). C. burnetii is the only true bacterium known to
delay phagolysosomal fusion as a prelude to replication in an acidified,
proteolytically-active environment (205). Early, transient interactions with the
autophagy pathway have been postulated to contribute to C. burnetii delay of
phagosomal maturation (388). During early stages of infection, C. burnetii
upregulates expression of a T4SS (332) capable of translocating effectors into
the host (76); many effectors contain eukaryotic-like domains capable of
modifying host proteins and modulating signalling pathways (76). Although L.
pneumophila employs multiple strategies for intracellular survival, the bacterium
has been shown to delay autophagosomal maturation (221); it is thought that this
delay involves developmental regulation and shedding of LPS (430) and the
release of OMV (151), though modulation of phagosomal membrane composition
(436) and host trafficking via T4-secreted effectors (142, 528) are also likely.

1.3.4

The immune response

Ligand binding to PRRs initiates the immune response by activating a signalling
cascade, leading to gene expression, biosynthesis, and secretion of inflammatory
mediators, including cytokines and chemokines. In particular, bacterial ligands
binding to TLRs activate type I interferons (IFN) and/or transcription factor NF-B
(165), which controls expression of a wide variety of genes involved in the
immune response, including cytokines TNF-, IL-6, IL-8, and IL-2 (33).
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Membrane-associated receptors, both surface and endosomal, are
complemented by a family of cytosolic PRRs, deemed NOD-like (NLRs), which
detect microbial products present in the cytosol following effector injection or
escape from the phagosome (127). NLRs form a critical component of the
inflammasome, a complex containing a NOD-like receptor linked to pro-caspase1 by an adaptor protein; signalling through the NLR results in cleavage of procaspase-1 to the active form (127). Cross-talk between membrane-associated
and cytosolic signalling systems is seen in the activation of IL-1; TLR-mediated
NF-B activation produces pro-IL-1, which is cleaved to form active IL-1 by
NLR-activated caspase-1 (226). Caspase-1 also promotes maturation of other
cytokines, including IL-18, and IL-33, an inducer of IL-4, IL-5, and IL-13 (165);
caspase 1 also contributes to unconventional protein secretion and pyroptosis
(251). Since potential host responses to infection include oxidative stress,
inflammasome activation, autophagy, apoptosis, pyroptosis, and necrosis, host
survival depends on both control of the infection and activation of a protective
response, including downregulation of sensory receptors and induction of stress
response mechanisms (364).

1.3.4.1

Pathogen response to inflammation

Controlling or evading the host immune response is essential to the survival of
intracellular pathogens. Some bacteria have modified forms of TLR ligands,
thereby preventing activation of the immune response; Campylobacter jejuni,
Helicobacter pylori, and Bartonella bacilliformus all produce flagellin that is not
recognized by TLR5 (17). Other bacteria exploit TLR2 signalling to induce
immunosuppression: M. tuberculosis produces a lipoprotein that persistently
activates TLR2, thus inhibiting IFN- production (160), whereas Yersinia spp.
secrete V antigen to stimulate production of IL-10, and resultant suppression of
IFN- and TNF (441). Inflammasome activation can be inhibited by microbial
products, including M. tuberculosis zinc metalloprotease Zmp1 (315), and P.
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aeruginosa T3-secreted exoenzymes ExoU (471) and ExoS (169). Yersinia spp.
also produce a range of T3-secreted effectors that can interfere with the immune
response; YopP and YopJ prevent activation of NF-B (394, 540), while YopE
and YopT inactivate Rac1, causing inhibition of caspase-1 activation and IL-1
secretion (424), and YopK prevents NLR recognition of the T3SS, thus
preventing inflammasome activation (61). L. pneumophila manipulates
expression of the inflammasome adaptor ASC (3), thereby downregulating
inflammasome activation; ASC is also able to modulate expression of NF-B
(462). L. pneumophila also inhibits host protein synthesis via T4-secreted
effectors, causing prolonged activation of NF-B due to decreased synthesis of
inhibitor IB (159). Chlamydia spp. produce a protease which degrades a
subunit of NF-B (248), thereby reducing host sensitivity to proinflammatory
stimuli (85).

1.3.5

Cell death

The three principal mechanisms of host cell death are apoptosis, necrosis, and
pyroptosis, which differ in initiation and outcome; under certain conditions,
autophagy can also lead to cell death. Apoptosis is an immunologically silent
form of programmed cell death characterized by chromosome fragmentation and
nuclear condensation, cytoplasmic shrinkage, plasma membrane blebbing, and
eventual cell dispersion in membrane-bound fragments known as apoptotic
bodies with exposed phosphatidylserine residues (355). Apoptosis may be
induced by both intrinsic and extrinsic pathways, the former caused by the
release of pro-apoptotic proteins from the mitochondria, and the latter involving
ligand binding to cell surface-associated death receptors; both pathways activate
a caspase-signalling cascade, ultimately leading to the activation of executioner
caspase 3, which cleaves cellular substrates and induces apoptosis (250).
Release of pro-apoptotic proteins through the mitochondrial outer membrane
occurs through the Mitochondrial Apoptosis-induced Channel, and is regulated by
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the Bcl-2 family of proteins; the Bcl-2 family includes anti-apoptotic effectors such
as Bcl-2, pro-apoptotic effectors such as Bax, Bak, and Bim, and pro-apoptotic
BH3-only sentinels such as Bad (121).
Necrosis is a caspase-independent mode of cell death characterized by
increased cell volume and permeability, but uncondensed DNA content; necrosis
is also characterized by an oxidative burst, mitochondrial hyperpolarization, and
lysosomal membrane permeabilization, releasing hydrolytic enzymes (44). Due
to membrane permeabilization, necrotic cells spill intracellular contents into the
extracellular milieu, triggering a significant inflammatory response and tissue
damage (250). Though originally considered an accidental form of death due to
severe cellular insult, necrosis can be regulated by ligand-bound death receptors
in the absence of caspase activation; such a mechanism, employing the RIP1
kinase, is termed necroptosis (494).
Pyroptosis is a form of programmed cell death initiated by excessive
inflammasome activation, and thus typically induced by infection (54). Pyroptosis
is characterized by cellular DNA damage, cell lysis, and inflammatory cytokine
release; activation of caspase-1 causes membrane perturbations and an influx of
extracellular calcium, leading to lysosome exocytosis (45). Pyroptosis is highly
inflammatory, due to the release of inflammatory cytokines, antimicrobial
lysosomal contents, and potentially degraded microbial products suitable for
presentation as antigens by neighbouring cells (45).
Though autophagy is typically a protective response to cellular starvation and
stress, when excessive, the process can result in cell death. The kinase mTOR
and ATG/Beclin proteins regulate autophagosome formation, resulting in the
engulfment of a portion of the cytoplasm into a double membrane-bound
organelle. The autophagosome, characterized by marker LC3-II, fuses with
lysosomes to degrade phagosomal contents, including damaged organelles or
intracellular bacteria (54). Autophagy can be induced by TLR ligands, and can
thus be used to control bacterial infections, including those that can alter the
classical phagosomal pathway (54). In comparison to necrosis and pyroptosis,
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by very nature, autophagy is an immunologically silent death process, similar to
apoptosis.

1.3.5.1

Bacterial influence on host cell death

Bacterial modulation of host cell death is common; intracellular pathogens seek
to inhibit host death to promote bacterial survival and replication, while other
pathogens evade macrophage-mediated killing by rapidly inducing host cell
death. Bacterial targetting of caspases, Bcl-2 family proteins, and survival
pathways (52) can inhibit cell death. Intracellular C. burnetii blocks apoptosis via
T4-secreted effector AnkG, which prevents cytochrome c release from
mitochondria (281, 282). C. burnetii also recruits anti-apoptotic Bcl-2 (498) and
activates prosurvival kinases Akt and Erk1/2 (508). T4SS effectors of L.
pneumophila are capable of specific interaction with and neutralization of
proapoptotic Bcl-2 family proteins (36), induction of NF-B nuclear translocation
(5), and upregulation of antiapoptotic genes (276). C. trachomatis prevents
apoptosis by degrading multiple pro-apoptotic BH3-only proteins (534), and
activating Akt, leading to sequestration of proapoptotic Bad (501).
Some pathogens may induce host cell death to eliminate host cells required to
mount an immune response. Clostridium septicum produces a pore-forming toxin which induces programmed necrosis (233), while H. pylori secretes a
protein which induces apoptosis by binding to the death receptor Fas (15).
Yersinia and Salmonella promote apoptosis in naïve macrophages by T3secreted effector inhibition of NF-B activation (422) (94); however, infection of
activated macrophages with the same bacteria results in pore formation in the
host membrane, calcium influx, and lysosome exocytosis in a caspase-1
dependent manner (45). Following escape from the phagosome, intracellular S.
flexneri induces pyroptosis in macrophages (544, 545) via a T3SS-secreted
effector IpaB that activates caspase-1 (193). L. monocytogenes induces
pyroptosis through the activation of multiple inflammasomes by bacterial ligands,
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including DNA (526); oddly, L. monocytogenes infection also causes metabolic
signalling which inhibits activation of caspase-1 (542), potentially balancing proand anti-pyroptotic effects in macrophage infection. L. pneumophila induces
apoptosis in a T4SS-dependent manner at late stages of infection (414);
however, Legionnaire’s disease is typically characterized by extensive
inflammation, and L. pneumophila can also induce pyroptosis (440), and necrotic
macrophage death, especially with high bacterial load (333). Intracellular
pathogens may induce cell death at the end of their replication cycle to facilitate
escape from the macrophage. In M. tuberculosis, induction of caspaseindependent necrosis occurs in response to a high bacterial burden (259, 518).
Similarly, Francisella tularensis, which escapes to the cytosol, prevents
inflammasome activation and modulates caspase-3 activity to inhibit apoptosis
until late stage infection (23, 415).
Bacteria have also developed strategies to counteract autophagy. M.
tuberculosis is able to non-specifically inhibit autophagy, which also inhibits
necrotic-like host cell death (437). VirG, an intracellular ABM protein produced
by S. flexneri binds Atg5 to induce autophagy; S. flexneri prevents induction of
the autophagy signalling cascade by T3-secretion of an effector to competitively
bind VirG (351). L. monocytogenes evades autophagy by recruiting host
cytoskeleton proteins to the bacterial surface via ABM protein ActA (537).
Conversely, Y. pseudotuberculosis activates autophagy, but prevents
acidification to survive and replicate within an autophagosome (330).

1.4 Identification of intracellular gene expression by
prokaryotic cells
While many studies have examined the transcriptional response of bacteria to in
vitro host-like conditions, true understanding of bacterial response to
internalization by macrophages requires analysis of global transcription by
intracellular bacteria. Such studies are inherently challenging, being hampered

51

by the quality and quantity of microbial mRNA compared to host RNA, especially
at a lower multiplicity of infection (MOI) and early time points p.i.. However, a
lower MOI is desirable for physiological relevance, and though pathogen
numbers are low and transcriptional changes often subtle, early time points p.i.
represent the greatest potential for therapeutic intervention (466). Typical
bacteria contain 0.05-0.10 pg of RNA, of which mRNA comprises only 4% and
has a half-life of mere minutes (246, 376). Because bacterial gene expression
can change rapidly, chemical disruption of the host cell and/or bacterial
purification from the cell is impractical; thus, total RNA from both host and
pathogen is extracted, from which bacterial mRNAs must be purified.

1.4.1

Bacterial mRNA purification and enrichment

In the last decade, a wide variety of strategies have been employed to separate
mixed populations of prokaryotic and eukaryotic transcripts in an infectious
context (246). Some enrichment strategies employ commercial kits to selectively
remove host ribosomal transcripts and polyadenylated eukaryotic mRNA; though
simple and relatively swift, such practices risk loss of pathogen RNA, particularly
small transcripts (466). Other strategies, including differential expression using
customized amplification libraries (DECAL) (13), coincidence cloning (CC) (26),
and selective capture of transcribed sequences (SCOTS) (180), rely on
purification of bacterial sequences from a pool of mixed eukaryotic and
prokaryotic cDNAs.
DECAL first requires construction of a customized amplification library (CAL)
containing size-fractionated genomic DNA lacking ribosomal sequences; each
library fragment is ligated to PCR adaptors, allowing total library amplification.
Total RNA from the infection system of interest is reverse-transcribed with
biotinylated primers; CAL fragments that hybridize to cDNA are retained with
streptavidin-coated magnetic beads, and can be PCR amplified for infectionproportional representation of prokaryotic-specific cDNA sequences (13).
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DECAL has been applied to analysis of the Borrelia burgdoferi transcriptome in
the central nervous system of infected non-human primates (341).
Coincidence cloning is a recent development wherein total cDNA from infected
tissue is hybridized with a great excess of bacterial genomic DNA, followed by
selective PCR amplification. RNA from the system of interest is reversetranscribed using nonanucleotides linked to a 5’ 25-nucleotide constant region
containing a restriction endonuclease site. Both genomic DNA and cDNA are
digested with the restriction endonuclease, and each pool is ligated to a separate
suppression adaptor. When the two pools are hybridized together, DNA
fragments unique to one set – eukaryotic sequences – can only self-hybridize,
forming homo-duplexes, while sequences common to both pools – presumably
prokaryotic – form hybrid duplexes. While hybrid duplexes can be PCRamplified, the matching 5’ adaptors in homo-duplexes cause PCR-selective
suppression. CC has been used with M. tuberculosis-infected murine lung tissue;
random sequencing of CC-selected amplicons showed 30% murine sequences
and 70% M. tuberculosis sequences, while pyrosequencing demonstrated greater
than 1000-fold increase in bacterial transcripts following a single round of CC
(26).
SCOTS shares features with both DECAL and CC. Transcripts isolated from the
system of interest are reverse-transcribed and double-stranded with random
nonanucleotides linked to a 5’ 25-nucleotide linker sequence containing a
restriction site. Microbial cDNAs can be positively selected by hybridization to
biotinylated bacterial genomic DNA fragments pre-blocked with ribosomal
sequences; hybrids retained via streptavidin-coated magnetic beads can be PCR
amplified with a linker-specific primer (180). Successive rounds of SCOTS
amplification can enrich low abundance transcripts. SCOTS can also be used to
create multiple libraries for a single species under different conditions or at
different infection time points, each library bearing a unique linker sequence. This
technique has been used to identify genes expressed by several intracellular
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pathogens, including M. tuberculosis (180), S. enterica serovar Typhi (109, 149),
E. coli O157:H7 (365), Ehrlichia ruminantium (140), and L. pneumophila (148).

1.4.2

Analysis of intracellular transcription

Following purification and amplification of the infectious prokaryotic
transcriptome, there are different methods available for transcript identification.
Several techniques, including SCOTS competitive enrichment (SCOTS-CE) (180)
and suppressive subtractive hybridization (128), allow isolation and enrichment of
sequences preferentially transcribed in vivo; this requires creation of a second
cDNA pool representing sequences transcribed in vitro. For SCOTS-CE, the
capturing chromosome is pre-blocked with both rDNA and an excess of cDNA
from non-macrophage-exposed bacteria, such that only infection-specific cDNAs
will be captured. By using different linkers for each cDNA pool, infection-specific
cDNAs can be selectively PCR-amplified. Restriction sites present in the linker
allow cDNA cloning into a vector for single-transcript analysis.
Practical global transcriptome analysis requires a high-throughput method.
Bacterial DNA microarrays hybridized to initial macrophage-infected cDNA show
few and faint signals; however, purification and amplification of prokaryoticspecific transcripts through one of the above methods produces cDNA probes
suitable for microarray analysis (149, 341). Recently, B. cenocepacia J2315
genomic microarrays have been developed, leading to an explosion in B.
cenocepacia transcriptomic research (133). More recently, high-throughput
massively parallel sequencing technologies have led to direct sequencing of
prokaryotic cDNA pools in a technique known as RNA-seq (43, 105), which has
been used to examine the intra-amoebae transcriptome of L. pneumophila (517);
despite removal of ribosomal sequences, of the total sequences from two broth
cultures and two infection time points, nearly half represented amoebae
transcripts. RNA-seq has been applied to in vitro investigation of B. cenocepacia
niche-specific gene expression (535). High-throughput pryosequencing has also
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been applied to the downstream analysis of the CC amplicon derived from M.
tuberculosis infecting murine lung tissue (26). Both DNA hybridization-based
microarrays and massively parallel next-generation sequencing present
advantages in the analysis of cDNA pools: Microarrays are low cost, and have
rapid multiple-sample throughput, low requirements for initial starting material,
and a well-established bioinformatic infrastructure (466); sequence-based
analyses are less subject to experimental design artefacts, and have digital rather
than analog signal quantitation, offering greater sensitivity and inter-platform
reproducibility (435).

1.5 Hypothesis and research objectives
The overall hypothesis of this work is that B. cenocepacia adapts to persist within
murine macrophages; this adaptation is a result of changing gene expression,
and may involve classical multi-gene secretion systems. The first hypothesis was
addressed by surveying intracellular transcription at a global level, and the
second by a reductionist approach involving the deletion of secretion systems to
examine individual and combined contributions to the intracellular behaviour of B.
cenocepacia.
The results of this work are divided into two separate sections. The first section
details the optimization of the SCOTS technique for B. cenocepacia, and its
subsequent application to B. cenocepacia-infected murine macrophages. Global
gene expression is described at an early post-infection stage in an attempt to
identify gene products involved in avoidance of macrophage microbicidal activity
and adaptive response to the phagosomal environment. The second section
describes the contribution of the T2SS, T3SS, T4SS-1, T4SS-2, and T6SS both
individually and collectively, in internalization by macrophages, intracellular
replication, and host-directed cytotoxicity.
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Chapter 2

2

Materials and Methods

2.1 Bacterial strains, plasmids, media, and growth
conditions
Bacterial strains and plasmids used in this study are listed in Tables 1 and 2,
respectively. Bacteria were grown at 37oC in Luria-Bertani (LB; Difco) broth with
agitation or on LB plates with 1.6% Bacto agar. Escherichia coli cultures were
supplemented as required with 20 μg/ml tetracycline, 50 μg/ml trimethoprim, and
40 μg/ml kanamycin; B. cenocepacia cultures were supplemented as required
with 100 μg/ml tetracycline and 100 μg/ml trimethoprim. Plasmids were
conjugated into B. cenocepacia by triparental mating at 37oC using E. coli DH5α
carrying helper plasmid pRK2013 (153). E. coli donor and helper strains were
selected against with 50 μg/ml gentamicin or 100 μg/ml ampicillin and 25 μg/ml
polymyxin B. To determine growth rates of parental and mutant strains of B.
cenocepacia, overnight cultures were inoculated into fresh medium at a starting
optical density at 600 nm (OD 600 ) of 0.01. Growth rates with high-amplitude
shaking were determined in 100-well microtiter plates via Bioscreen C automated
microbiology growth curve analysis system (MTX Lab Systems).

2.2 General molecular techniques
DNA manipulations were performed as in (413). DNA was amplified by PCR
using a PTC-221 DNA engine (MJ Research) with Taq DNA polymerase or
HotStar DNA polymerase (Qiagen). Amplification of B. cenocepacia DNA was
aided by the inclusion of Qiagen Q solution. DNA sequencing was performed at
the York University Core Molecular Biology and DNA Sequencing Facility in
Toronto, Ontario, Canada. Sequence analysis was done by BLAST. Restriction
enzymes, T4 DNA ligase (Roche Diagnostics) and Antarctic alkaline
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Table 1: Bacterial strains and cell lines
Strain or
Relevant characteristics
cell line
Escherichia coli
F-, f80 lacZ DM15 D(lacZYA-argF) U169 endA1
recA1 hsdR17 (r K - m K +) supE44 thi-1 DgyrA96
DH5α
relA1
SY327
araD D(lac pro) argE(Am) recA56 rifr nalA, l pir
Burkholderia cenocepacia
J2315
epidemic strain ET12 clone, CF clinical isolate
K56-2
epidemic strain ET12 clone, CF clinical isolate
MH1K
K56-2 ∆BCAL1674-6
JST19
MH1K ∆BCAL0124
JST71
MH1K ∆BCAS0186
JST75
MH1K ∆BCAM2837
JST128
MH1K ∆BCAL1726
JST130
MH1K ∆BCAM0276
JST132
MH1K ∆BCAM0411
JST134
MH1K ∆BCAM2446
JST136
MH1K ∆BCAM0434-5
JST190
MH1K ∆BCAL0340
JST194
MH1K ∆BCAM1679
JST89
K56-2 ∆T2SS ∆BCAL1674-6
JST40
MH1K ∆T3SS
JST17
K56-2 ∆T4SS-1 ∆BCAL1674-6
JST39
MH1K ∆T4SS-2
JST53
K56-2 ∆T6SS ∆BCAL1674-6
JST112
K56-2 ∆T2SS ∆T3SS ∆T4SS-1 ∆T4SS-2 ∆T6SS
∆BCAL1674-6
JST178
MH1K ∆BCAL3516
JST182
MH1K ∆pBCA025
JST184
MH1K ∆BCAM0333
JST162
K56-2 ∆BCAL0343 ∆BCAL1674-6
Macrophage cell lines
C57BL/6 murine bone marrow-derived
ANA-1
macrophage cell line
RAW 264.7 BALB/c murine macrophage cell line
a
b

Source or
reference
Laboratory
stock
(328)
P.A. Sokol
BCRRCa
(185)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

(103)
ATCCb

B. cepacia complex Research and Referral Repository for Canadian CF Clinics
American Type Culture Collection
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Table 2: Plasmids
Plasmid

Relevant characteristics

pRK2013
pUC19
pJT25
pGPI-SceI
pDAI-SceI
-SacBN
pDA12
pDA42
pJT31
pJT41
pJT42
pJT45
pJT46
pJT47
pJT48
pJT49
pDelbcsM
pJT72
pMH306
pJT43
pJT30

RK2 derivative, KanR, mob+, tra+, ori colE1
ori pMB1 , ApR, mob+, P lac
pUC19 with K56-2 rDNA (23S, 16S, 5S), ApR
ori R6K , TpR, mob+, carries I-SceI cut site
ori pBBR1 , TetR, mob+, P dhfr , sacB, encodes I-SceI
endonuclease
ori pBBR1 , TetR, mob+, P dhfr
pDA12, eGFP
pGPI-SceI with regions flanking BCAL0124
pGPI-SceI with regions flanking BCAS0186
pGPI-SceI with regions flanking BCAM2837
pGPI-SceI with regions flanking BCAL1726
pGPI-SceI with regions flanking BCAM0276
pGPI-SceI with regions flanking BCAM0411
pGPI-SceI with regions flanking BCAM2446
pGPI-SceI with regions flanking BCAM0434-5
pGPI-SceI with regions flanking BCAL0340
pGPI-SceI with regions flanking BCAM1679
pGPI-SceI with regions flanking gspDEF (T2SS)
pGPI-SceI with regions flanking T3SS (BCAM2040-57)
pGPI-SceI with regions flanking T4SS-1 (pBCA017-59)
pGPI-SceI with regions flanking T4SS-2 (BCAM032435)
pGPI-SceI with regions flanking T6SS (BCAL0333-52)
pGPI-SceI with regions flanking BCAL3516
pGPI-SceI with regions flanking pBCAL025
pGPI-SceI with regions flanking BCAM0333
pGPI-SceI with regions flanking BCAL1674-6
pDA12, BCAL0124
pDA12, BCAL0340
pDA12, BCAL1726
pDA12, BCAM0411
pDA12, BCAL3516
pDA12, BCAM0333
pDA12, pBCA025
pDA12, BCAL0343

pJT44
pDelT6SS
pJT59
pJT61
pJT62
pMH304
pJT57
pJT71
pJT52
pJT54
pJT62
pJT67
pJT69
pHcp

Source or
reference
(153)
(532)
This study
(156)
(185)
(25)
(25)
This study
This study
This study
This study
This study
This study
This study
This study
(24)
This study
M. Hamad
This study
This study
This study
(24)
This study
This study
This study
(185)
This study
This study
This study
This study
This study
This study
This study
(25)
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phosphatase (New England Biolabs) were used as recommended by
manufacturers. Transformation of E. coli SY327 and DH5α was done by the
calcium chloride protocol (93).

2.3 Cell culture and infection
Macrophage cell lines listed in Table 1 were maintained in Dulbecco's modified
Eagle medium (DMEM; Wisent) supplemented with 10% fetal bovine serum
(FBS; Wisent) at 37oC in a 95% humidified atmosphere with 5% CO 2 . For
macrophage infection, cells were seeded in a 12-well plate at 1.25 x 105 cells per
well or a 6-well plate at 2.5 x 105 cells per well and grown 15 h. Bacterial cultures
grown at 37oC for 16 h were washed twice and resuspended in DMEM-10% FBS.
Macrophage monolayers were washed with phosphate-buffered saline (PBS;
Wisent). Bacteria were added at a multiplicity of infection (MOI) of 50:1 or 10:1 in
1-2 ml DMEM-10% FBS. Plates were centrifuged 1 min at 300 x g and incubated
at 37oC, 95% humidity and 5% CO 2 .

2.4 RNA extraction, cDNA synthesis, and amplification
RNA was extracted from two 6-well plates containing equal numbers of B.
cenocepacia, differing only in the presence (intracellular (I) RNA) or absence
(non-macrophage-exposed (NME) RNA) of macrophages. At 4 h post-infection,
macrophage monolayers were washed three times with PBS and lysed in 1 ml
cold deionized H 2 O. NME cells were resuspended and collected. For each
condition, cells from 6 wells were resuspended in 1 mg/ml lysozyme (Roche).
Total RNA was extracted using TRIzol (Invitrogen) and treated with RNase-free
DNase (Roche) according to the manufacturer's instructions. RNA purity,
integrity, and concentration were determined by PCR, agarose gel
electrophoresis, and A 260 /A 280 spectrophotometer readings, respectively. A 5 μg
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RNA sample from each condition (“intracellular” and “NME”) was converted to
first-strand cDNA by random priming with Transcriptor reverse transcriptase
(Roche) according to the manufacturer's specifications. Primers had a defined 5'
terminal sequence and a 3' random nonamer; different terminal sequences were
used for intracellular (I-3025) and NME RNA (N-3017) (Table 3). cDNAs were
double-stranded using Klenow fragment (Roche) as described in (164); cDNA
libraries were amplified for 25 cycles using defined primers I-3032 (intracellular)
or N-3033 (NME).

2.5 Selective capture of transcribed sequences
The SCOTS protocol was carried out as described (110). In brief, 0.3 μg of
denatured, sonicated, biotinylated B. cenocepacia K56-2 chromosome were
mixed with 5 μg denatured ribosomal DNA fragments (sonicated pJT25; Table 2)
and hybridized 30 min at 68oC to pre-block rRNA-encoding DNA regions. 3 μg of
cDNA were denatured and re-annealed 30 min at 68oC to remove abundant
transcripts. cDNA and chromosomal DNA were combined and hybridized 24 h at
68oC. Chromosome-cDNA hybrids were removed from solution with streptavidincoated magnetic beads (Invitrogen). Captured cDNA was eluted, precipitated,
and amplified using library-specific defined primers (Table 3). For each condition,
10 parallel first-round reactions were done to maximize the cDNA sample
diversity; the resultant cDNA was pooled for each condition and two subsequent
rounds of SCOTS carried out. The final cDNA libraries were used both for
competitive enrichment hybridization and as probes for B. cenocepacia
microarrays. A detailed protocol may be found in Appendix 2.
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Table 3: Oligonucleotide primers
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62

63

a

Restriction endonuclease sites incorporated into the oligonucleotide sequences
are underlined
b
N/A indicates the absence of a restriction site
c
native ClaI site in chromosome
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2.6 Competitive enrichment
To preferentially enrich for phagosomally-expressed or -upregulated transcripts,
0.3 μg of B. cenocepacia K56-2 chromosome was pre-blocked with both 5 μg
rDNA and 10 μg of denatured triple-SCOTS enriched NME cDNA (above). 3 μg
of triple-SCOTS enriched intracellular cDNA (above) was denatured and reannealed 30 min at 68oC to remove abundant transcripts. cDNA and blocked
chromosomal DNA were combined and hybridized 18 h at 68oC. ChromosomecDNA hybrids were removed from solution with streptavidin-coated magnetic
beads. Captured cDNA was eluted, precipitated, and amplified using intracellular
library-specific defined primer I-3032. Following three rounds of enrichment,
cDNA were digested with restriction enzyme XbaI, cloned into XbaI-digested,
dephosphorylated pUC19, and transformed into E. coli DH5α. Individual cDNA
inserts were screened by Southern blot for hybridization to DIG-labelled cDNA
libraries. cDNA which hybridized to intracellular cDNA, but not to NME cDNA,
were sequenced and identified by BLAST analysis.

2.7 Microarray experimental design and analysis
SCOTS cDNA or B. cenocepacia J2315 genomic DNA was labelled with
CyScribe™ Array CGH Labeling Kit (GE Healthcare) according to the
manufacturer's protocols. SCOTS cDNA was labelled with Cy5 and genomic
DNA with Cy3; cDNA samples were mixed, hybridized to custom B. cenocepacia
microarrays (Agilent) according to the Agilent 60-mer oligonucleotide microarray
processing protocol, and scanned. Labelling of cDNA, hybridization, and
scanning of arrays were performed by the Mahenthiralingam Laboratory, Cardiff
University, Wales.
Microarray data analysis was done using GeneSpring GX 7.3.1 (Agilent). Raw
data was preprocessed via the enhanced Agilent FE import prior to per-spot and
per-chip normalizations for each array. Feature intensity varied across the six
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arrays. Genes were selected as “expressed” at a threshold of 1.0 relative to
genomic DNA. Statistical analysis between intracellular and non-macrophageexposed conditions was performed using a paired Student’s t-test; genes were
considered differentially expressed at an I:NME ratio of 2-fold with a p < 0.05.
The microarray dataset has been deposited in the ArrayExpress database
(http://www.ebi.ac.uk/arrayexpress/) under accession number E-MEXP-3408.

2.8 Quantitative reverse transcriptase PCR (qRT-PCR)
To validate microarray data, five genes with altered expression (4 upregulated:
BCAM0314, BCAM2141, BCAM0276, and BCAS0186; and 1 downregulated:
BCAM1928) were examined individually using qPCR. Sigma factor gene rpoD
(BCAM0918) was used as a reference gene. Oligonucleotide primers for each
gene (Table 3) were designed with Primer3 (393). Total RNA was isolated as
described above. cDNA was synthesized using random hexamers (Invitrogen)
and Transcriptor reverse transcriptase. Quantitation and melting curve analyses
for qPCR were performed using the Rotor Gene 6000 (Corbett Life Science) with
FastStart SYBR Green (Roche) according to the manufacturer's instructions.
Expression of the target gene was normalized to the reference gene for each
condition, allowing inter-condition comparison. Data shown are representative of
at least two independent experiments.

2.9 Mutagenesis of B. cenocepacia K56-2
The I-SceI homing endonuclease system was used for all deletions of genes or
gene clusters in B. cenocepacia K56-2 (156, 185). In brief, regions flanking the
gene or region to be deleted were amplified with gene-specific primers containing
restriction sites (Table 3). Upstream amplicons were digested with restriction
enzymes XbaI-ClaI; downstream amplicons were digested with ClaI-EcoRI. Both
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upstream and downstream amplicons were cloned into XbaI-EcoRI digested, dephosphorylated pGPI-SceI, giving rise to mutagenesis plasmids (Table 2).
Mutagenesis plasmids were introduced to either B. cenocepacia K56-2 or MH1K
by triparental mating. A plasmid - pDAI-SceI-SacBN – carrying the homing
endonuclease was conjugated into single crossover mutants, causing a doublestrand break resolved by either a second crossover, yielding mutant genotype, or
by reversion to wild-type. Exconjugants were screened by PCR, and confirmed
mutants were plated on LB with 5% sucrose to cure pDAI-SceI-SacBN. For the
T2SS, T4SS-1, and T6SS, deletions were made in K56-2, followed by deletion of
BCAL1674-6 to confer gentamicin sensitivity. For the T3SS and T4SS-2,
deletions were made directly in MH1K. For JST112 (Table 1), lacking all
secretion systems, deletions were performed sequentially. PCR and Southern
blot hybridization confirmed that the deletion had occurred, yielding gentamicinsensitive mutants (Table 1). In the same manner, single gene deletions in MH1K
were made in the T2SS (BCAL3516), T4SS-1 (pBCA025), T4SS-2 (BCAM0333),
and T6SS (BCAL0343), as well as SCOTS-identified genes BCAL0124,
BCAL0340, BCAM1679, BCAS0186, BCAM2837, BCAL1726, BCAM0276,
BCAM0411, BCAM2446, and BCAM0434-5.

2.10 Complementation experiments
To complement single gene deletions, wild-type genes were PCR amplified from
B. cenocepacia K56-2 with gene-specific primers (Table 3) and the following
thermal cycling conditions: 95oC for 5 minutes, 30 cycles of 95oC for 45s, 60oC
for 45s, and 72oC for 90s, and a final extension at 72oC for 10 min. The resulting
amplicon was digested with restriction enzymes XbaI and NdeI, and ligated into
similarly-digested, dephosphorylated pDA12, giving rise to a complementation
plasmid (Table 2) which could be introduced to the mutant strain through
conjugation. pDA12 was used as a vector control in all experiments.
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2.11 Motility plate assays
Swimming and swarming motility were assessed by the appearance of rings of
growth away from the site of inoculation on specialized agar plates; motility was
quantified by measuring the diameter (in mm) of the bacterial growth. Swimming
motility was determined following stab inoculation of LB plates with 0.3% agar.
Swarming motility was determined following drop inoculation onto nutrient broth
plates with 0.2% glucose and 0.5% agar.

2.12 Exoenzyme secretion assays
Secretion of protease, lipase, and phospholipase C (PLC) was measured via
plate assays. Protease secretion was measured as a zone of clearing on
dialyzed brain-heart infusion agar with 1.5% skim milk (448). Lipase secretion
was measured as the width of the insoluble precipitate halo formed upon
inoculation of Tween 80 agar (82). PLC activity was measured as the zone of
clearing on LB plates containing one hen egg yolk per 100 mL (227); egg yolk
plates also show activity of lipase and lecithinase, the former by the appearance
of an iridescent sheen on the surface of the bacterial growth, and the latter by the
production of an insoluble opaque precipitate surrounding bacterial growth.

2.13 Lipopolysaccharide analysis
LPS was extracted as described previously (307, 309). Briefly, bacteria were
resuspended in PBS, and boiled for 10 min in lysis buffer containing 2% sodium
dodecyl sulfate (SDS), 4% -mercaptoethanol, 10% glycerol, and 1M Tris (pH
6.8). The lysate was treated with proteinase K at 60oC for 12h, and stored at 20oC. LPS was separated on a 14% polyacrylamide gel using Tricine-SDS buffer
and silver-stained as described previously (309).
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2.14 Gentamicin protection assays
30 min post-infection, B. cenocepacia-infected cells were washed three times
with PBS and DMEM-50 μg/ml gentamicin was added to kill extracellular bacteria.
After 30 min, the media was replaced with DMEM-10 μg/ml gentamicin. Infected
monolayers were washed with PBS, and lysed with 0.1% Triton X-100 (Sigma) in
PBS at 1 and 24 h post-infection. Surviving bacteria were enumerated by
bacterial plate count (CFU). Bacterial entry was calculated as a percentage of
initial inoculum. Intracellular replication was calculated as a percentage of
bacterial entry for each strain. To compare between experiments, percentage
recovery was normalized against the parental control, set as 100% entry and
replication.

2.15 Flow cytometry
B. cenocepacia expressing eGFP from the plasmid pDA42 (25) were infected as
above in 12-well plates at a multiplicity of 50:1. At 2 h post-infection cells were
washed three times with PBS and DMEM-50 µg/ml gentamicin was added to kill
extracellular bacteria. After 30 min, the media was replaced with DMEM with and
without 10 μg/ml gentamicin. Infected monolayers were washed with PBS, and
removed with cold 0.04% EDTA in PBS at 24 h post-infection. Cells maintained
in media with gentamicin represented initial infection, while cells maintained in
antibiotic-free media represented uncontrolled infection. Macrophages were
collected by centrifugation for 5 min at 400 x g and 4oC . Cells were resuspended
in cold PBS with 2.5 µg/mL 7-aminoactinomycin D (7AAD; Invitrogen) and
maintained on ice. Samples were enumerated using a FACSCalibur with
CellQuest Pro acquisition software (Becton Dickinson). Data analysis was done
via FlowJo (Tree Star, Inc.). All results were normalized against uninfected
controls.
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2.16 Fluorescence microscopy
The B. cenocepacia-containing vacuole (BcCV) in macrophages was
characterized 24 h post-infection. Macrophages were infected with B.
cenocepacia MHK1 at a moi of 50:1; 2h post-infection, extracellular bacteria were
killed as above, and the infection maintained in DMEM-10 μg/ml gentamicin.
Labelling of the endocytic pathway, including lysosomes, was done using 250
g/ml tetramethylrhodamine-dextran (TMR-dextran; Invitrogen). To label
lysosomes, macrophages were pulsed with TMR-dextran for 2 h, followed by a 1
h chase in dextran-free media prior to bacterial infection. To label the endocytic
pathway, 21 h post-infection, macrophages were pulsed with TMR-dextran for 2
h, followed by a 1 h chase in dextran-free media. Acidic compartments were
labelled with 0.5 M Lysotracker Red (Invitrogen) for 30 s prior to visualization.
Live images were acquired using a Qimaging cooled charged-coupled device
camera (Burnaby) on an Axioscope 2 (Carl Zeiss) microscope with a 100x oil
immersion objective and a 50W mercury arc lamp. Images were digitally
processed using Northern Eclipse imaging software (Empix Imaging).
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Chapter 3

3

Global changes in gene expression by the opportunistic
pathogen B. cenocepacia in response to internalization
by murine macrophages

3.1 Construction of SCOTS components for B. cenocepacia
Application of the SCOTS technique to any system requires the creation of two
organism-specific elements: The first is a library of biotinylated bacterial
chromosome fragments with ribosomal blocking sequences; the second is a
cDNA library containing the transcripts of interest, where both ends of each cDNA
contain a 25-nt defined “linker” sequence not found within the bacterial
chromosome.
B. cenocepacia J2315 encodes four complete rRNA operons on the first
chromosome, and one on each of the second and third chromosomes; all six
operons are 99-100% identical (195). The 16S rRNA gene, and 23S/5S rRNA
genes were each amplified from the final operon on chromosome 1, which does
not contain any tRNA sequences. All genes were cloned into pUC19, a high-copy
number plasmid, to form pJT25 (Figure 1A), the source of ribosomal blocking
sequences. Chromosomal DNA extracted from B. cenocepacia K56-2 was
biotinylated (Figure 1B) and sonicated together with an excess of pJT25 to form
the chromosomal library (Figure 1E).
Two linker primers were created, each containing a different restriction site (Table
3). When added to a random nonamer, the linker primer can be used for both
single-strand cDNA synthesis and double-stranding to create a pool of cDNAs
with the linker sequence at both ends; this allows the entire cDNA pool to be
amplified with a single primer (Figure 1E). Neither linker primer binds to the K562 chromosome, as PCR amplification occurs only in the presence of linkered
cDNA.
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Figure 1. SCOTS components for B. cenocepacia.
(A) Ribosomal blocking plasmid pJT25. (B) Biotinylated B. cenocepacia
chromosome. Biotinylated (2) and unbiotinylated (1) K56-2 chromosome
were electrophoresed, and the gel stained with IRDye800 streptavidin
(right), labeling biotinylated DNA, followed by ethidium bromide (left),
labeling all DNA. (C) RNA isolated from K56-2 shown pre- (1) and post- (2)
DNase treatment. (D) DNase treatment is effective, as neither bacterial nor
eukaryotic sequences can be PCR-amplified from RNA template. 1 – IRNA, 2 – NME-RNA, 3 – K56-2 DNA, 4 – macrophage cDNA. (E)
Complete B. cenocepacia chromosomal library fragments (1) and cDNA
libraries from intracellular (2) and NME (3) B. cenocepacia. L – GeneRuler
Ladder mix.
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3.2 Optimization of the SCOTS protocol for B. cenocepacia
The SCOTS protocol is complex, with no readout of functionality until the final
screening step. Thus, a simple artificial system was created to test the individual
steps of the protocol, including capture of cDNA with biotinylated chromosomal
fragments, cDNA amplification with a linker primer, and blocking the capture of
duplicate sequences during competitive enrichment. We created this artifical
system using three test genes of different sizes: 500bp BCAL2831 (T1), 700bp
mgtC (T2), and 900bp arnA1 (T3), all easily separated and visualized by simple
gel electrophoresis. All three genes were amplified with linker sequence 2 (N) at
either end; the first two genes were also amplified with linker sequence 1 (I) at
either end (Figure 2). These artificial cDNA constructs enabled testing and
optimization of every aspect of the B. cenocepacia-specific SCOTS protocol in
five separate tests; cDNA captured from each test library was divided in half and
amplified separately with each linker primer (I or N) (Table 3). Sonicated herring
sperm DNA was used to represent eukaryotic sequences, to which the test genes
were added in known quantities to form the test cDNA libraries (L1-L5). L1
contained only genes I1 and I2, while L2 contained N1, N2, and N3; these two
libraries tested the capture of bacterial sequences and the specificity of linker
primer amplification. L3 contained the five test genes, but capture was carried
out in the absence of biotinylated library fragments to ascertain the necessity of
hybridization for cDNA capture. The fourth test pre-hybridized a ten-fold excess
of L2 to the chromosome prior to the capture of L1 to examine the efficacy of
blocking during competitive enrichment; in a successful test, pre-hybridization of
L2 would prevent the capture of L1. The fifth test pre-hybridized a ten-fold
excess of T1-N and T3-N to the chromosome prior to capture of L1; in this case,
successful competitive enrichment would prevent binding of T1-I while capturing
T2-I.
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Figure 2. An artificial system to optimize SCOTS for B. cenocepacia
Test genes (A) can be clearly distinguished by size via gel electrophoresis
(B). (C-E) Optimization of SCOTS conditions. (C) Expected results. (D)
Pre-hybridization effectively removes abundant sequences. (E) Genes can
be effectively captured and amplified, but blocking sequences are
insufficient. (F) 100x NME genes are required to effectively prevent
capture of I genes.
Legend: L – GeneRuler Ladder mix
PCR amplification with I linker primer (A) or N linker primer (B)
1 – Capture of I2 and I3 ; 2 – Capture of N1, N2, and N3
3 – Capture of all five genes in the absence of biotinylated chromosome
4 – Capture of I2 and I3 following pre-hybridization with 10x N1, N2, and N3
5 – Capture of I2 and I3 following pre-hybridization with 10x N1 and N3
6 – Capture of I2 and I3 following pre-hybridization with 100x N1, N2, and N3
7 – Capture of I2 and I3 following pre-hybridization with 100x N1 and N3
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The initial experiment revealed the efficacy of the pre-hybridization step to
remove abundant transcripts (Appendix 2), as only cDNA hybridized to the
chromosome immediately following denaturation could be amplified (Figure 2D).
After eliminating pre-hybridization of the cDNA pools, the second experiment
demonstrated successful capture in the presence of biotinylated bacterial
chromosome fragments and linker-specific amplification of cDNA; however,
blocking for competitive enrichment was ineffective (Figure 2E). Successive
experiments demonstrated successful competitive enrichment by decreasing the
hybridization temperature, and increasing both the duration of pre-hybridization
with blocking sequences and the quantity of blocking sequences (Figure 2F).

3.3 Preliminary applications of SCOTS: Transcriptional
changes during growth in sub-inhibitory concentrations
of tetracycline
Sub-inhibitory concentrations of tetracycline modulate outer membrane protein
expression in B. cenocepacia J2315, implying changes in gene transcription
(295); SCOTS and CE were applied to identify these transcriptional changes
while optimizing later steps in the SCOTS-CE protocol. cDNA from J2315 grown
to log phase in LB with and without 25 g/mL Tet was subjected to three rounds
of SCOTS, followed by three rounds of CE. The resultant selectively captured
sequences (scs) were cloned into pUC19 (Table 2) for individual screening by
Southern blot hybridization; cDNAs were identified that hybridized to DIG-labelled
cDNA from tetracycline-grown J2315 more strongly than to cDNA from brothgrown J2315 (Figure 3). Sequencing of tetracycline-enhanced transcripts
identified an imidazole glycerol phosphate synthase, a putative exported protein
with a coagulation factor domain, an extracellular solute-binding protein, a
putative cell wall lysis peptidase, and several hypothetical proteins. Previous
studies in protein expression changes also identified an extracellular solutebinding protein, as well as a peptidoglycan-associated lipoprotein, and multiple
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Figure 3. Modulation of bacterial transcript levels during growth in subinhibitory concentrations of tetracycline.
Each lane contains captured cDNAs amplified from a single recombinant
plasmid, transferred to a membrane, and probed with SCOTS-amplified
DIG-labelled cDNA from growth in tetracycline (A) or LB (B).
indicate genes upregulated during growth in tetracycline.

Arrows
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conserved hypothetical proteins (295).
Originally, cDNA inserts were amplified with M13 vector primers (Table 3), such
that empty vectors would show a small product. However, PCR amplification with
linker primers revealed the presence of multiple cDNAs within a single vector
(Figure 4). Such a situation could lead to false-negatives during Southern blot
screening, should both probes detect one of several cDNAs in a single amplicon.
Modification to the ligation procedure decreased the incidence of multiple cDNA
inserts within a single vector.

3.4 Intracellular gene expression by B. cenocepacia in
murine macrophages
SCOTS was used to examine gene expression by intracellular B. cenocepacia in
murine macrophages at 4 h p.i.. We have previously demonstrated that at 4 h
p.i., most intracellular bacteria reside in vacuoles that do not fuse with the
lysosome (230, 252, 296). In addition, by 4 h p.i., infected macrophages display
observable alterations to the actin cytoskeleton caused by the bacterial T6SS,
which is not well-expressed under normal culture conditions in LB medium (25).
These observations suggest that at 4 h p.i., there are changes in bacterial gene
expression reflecting response and adaptation to the intracellular environment.
As a control, we used bacteria grown for 4 h under the same conditions in
macrophage growth medium (DMEM-10% FBS), but without macrophages. To
isolate and enrich bacterial transcripts, three rounds of SCOTS were performed
on both intracellular and non-macrophage-exposed (NME) bacterial cDNA
samples. The resultant cDNA pools were subjected to competitive enrichment for
transcripts specific to the phagosome, and to microarray analysis with B.
cenocepacia J2315 DNA arrays.
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Figure 4. Multiple cDNAs may be present in a single recombinant plasmid.
PCR amplification with M13 vector primers shows a negative product from
an empty vector (1), or a single product containing all cDNA inserts (2).
PCR amplification with I linker primers reveals multiple cDNA inserts
present in a single recombinant plasmid (3). L – GeneRuler Ladder Mix
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3.4.1

Low abundance transcripts identified by competitive
enrichment

Competitive enrichment is similar to the initial SCOTS technique, but pre-blocks
the chromosome with both rDNA and control NME cDNA prior to capture of
intracellular cDNA. This encourages the capture of sequences specifically or
more highly expressed within the phagosome. Following three rounds of
competitive enrichment, cDNA sequences were cloned into pUC19, a high-copynumber vector, and introduced into E. coli DH5α by transformation. DNA inserts
from colonies were individually amplified by PCR and screened by Southern blot
for differential hybridization to DIG-labelled cDNA libraries. A number of
recombinant plasmids contained multiple cDNA inserts; however, these could be
differentiated during Southern blot analysis. Following competitive enrichment,
many scs clones were obtained which hybridized to labelled intracellular cDNA
but not to NME cDNA (Figure 5). One hundred eighteen unique scs sequences,
encoding 124 proteins, were mapped to the B. cenocepacia genome (Table 4); of
these sequences, four were secondary sequences in an already-identified gene,
two were within a duplicated region on chromosome one, and one was a
transposase with nine identical copies distributed throughout the genome.
Identified sequences were proportionally represented in each of the three
chromosomes and the plasmid: 57 scs mapped to chromosome one, 51 to
chromosome two, 14 to chromosome three, and 2 to the plasmid. For the latter
three genetic elements, this represents approximately 2 percent of coding
sequences, whereas for chromosome one, only 1.5 percent of the genes were
identified. While this is a small difference, it is interesting to note that the core
functions of the cell, including cell division, central metabolism, and
“housekeeping genes” are overrepresented on chromosome one, while the latter
three genetic elements carry a higher proportion of accessory functions and
unknown proteins (195). Identified scs were classified into functional categories
based on clusters of orthologous groups of proteins (COG) designations (Figure
6). The COGs database (http://www.ncbi.nlm.nih.gov/COG/) predicts the
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Figure 5.

Modulation of bacterial transcript levels by intracellular B.

cenocepacia
Selectively captured sequences (scs) isolated from intracellular bacteria
were hybridized with DIG-labelled SCOTS-derived B. cenocepacia cDNA
pools from (A) intracellular bacteria or (B) non-macrophage-exposed
bacteria. Each lane represents cDNA amplified from a single recombinant
plasmid. L indicates equally loaded DIG-labelled ladder.
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Table 4: Intracellular-specific selectively captured sequences
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a

Genes are strongly upregulated (log2 > 2, p < 0.05)
Genes are in a transcriptional unit with strongly upregulated genes (log2 > 2, p
< 0.05)
Genes are upregulated in intracellular bacteria
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Figure 6. Functional classification of selectively captured sequences.
Profile of each COG functional class is shown as a percentage of all scs. Also
shown is the functional profile of the genome as a whole.

85

function of a protein based on orthology, or homology among species (476).
Almost half (46%) of identified scs represented poorly characterized genes, of
which two-thirds had no functional classification. Several major COGs were not
represented in the set, including nucleotide metabolism and transport, trafficking,
secretion and transport, posttranslational modification and chaperones, and
defense mechanisms; however, genes classified as cell motility were
overrepresented relative to genome content. This COG profile is representative
of 115 genes; B. cenocepacia J2315, a sequenced clonal isolate of K56-2, has
over 7000 identified genes (195). Therefore, to determine if these trends hold true
across the entire cDNA library, SCOTS-derived cDNA pools were applied to B.
cenocepacia-specific microarrays to gain a more complete overview of
intracellular gene expression.

3.4.2

Global intracellular gene expression identified by microarray
analysis

Each cDNA pool was hybridized against reference genomic DNA; expression
was set as a value of 1.0 or greater versus the genomic control. Using this
threshold, 55 percent of all genes, or approximately 4000 genes, were expressed
under each condition. Of the 115 unique genes identified by competitive
enrichment, only 6 failed to meet the arbitrary level for expression by intracellular
bacteria; of the remainder, more than half were upregulated by intracellular
bacteria. Twenty percent of sequences identified by competitive enrichment
showed significant intracellular upregulation (> 4-fold, p < 0.05) of the gene itself
or of a putative transcriptionally-associated gene. Gene expression was
compared between intracellular and non-macrophage-exposed bacteria; seven
hundred sixty-six microarray genes or intergenic sequences showed significant
changes in expression (-2 > log2 > 2, p < 0.05), of which 329 were induced and
437 were repressed. Distribution of these genes among and throughout the four
genetic elements of B. cenocepacia was relatively proportionate to the size of the
genetic element, regardless of G+C content (Figure 7), with the exception of the
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Figure 7.

Genes differentially expressed by intracellular bacteria are

distributed among the four genetic elements of B. cenocepacia
The outer pair of concentric circles represents both coding strands of the
B. cenocepacia genome. The second pair of concentric circles represents
gene

induced

(outer)

and

repressed

(inner)

by

intracellular

B.

cenocepacia. Percentage of G+C is also shown, with above average in
yellow and below average in purple.
plasmid is 17.5x scale.

Chromosome 3 is 3x scale; the
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plasmid, where 20% of the plasmid-encoded genes were repressed in
intracellular bacteria. Among the differentially expressed genes, 145 were
regulated greater than  10-fold (p < 0.05) (Figure 8); many of these genes are
poorly characterized (Tables 5 & 6), suggesting a novel survival strategy.
Differentially regulated genes were classified into functional categories based on
COG designations (Figure 9). Expression was altered in every COG designation
represented in B. cenocepacia. Metabolic adaptation accounts for one-third of
differentially regulated genes in intracellular bacteria, though more metabolic
genes were induced than were repressed. Genes involved in amino acid, lipid,
and carbohydrate transport and metabolism, and energy production and
conversion account for 25% of all induced genes. The large categories of
information storage and processing, and cellular processes and signaling each
accounted for one-sixth of differentially regulated genes; in particular, significant
changes were seen in the expression of transcriptional regulators, accounting for
9% of all differentially regulated genes. Similar to the over-representation seen in
the SCOTS-CE profile (Figure 6), cell motility (flagellar) genes were mainly
induced. Interestingly, genes involved in the synthesis and transport of
phospholipid precursor sn-glycerol-3-phosphate were induced by intracellular
bacteria, as were genes involved in the production and transport of cholesterollike hopanoids, exoenzymes, ion transporters, an osmolarity-dependent twocomponent regulatory system, and catalase katB. Unexpectedly, many genes
involved in the acquisition of iron were repressed, including ornibactin receptor
orbA, the transcriptional activator of the pyochelin receptor, and a putative
pyochelin biosynthesis protein. Other repressed genes of note include B.
cenocepacia-specific quorum sensing regulator cciR, adhesin adhA, and many
transport genes, including the Sec and Tat systems, and elements of the type II
and both type IV secretion systems. However, at least one-third of both induced
and repressed genes fall into the poorly characterized classification; of these,
greater than half lack a COG designation. In total, 25% of all differentially
regulated genes are annotated only as hypothetical proteins.
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Figure 8. Relative expression of genes strongly regulated by intracellular
B. cenocepacia.
Heat map of the I:NME expression ratio of

genes induced (A) or

repressed (B) greater than 10-fold (p < 0.05). Colour scale shows green
as high expression, red as low expression, and yellow as intermediate.

Table 5: Genes strongly induced by intracellular B. cenocepacia
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Table 6: Genes strongly repressed by intracellular B. cenocepacia
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Figure 9.

Functional classification of genes differentially expressed by

intracellular B. cenocepacia
Profiles of functional classes are shown as a percentage of all induced
(green bar) or repressed (red bar) genes (-2 > log2 > 2, p < 0.05).
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3.5 SCOTS-identified changes in gene expression validated
by other means
A previous study identified B. cenocepacia K56-2 signature-tagged transposon
mutants (STM) attenuated for survival in a rat agar bead model of chronic lung
infection (207); in total, the study mapped 84 unique insertions within genes
essential for in vivo survival. Four of these genes were identified directly by
SCOTS competitive enrichment; another three SCOTS-identified genes were
found in genes located within a putative transcriptional unit with an STM insertion
(Table 7). SCOTS microarray analysis identified 26 of the 84 STM genes as
being expressed by intracellular bacteria (Table 7), a significant finding
considering the lung environment exposes the bacteria to many factors other
than macrophages.
Quantitative RT-PCR was performed for a subset of genes to experimentally
validate trends seen in the microarray data in the absence of any capture or
enrichment. Total RNA was extracted and DNase-treated as was done for
SCOTS, and reverse transcribed to cDNA using random hexamers. Microarray
data indicates conserved hypothetical protein BCAM0314, ABC transporter ATPbinding protein BCAM2141, putative universal stress protein BCAM0276, and
putative acyl carrier protein phosphodiesterase BCAS0186 should be induced by
intracellular bacteria, while putative transcription elongation factor BCAM1928
should be repressed. Sigma factor BCAM0918, or rpoD - also designated sigA
(297) or sigE (297, 349) – was chosen as an internal control. An internal
reference gene allows comparison across samples; despite reverse transcribing
equal amounts of RNA, expression of the reference gene averaged 60-fold less
in intracellular samples as compared to NME samples due to eukaryotic content.
Expression of the gene of interest was first related to the internal control; this
ratio was compared between samples to give fold increase in expression in
intracellular bacteria. qRT-PCR confirmed the expected trends of higher
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Table 7: In vivo essential genes expressed by intracellular bacteria

a

Tag assigned to mutant in STM in vivo study (207)
Gene names in bold were strongly induced (>3.5-fold, p<0.05)
c
Immediately adjacent gene identified by SCOTS
b
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expression of BCAM0314, BCAM2141, BCAM0276, and BCAS0186, and
negligible expression of BCAM1928 in intracellular bacteria (Figure 10).

3.6 SCOTS-identified genes are involved in bacterial entry
and intracellular replication
Because survival within macrophages may contribute to the pathogenesis of B.
cenocepacia, the role of several SCOTS-identified genes in intracellular survival
was examined. Ten genes were deleted in the gentamicin-sensitive B.
cenocepacia MH1K, allowing intracellular survival to be assessed via the
gentamicin protection assay (185). The ten deleted genes encoded the following
proteins: a subunit of the flagellar regulon master regulator (BCAL0124), a
putative acyl carrier protein phosphodiesterase (BCAS0186), a cation efflux
system (BCAM0434-5), the response regulator component of a two-component
regulatory system (BCAM2837), a putative oxidoreductase (BCAL1726), a
putative universal stress protein (BCAM0276), an MgtC family protein
(BCAM0411), a putative lipoprotein (BCAL0340), a putative
lysylphosphatidylglycerol synthetase (BCAM1679), and a putative Gram-negative
porin (BCAM2446). These genes were chosen based on high intracellular
expression by microarray data; the first three genes were also identified by
competitive enrichment.
The ability of mutant strains to enter and replicate within macrophages was
assessed relative to the parental strain (Figure 11). While six of the ten mutant
strains showed a defect in macrophage entry, the defect was statistically
significant only for BCAL0124 (p < 0.01) and BCAM0411 (p < 0.05). In contrast,
deletion of BCAL1726 resulted in a significant increase in macrophage entry (p <
0.001). While none of the deletions negatively affected intracellular survival,
deletions in BCAL0340 and BCAM0411 increased the ability of the bacteria to
replicate intracellularly. Statistically significant differences could be
complemented by introducing the deleted gene encoded in a plasmid under the
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Figure 10. n-Fold changes in the intracellular expression of SCOTSidentified B. cenocepacia genes as measured by qRT-PCR.
Fold change represents the induction of expression by intracellular
bacteria over NME bacteria, each relative to a reference gene presumed
to have stable transcriptional levels.
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Figure 11. Comparative macrophage entry and intracellular replication of
parental B. cenocepacia and scs mutants in murine macrophages.
Entry (A) was calculated relative to initial inoculum, and replication (B) was
calculated relative to entry; both were normalized relative to the parental
control, set at 100% entry and 100% replication. Standard error bars are
indicated. Significance was determined using one-way ANOVA and
Dunnett’s Multiple Comparison Test. Mutants demonstrating significant
difference from the wild-type are indicated (*p<0.05, **p<0.01, ***p<0.001).
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control of a constitutive promoter (Figure 12). Among the deletion strains, the
only gene with an obvious phenotype is JST19, or ∆BCAL0124, which is
defective in both swimming and swarming motility; complementation restored
motility to the deletion strain (Figure 13). JST75, or ∆BCAM2837, is impaired in
swarming motility, but not in swimming motility (Figure 14).

3.7 SCOTS-identified genes are involved in bacterial
spread and macrophage cytotoxicity
The gentamicin protection assay allows the enumeration of intracellular bacteria.
However, the results may be misleading if the survival of the host cell is not
considered, as bacterial toxicity associated with membrane damage of the host
cell will allow entry of the antibiotic, which will in turn result in the killing of
intracellular bacteria. Analysis of toxicity of the host cell can be performed via
flow cytometry. The membrane impermeant fluorescent dye 7-AAD binds DNA
only in macrophages with permeabilized membranes. Macrophages were
infected with GFP-expressing bacteria and assessed on three different
parameters: entry, cytotoxicity, and spread. Parental B. cenocepacia was found
in 3% of all macrophages, and was cytotoxic to macrophages at a 1:1 ratio, killing
approximately 3% of all cells (Figure 15A). Despite infecting nine-fold better than
parental, ∆BCAM2837 was also cytotoxic at a 1:1 ratio, killing 27% of all
macrophages. Though ∆BCAL0340 infected two-fold better than the parental
isolate, it was only half as cytotoxic, whereas ∆BCAL0124 demonstrated the
opposite trend with two-fold less infection, but seven-fold greater cytotoxicity.
Other mutants, including ∆BCAM0276 and ∆BCAM2446, appear to prevent
permeabilization of the macrophage membrane, decreasing cytotoxicity below
the level seen in uninfected macrophages (Figure 15). In total, of the ten
mutants, only four were cytotoxic, defined as permeabilization of the host cellular
membrane greater than seen in uninfected cells. However, a permeable
membrane would permit gentamicin to enter the cell, thereby killing intracellular
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Figure 12. Comparative macrophage entry and intracellular replication of
parental B. cenocepacia and complemented scs mutants in murine
macrophages.
Plasmid pDA12 is a vector control; pJTx is a constitutively active
complementation plasmid (Table 2). Entry (A) was calculated relative to
initial inoculum, and replication (B) was calculated relative to entry; both
were normalized relative to the parental control, set at 100% entry and
100% replication. Standard error bars are indicated. Significance was
determined using one-way ANOVA and Dunnett’s Multiple Comparison
Test. Mutants demonstrating significant difference from the wild-type are
indicated (*p<0.05, **p<0.01, ***p<0.001).
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Figure 13. A mutation in the flagellar regulon master regulator results in a
strain (JST19) defective in both swimming and swarming motility.
This defect can be restored by complementation on a constitutively active
plasmid pJT57.

pDA12 is a vector control.

Bacterial cultures were

adjusted to an OD 600 of 0.1; 2 L was stab-inoculated into LB 0.3% agar to
observe swimming motility, and 2 L was drop-inoculated onto NB 0.2%
glucose, 0.5% agar to observe swarming motility.
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Figure 14. Deletion of a putative response regulator results in a strain
(JST75) defective in swarming, but not in swimming motility.
Bacterial cultures were adjusted to an OD 600 of 1.0; 2 L was stabinoculated into LB 0.3% agar to observe swimming motility, and 2 L was
drop-inoculated onto NB 0.2% glucose, 0.5% agar to observe swarming
motility.
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Figure 15. B. cenocepacia entry and host cytotoxicity in murine
macrophages.
Bacterial entry and cytotoxicity are shown as a percentage of total cells.
Cytotoxicity was normalized against cell death in uninfected cells. 50 000
cells were counted in each of three independent experiments. Standard
error bars are indicated.

Significance was determined using one-way

ANOVA and Dunnett’s Multiple Comparison Test. Mutants demonstrating
significant difference from the wild-type are indicated (*p<0.05, **p<0.01,
***p<0.001).
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bacteria and preventing quantification in the gentamicin protection assay. Thus,
intracellular replication was normalized for cytotoxicity (Figure 16), revealing
significant intracellular replication by ∆BCAL0124. In contrast, normalization
revealed that ∆BCAL0340 replicates at a rate similar to the parental isolate, but is
protected from gentamicin because it is less cytotoxic. Mutants displaying a
cytotoxic ratio (Figure 16A) less than zero were not normalized, as in the
absence of membrane permeability, intracellular bacteria would not be affected
by gentamicin.
Flow cytometry also permits investigation of the spread of B. cenocepacia in an
unchecked infection. Following killing of extracellular bacteria, infected
macrophages were maintained in antibiotic-free media; any bacteria able to
escape the macrophage, whether through lysis or otherwise, were able to infect
neighbouring macrophages. Under such conditions, the number of macrophages
infected with the parental strain increased six-fold (Figure 17), indicating that B.
cenocepacia was able to escape the macrophage by some means. With the
exception of ∆BCAM2837, which spread with half the efficiency of parental, the
scs mutants spread as well or better than parental. ∆BCAL1726 and
∆BCAM1679 spread efficiently, increasing macrophage infection by 15-fold in an
uncontrolled environment. The ratio of dead:infected cells remained
approximately 1:1 in an unchecked infection, suggesting that viable B.
cenocepacia escaped from dead macrophages. The two exceptions to this ratio
were seen in ∆BCAL0124, which killed 2.5 cells for every cell infected at the time
of analysis, and ∆BCAM2837, which killed only 30% of infected cells.

3.8 B. cenocepacia remains in an acidic vacuole associated
with the endocytic pathway
Despite using 24 h as an endpoint in gentamicin protection assays, the BcCV has
not been extensively characterized beyond 6 h p.i., where greater than 80%
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Figure 16. Intracellular replication normalized for host cytotoxicity of B.
cenocepacia parental strain and scs mutants.
(A) Cell death was normalized against infection, determined by flow
cytometry. (B) Intracellular replication, determined by the gentamicin
protection assay, was then multiplied by this ratio to give the total
expected ratio of intracellular bacteria in the absence of cell death.
Mutants with a ratio in (A) less than zero were unchanged in (B).
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Figure 17. B. cenocepacia spread of infection and host cytotoxicity in an
unchecked infection of murine macrophages.
Capacity to spread (A) is calculated as the fold increase in infected
macrophages when maintained in antibiotic-free media rather than 10
µg/mL gentamicin in the same experiment.

Host cytotoxicity (B) is

calculated as the ratio of total dead cells to infected cells. 50 000 cells
were counted in each of three independent experiments. Standard error
bars are indicated. Significance was determined using one-way ANOVA
and Dunnett’s Multiple Comparison Test.

Mutants demonstrating

significant difference from the wild-type are indicated (*p<0.05, **p<0.01,
***p<0.001).
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of BcCVs remain associated with the endocytic pathway, and approximately 50%
of BcCVs are acidic phagolysosomes (252). At 24 h p.i., B. cenocepacia is still
found within a vacuole, and a proportion of BcCVs contain numerous bacteria
(Figure 18).

92% of BcCVs are acidic, indicated by colocalization with the

acidotropic dye LysoTracker Red; in some vacuoles, rapidly-moving bacteria are
strongly-labelled with Lysotracker Red, while the surrounding vacuole is only
weakly-stained (Figure 18B). The BcCV remains associated with the endocytic
pathway, as TMR-dextran added 21 h p.i. is delivered to 90% of BcCVs during a
2 h pulse followed by a 1 h chase (Figure 19). A fluid phase marker internalized
via endocytosis, dextran follows the typical endocytic pathway, ultimately and
rapidly accumulating in the lysosome. A dextran pulse-chase prior to bacterial
infection is often used to pre-label lysosomes (252).

However, 24 h post-B.

cenocepacia infection, the dextran signal is weak in infected macrophages
(Figure 19B); while some BcCVs are labelled with dextran, the weakness of the
signal precludes designation of non-labelled BcCVs as non-lysosomal.
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Figure 18. B. cenocepacia remains within a membrane-bound vacuole that
accumulates acidotropic probe Lysotracker Red.
RAW 264.7 macrophages infected with B. cenocepacia were observed at
24 h p.i. after treatment with Lysotracker red. Panel A shows accumulation
of Lysotracker in the BcCV, while panel B shows accumulation of
Lysotracker by B. cenocepacia. From left to right, panels show the phase
contrast image, red fluorescence (Lysotracker red), and a merged image.
Arrow indicates representative BcCVs.
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Figure 19. The B. cenocepacia-containing vacuole remains associated with
the endocytic pathway.
Panel A shows RAW 264.7 macrophages infected with B. cenocepacia
that were pulsed with dextran at 21 h p.i. and observed 3 h later. Panel B
shows the opposite experiment, where RAW 264.7 macrophages were
pulsed with dextran, then infected with B. cenocepacia and observed at 24
h p.i. From left to right are the phase contrast image, red fluorescence,
and a merged image. Arrows indicate representative BcCVs.
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Chapter 4

4

The role of secretion systems in the intracellular
behaviour of B. cenocepacia in murine macrophages

4.1 Identification and deletion of secretion systems in B.
cenocepacia K56-2
Large, specialized, multi-protein secretion systems are a common device
employed by intracellular pathogens to interact with eukaryotic cells (188). The
specific contribution of secretion systems to the intracellular lifestyle of B.
cenocepacia is not well understood. The recent development of a system to
create unmarked deletions in B. cenocepacia (156) permits construction of large,
sequential deletions in the same strain. For each of the various secretion
systems in B. cenocepacia, we deleted the entire gene cluster; we also created
combination mutant strains with deletions in multiple secretion systems. This
strategy served a dual purpose in preventing both any potential crosscomplementation from paralogous genes, as well as a potentially toxic build-up of
inactive or partial secretion systems. Because the clusters encode numerous
proteins, deletion entailed removal of large segments of DNA: 28.7 kbp of
chromosome 2 for the T3SS, 41.5 kbp of the plasmid for T4SS-1, 11.3 kbp of
chromosome 2 for T4SS-2, and 22.3 kbp of chromosome 1 for the T6SS. For the
plasmid, in particular, deletion of all putative T4SS-1-associated genes – a stretch
of DNA including 45 genes - represented 45% of the entire plasmid sequence.
We also deleted multiple essential genes of the T2SS, totalling 5 kbp of
chromosome 1. In the strain JST112, lacking all secretion systems, this totals
deletion of 108.7 kbp of genetic material. Despite these large deletions, growth
of all strains in culture was unaffected (Figure 20).
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Figure 20. Deletion of secretion system clusters does not affect growth in
culture.
Data represents the mean of two independent experiments, each
performed in triplicate.
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4.2 Characterization of secretion system deletion mutants
Secretion system mutants were examined for in vitro phenotypes, including
exoenzyme secretion and LPS production. Among the secretion system mutants,
∆T2SS and ∆allSS were defective in secretion of casein-degrading protease, and
lipase; ∆T3SS was also attenuated for secretion of protease, but not lipase
(Figure 21). Results on the egg yolk agar were less clear; ∆T2SS and ∆allSS
could not clear the media – characteristic of phospholipase A or protease
secretion – nor form an opaque precipitate – characteristic of phospholipase C
secretion (84, 275). The ∆T3SS mutant cleared the media more slowly than the
parental strain; however, bacterial growth resembled neither ∆T2SS nor the
parental strain, appearing flat, rough, dry, and white (Figure 21). None of the
deletions had any effect on LPS production (Figure 22).

4.3 Secretion systems are involved in bacterial entry and
intracellular replication
B. cenocepacia has previously been shown to enter (252, 402) and replicate
within murine macrophages (185). Early studies of intracellular B. cenocepacia
either relied on microscopic techniques (252), or utilized high concentrations of
ceftazidime and gentamicin to overcome high aminoglycoside resistance and kill
extracellular bacteria (409). Recent construction of an aminoglycoside-sensitive
strain of B. cenocepacia with intramacrophage behaviour similar to the parental
isolate (185) has enabled use of the gentamicin protection assay to reliably
quantify intracellular survival using only low doses of antibiotic. We utilized the
gentamicin protection assay to examine whether any of the secretion systems
play a role in the entry and intracellular replication of B. cenocepacia in murine
macrophages (Figure 23). After an initial infection period, extracellular bacteria
were killed with gentamicin, allowing quantitation of intracellular bacteria at 1h
(entry) and 24h (replication) post-infection. Because the generation time of
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Figure 21. Deletion of secretion system clusters affects exoenzyme activity.
Protease secretion (A) was measured as the zone of clearing on skim milk
agar. Lipase secretion (B) was measured as the zone of precipitation on
Tween 80 agar. Phospholipase C secretion (C) was measured as the
zone of clearing on egg yolk agar.
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Figure 22.

Lipopolysaccharide production is unaffected in secretion

system deletion mutants.
Samples were separated on a 14% Tricine-SDS-PAGE gel, and stained
with silver nitrate.
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Figure 23. Secretion systems play a role in B. cenocepacia entry into
murine macrophages and intracellular replication.
Entry was calculated relative to initial inoculum, and replication was
calculated relative to entry; both were normalized relative to the parental
strain, set at 100% entry and 100% replication. Standard error bars are
indicated. Significance was determined using one-way ANOVA and
Dunnett’s Multiple Comparison Test. Mutants demonstrating significant
difference from the wild-type are indicated (*p<0.05, **p<0.01, ***p<0.001).
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B. cenocepacia in growth medium is approximately 1 h, the quantitation data at
this time point after macrophage infection were considered to reflect amount of
bacteria engulfed by macrophages prior to significant intracellular replication.
Deletion of the T3SS had no apparent effect on bacterial entry or intracellular
replication. Deletion of T4SS-1 resulted in slight, non-significant differences – a
two-fold decrease in bacterial entry coupled with a two-fold increase in
intracellular replication. Deletion of T4SS-2 resulted in a significant increase in
bacterial entry; however, once internalized, ∆T4SS-2 replicated at the same rate
as the parental strain. Deletion of the T2SS and the T6SS each showed the
opposite trend with a significant increase in intracellular replication despite no
effect on bacterial entry. Deletion of all secretion systems together showed no
demonstrable phenotype in terms of either bacterial entry or intracellular
replication.
Due to the large size of the cluster deletions, complementation of the original
secretion system mutants was not practical. Instead, we created
complementable single gene deletions in key structural components of each
secretion system demonstrating a role in bacterial internalization or intracellular
replication. To inactivate the T2SS, we deleted BCAL3516 (GspM), a key inner
membrane protein component of the T2 apparatus (225, 283). Successful
complementation by expression of the gene from plasmid pJT62 was evidenced
by restored secretion of lipase, protease, and phospholipase C (Figure 24).
Overexpression of GspM did not affect internalization of the bacteria, but
significantly reduced intracellular replication (Figure 25), thereby complementing
the phenotype seen in deletion of the entire cluster. To inactivate the T6SS, we
deleted BCAL0343, or Hcp, a structural and secreted protein critical to the
function of the T6SS in B. cenocepacia (25). Complementation of the deletion
reduced intracellular replication to parental strain levels (Figure 25B). To
inactivate the T4SS, we deleted pBCA025 (TraF) for T4SS-1, and BCAM0333
(VirB10) for T4SS-2. VirB10 is an essential inner membrane protein for the
formation of the core complex of the T4SS-2 (86, 214); TraF is the homologous
protein in the T4SS-1 (163). Deletion of VirB10 affected neither internalization
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Figure 24. Defects in exoenzyme release in a T2SS mutant can be
complemented.
Protease secretion was measured as the zone of clearing on skim milk
agar.

Lipase secretion was measured as the zone of precipitation on

Tween 80 agar. Phospholipase C (PLC) secretion was measured as the
zone of clearing on egg yolk agar. pDA12 is a vector control.
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Figure 25. Defects in macrophage entry (A) and intracellular replication (B)
of B. cenocepacia secretion system mutants can be complemented.
Complementation plasmids are indicated as pJTx (Table 2); pDA12 is a
vector control.

Entry was calculated relative to initial inoculum, and

replication was calculated relative to entry; both were normalized relative
to the parental strain, set at 100% entry and 100% replication. Standard
error bars are indicated.

Significance was determined using one-way

ANOVA and Dunnett’s Multiple Comparison Test. Mutants demonstrating
significant difference from the wild-type are indicated (*p<0.05, **p<0.01,
***p<0.001).
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nor replication (Figure 25). However, deletion of traF alone yielded marginal
increases in bacterial entry into the macrophage and intracellular replication,
phenotypes that could be complemented.

4.4 Secretion systems are involved in bacterial spread and
macrophage cytotoxicity
The fate of the host cells is not usually investigated in cellular infection models.
However, it is reasonable to assume that intracellular bacteria may exert various
effects on the host cells that could alter the gentamicin protection assay.
Therefore, we also utilized flow cytometry to examine bacterial infection and host
cell viability. Infected macrophages were identified by green fluorescence due to
B. cenocepacia expression of GFP from a constitutively-active plasmid. Host cell
viability was determined based on the permeability of cellular membranes; dead
macrophages were identified by red fluorescence from the marker 7-AAD, a
DNA-binding compound which cannot cross membranes. For initial infection, the
data produced by the gentamicin protection assay (Figure 23) correlated well with
the data produced by flow cytometry (Figure 26A). The single exception to this
correlation was seen with ∆T4SS-1. The gentamicin protection assay showed
two-fold less viable intracellular bacteria than the parental isolate, while flow
cytometry showed two-fold more infected cells than the parental strain; however,
neither difference was statistically significant from the parental isolate. It is
important to note that the two assays have different measures; whereas the
gentamicin protection assay quantifies the total number of intracellular bacteria,
flow cytometry quantifies the total number of infected eukaryotic cells. This data,
then, would suggest that, compared to infections with the parental strain, a
greater number of macrophages internalize a lower number of bacterial cells in
the absence of T4SS-1. Deletion mutants in T2SS, T3SS, and T6SS all showed
infection levels similar to those of the parental strain, whereas deletion of T4SS-2
resulted in a statistically significant (p < 0.05) four-fold increase in infected cells.
Deletion of all secretion systems caused a non-significant reduction in the
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Figure 26. Secretion systems are involved in B. cenocepacia entry and
host cytotoxicity in murine macrophages.
Bacterial entry (A) and cytotoxicity (B) are shown as a percentage of total
cells. Cytotoxicity was normalized against cell death in uninfected cells.
50 000 cells were counted in each of three independent experiments.
Standard error bars are indicated.

Significance was determined using

one-way ANOVA and Dunnett’s Multiple Comparison Test.

Mutants

demonstrating significant difference from the wild-type are indicated
(*p<0.05, **p<0.01, ***p<0.001).
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number of infected macrophages (Figure 26A). However, deletion of all secretion
systems also resulted in a significant decrease in cytotoxicity, equivalent to that
seen with deletion of the T6SS. In both these mutant strains, as well as the T2SS
mutant, membrane permeability was lower than that seen in natural cell death in
uninfected cells, one of the controls for flow cytometry experiments. It is possible
that these strains induce an alternate form of cell death in which the membrane is
not permeabilized, which would prevent 7-AAD access to the host DNA. The
cytotoxicity of B. cenocepacia towards the host macrophage was relatively
unaffected by deletion of the T3SS, nor by deletion of either of the T4SSs (Figure
26B). However, because permeabilization of the membrane in the presence of B.
cenocepacia allows gentamicin into the host cell, a measure of host cytotoxicity
could be used to correct intracellular replication. When the ratio of dead cells to
infected cells at 24 hours was taken into account (Figure 27A), intracellular
replication was higher for both the parental isolate and for ∆T3SS, but lower for
both T4SSs (Figure 27B); while ∆T4SS-1 appears to replicate at the same pace
as the parental isolate, intracellular ∆T4SS-2 is three-fold less.
In the gentamicin protection assay, extracellular bacteria are killed via 30 minute
incubation with a higher dose of gentamicin. In the classical assay, cells are then
maintained in a low concentration of gentamicin such that bacteria that escape
the macrophage cannot replicate in the media or re-infect neighbouring cells.
However, by maintaining parallel cells in antibiotic-free media – an unchecked
infection – bacteria which permeabilize the host membrane and escape from the
macrophage are free to re-infect neighbouring cells, and the capacity of the
bacteria to spread can be examined. The number of cells infected with the
parental strain increased eight-fold in an unchecked infection (Figure 28A), and
two-thirds of all infected cells had permeabilized membranes, and were
presumably dead (Figure 28B). Deletion of the T3SS, which showed no
discernable phenotype in gentamicin protection assays, appeared to facilitate the
spread of infection at more than three times the speed of the parental isolate
(27.4-fold increase for ∆T3SS versus 8.6-fold for parental). Deletion of all
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Figure 27. Intracellular replication normalized for cytotoxicity of B.
cenocepacia parental strain and secretion mutants in murine
macrophages.
(A)

Cell death was normalized against infection, determined by flow

cytometry.

(B)

Intracellular replication, determined by the gentamicin

protection assay, was then multiplied by this ratio to give the total
expected ratio of intracellular bacteria in the absence of cell death.
Mutants with a ratio in (A) less than zero were unchanged in (B).
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Figure 28. Secretion systems are involved in B. cenocepacia spread of
infection (A) and host cytotoxicity (B) in an unchecked infection of
murine macrophages.
Capacity to spread (A) is calculated as the fold increase in infected
macrophages when maintained in antibiotic-free media rather than 10
µg/mL gentamicin in the same experiment.

Host cytotoxicity (B) is

calculated as the ratio of total dead cells to infected cells. 50 000 cells
were counted in each of three independent experiments. Standard error
bars are indicated. Significance was determined using one-way ANOVA
and Dunnett’s Multiple Comparison Test.

Mutants demonstrating

significant difference from the wild-type are indicated (*p<0.05, **p<0.01,
***p<0.001).
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secretion systems significantly increased the ability of the bacterium to spread to
neighbouring macrophages, resulting in a 40-fold increase in infected cells
(Figure 28A). In the T3SS mutant, this increase in infected cells was
accompanied with a proportionate increase in cell death, such that the ratio of
dead:infected cells was equivalent to parental strain (Figure 28B). However,
∆T4SS-2, ∆T6SS, and ∆allSS all showed a significant decrease in cytotoxicity in
an unchecked infection, killing only 28%, 14%, and 23% of infected
macrophages, respectively.
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Chapter 5

5

Discussion

5.1 Transcriptional changes by intracellular B. cenocepacia
B. cenocepacia is a bacterium with a large genome and an ability to survive in
diverse environments, including within macrophages and other eukaryotic cells.
In this study, we sought to identify genes expressed by intracellular B.
cenocepacia. Microbial transcripts were initially isolated and amplified using the
SCOTS technique, which removes eukaryotic cell transcripts and amplifies
bacterial transcripts while discarding bacterial ribosomal RNA. Previous studies
in other bacteria have shown that application of SCOTS enriches microbial
transcripts without introducing a significant bias in gene expression data (148).
SCOTS-purified cDNA was subjected to both microarray analysis and a
competitive enrichment approach to identify gene regulation by intracellular B.
cenocepacia, producing a wealth of information towards understanding the
behaviour of intracellular B. cenocepacia following internalization by
macrophages.
The distribution of upregulated classes of genes was similar between both
analysis techniques, and 86% of the genes identified by SCOTS-CE also showed
upregulation in the microarray data. However, while competitive enrichment
identified 115 genes putatively upregulated by intracellular bacteria, microarray
analysis showed expression of over 4000 genes and significant upregulation of
329 genes by intracellular bacteria. In some instances, the analysis techniques
provided complementary information. For example, though CE-identified flagellar
regulon master regulator BCAL0124 itself is not significantly upregulated by
intracellular bacteria 4 h p.i., flagellar genes controlled by BCAL0124 show
increased expression, and BCAL0124 clearly plays a role in the interaction of B.
cenocepacia with macrophages (Figures 11-12, 15-17). Combining the SCOTS
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technique with microarray analysis yields global gene profiles of genes induced
and repressed in intracellular bacteria.

5.1.1

The gentamicin protection assay and flow cytometry:
Complementary analyses for cell culture infection models

The classical measure of bacterial intracellular survival in eukaryotic cells is the
gentamicin protection assay (139, 185), which is based on intracellular bacterial
colony forming unit (CFU) counts. Extracellular bacteria are eliminated by
treatment with gentamicin, which poorly permeates eukaryotic cells;
subsequently, host cells are lysed to quantify intracellular bacteria. However,
should the infecting bacterium be toxic to the host cell, resulting in a potentially
compromised host cell membrane, antibiotics present in the cell culture medium
would also kill intracellular bacteria, confounding plate counts. In addition, total
intracellular bacteria are quantified, rather than the actual number of host cells
infected. Population analysis by flow cytometry addresses some of these issues.
Flow cytometry links macrophage infection with cell death on a per cell basis.
Thus, combining the gentamicin protection assay with flow cytometry reveals
trends in bacterial entry into macrophages, including the numbers of bacteria
taken up per macrophage, as well as the capacity of bacteria to replicate within
the cell and induce host cell death.

5.1.2

The role of SCOTS-identified genes in interactions with
macrophages

The contribution of SCOTS-identified genes to macrophage entry, intracellular
replication, and host-directed cytotoxicity was examined through deletion of
genes upregulated by intracellular bacteria. In comparing initial infection data
between the gentamicin protection assay and flow cytometry assay, those scs
mutants that showed a defect in entry with the former assay generally show the
same trends with the latter. However, while the gentamicin protection assay
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shows a striking increase in infection by ∆BCAL1726, flow cytometry shows a
more modest increase in infection, coupled with a higher level of cell death. This
suggests two potentially-complementary possibilities: Either more mutant
bacteria may be present per macrophage, or ∆BCAL1726 is more cytotoxic than
the parental strain and, despite initially infecting at a higher level, has been killed
by gentamicin entering dying host cells. The enhanced ability of the mutant to
spread to neighbouring cells in an unchecked infection could support either
hypothesis; a greater number of bacteria per macrophage potentiates re-infection
of a greater number of host cells, while increased cytotoxicity could lead to more
rapid spread. However, complementation of the BCAL1726-mediated increase in
bacterial entry was unsuccessful (Figure 12). While complementation in B.
cenocepacia can prove generally difficult, it is possible that the lack of
complementation for BCAL1726 may be due to a secondary mutation, or to a lack
of regulation. BCAL1726, annotated as a putative oxidoreductase, is located in a
precorrin synthesis cluster, and is orthologous to precorrin-3B synthetase,
involved in aerobic cobalamin biosynthesis (224, 225). This gene is one of five in
B. cenocepacia regulated by a cobalamin riboswitch (195), which modulates the
expression of associated genes – all involved in cobalamin biosynthesis or
transport - in response to changing concentrations of the cofactor (338).
Although the complementing plasmid pJT52 encodes the complete sequence of
BCAL1726, it does not include the riboswitch found immediately upstream,
resulting in constitutive expression regardless of cobalamin concentration. It is
possible that overexpression of a single key enzyme in the biosynthetic pathway
disrupts cellular homeostasis in a manner equivalent to absence of the enzyme.
Cobalamin is an important cofactor, and has been shown to act as an intracellular
antioxidant (51), to inhibit nitric oxide synthase (516), and to regulate cytokines
IL-6 (419) and TNF-α (418), thus indirectly regulating transcription factor NFκB
(499).
A disparity between flow cytometry and gentamicin protection assays was also
seen for ∆BCAM2837. While the gentamicin protection assay shows a modest
increase in initial infection, flow cytometry shows a dramatic increase in infection,
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coupled with an equivalent increase in cell death; the failure of this particular
mutant to spread effectively suggests that host cell death may be rapid –
accounting for the more modest increase seen with the gentamicin protection
assay – and that the bacterium may not be able to escape the dying macrophage
as efficiently as parental strain, or may be killed during host cell death.
BCAM2837 is annotated as the response regulator component of a twocomponent regulatory system (TCS). Though it is indicated as a pseudogene in
the Artemis visualization of the J2315 genome (195, 395), it is evidently active in
K56-2, as deletion of the gene demonstrates a clear phenotype in macrophage
infection. Bioinformatic analysis shows that the protein consists of two distinct
domains, one homologous to the chemotaxis protein CheC, and the second
homologous to the response regulator CheY. Che proteins are typically involved
in chemotaxis, where phosphorylated CheY (CheY-P) binds to the flagellar switch
to alter rotation, affecting the ability of the bacterium to swim smoothly rather than
tumbling (366). CheC is a phosphatase for the dephosphorylation of CheY (473).
CheYC proteins – having an N-terminal CheY domain and a C-terminal CheC
domain – are also found in organisms such as Pseudomonas syringae (334),
although the function is unclear; CheYC proteins may function as standard TCS
phosphatases, as phosphate sinks, or as completely novel proteins (334). Unlike
the typical CheYC protein, BCAM2837 is likely cotranscribed with a putative
diguanylate cyclase and is found together with a histidine kinase, suggesting a
role in signal transduction. B. cenocepacia carries three other genes annotated
as CheY (224, 225), all of which show expression by intracellular bacteria. The
only recognized CheY-phosphatase gene within B. cenocepacia is a single CheZ
– BCAL0136 – which does not show expression by intracellular bacteria. If the
CheYC gene encoded by BCAM2837 does indeed function as a phosphate sink,
its inactivation will lead to increased levels of CheY-P and thus increased
bacterial tumbling; as bacterial reorientation becomes more frequent,
unidirectional smooth swimming decreases, slowing bacterial migration;
∆BCAM2837 shows a defect in swarming motility, but not in swimming motility
(Figure 14). Such impaired motility may enhance bacterial uptake by simply

133

decreasing the ability to move away from the phagocytic cell, and may also make
escape from a dying macrophage more difficult.
The contribution of bacterial motility to interaction with macrophages can also be
seen in ∆BCAL0124, which encodes FlhD, a subunit of the flagellar regulon
master regulator necessary for expression of the flagellar structural components
(270). The regulator is essential for both swimming and swarming motility (Figure
13), and appears to be required for efficient bacterial internalization (Figure 11).
Loss of the bacterial flagella through deletion of fliCD also results in a severe
defect in bacterial internalization by macrophages (data not shown). Related
strain B. pseudomallei requires flagellin for efficient invasion of macrophages
(88), while in CF-pathogen P. aeruginosa, loss of swimming motility results in a
resistance to phagocytosis (16). Mouse studies demonstrate a requirement of B.
cenocepacia flagella for lethality, but not for bacterial dissemination; survivors
showed no differences in bacterial load between non-flagellated versus parental
strain infection (487). Deletion of BCAL0124 increases cytotoxicity and
dissemination of the bacteria to neighbouring cells. In the aforementioned mouse
study, B. cenocepacia lacking flagellin was unable to activate NFκB or elicit
secretion of IL-8 through TLR signalling (487). ∆BCAL0124 may avoid activation
of classical proinflammatory signaling cascades, allowing it to replicate
undetected until it overwhelms the macrophage and escapes in large numbers to
re-infect neighbouring cells.
Modifications to membrane proteins of B. cenocepacia affect interactions with
macrophages. BCAM0411 is one of three genes in B. cenocepacia encoding an
MgtC family protein. Deletion of this gene, which has multiple transmembrane
helices, resulted in a defect in bacterial internalization, but an increase in
intracellular replication (Figure 11). This phenotype was gene-specific, as it could
be complemented (Figure 12). A second MgtC family protein in B. cenocepacia
was previously shown to be important for growth under magnesium-limiting
conditions and for intramacrophage survival (296), phenotypes common to those
identified for MgtC family proteins in intracellular pathogens such as Salmonella
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enterica (381) and Brucella suis (255). However, because B. cenocepacia
encodes three MgtC family proteins, it is possible that each protein serves a
different role within the bacterium. BCAL0340 encodes a putative lipoprotein
located within the Type VI secretion cluster of B. cenocepacia; deletion of this
protein promotes replication of intracellular bacteria (Figure 11) but does not
inactivate the secretion system itself, as actin protrusions are still seen in infected
macrophages (data not shown). Thus, the contribution of BCAL0340 to the
intracellular persistence of B. cenocepacia remains unclear. ∆BCAM1679,
lacking a putative lysylphosphatidylglycerol (Lys-PG) synthetase, shows a minor
decrease in host cell cytotoxicity, but paradoxically, also shows a significant
increase in infected cells in an unchecked infection, demonstrating a capacity for
rapid spread. The addition of lysine to PG lowers the net negative charge of the
cellular envelope, already lowered in B. cenocepacia by the constitutive
expression of 4-amino-4-deoxy-L-arabinose linked to lipid A (358). Lys-PG may
also decrease permeability to cations and protons by raising the surface potential
of the membrane, increase membrane fluidity, inhibit genomic DNA replication,
and decrease activity of the host defense factor phospholipase A2 (PLA2)
[reviewed in (392)]. Deletion of the Lys-PG synthetase may enhance intracellular
replication – a small increase is seen in the gentamicin protection assay (Figure
11B) – leading to more rapid host cell death, possibly potentiated by an increase
in PLA2 activity. Interestingly, secretory PLA2 is capable of hydrolyzing the
membrane of cells undergoing early stages of apoptosis (343), possibly providing
a more rapid exit for intracellular bacteria.

5.1.3

Gene expression in intracellular B. cenocepacia

Internalization of B. cenocepacia by macrophages causes changes in bacterial
gene expression. In particular, large changes are seen in the expression of
genes associated with signal transduction mechanisms and transcription,
showing that B. cenocepacia senses the phagosomal environment and activates
mechanisms necessary for survival in a new niche. Repression of many
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transcriptional regulators may indicate downregulation of non-essential genes
and a shifting of resources towards survival. This hypothesis is supported by the
repression of genes associated with invasion or entry, which would be no longer
required by internalized bacteria.
Though motility clearly plays a role in the intracellular behaviour of B.
cenocepacia, based on the phenotypes seen for ∆BCAL0124 and ∆BCAM2837, it
is possible that upregulation of flagellar genes may be a stress response.
Escape is a logical response to exposure to a harsh environment, and indeed,
similar upregulation of motility-associated genes has been found in microarray
analyses of B. cenocepacia response to other stressors (data not shown). Strong
upregulation of flagellar genes may be a common response by intracellular
bacteria, as it is also seen in intracellular L. pneumophila (148).
The largest category of characterized genes affected by bacterial internalization
is that of metabolism suggesting metabolic adaptation to the phagosomal
environment is key to survival and replication of the bacterium. Genes involved
in carbohydrate transport and metabolism were prominently upregulated in
intracellular bacteria, accounting for 6% of all differentially upregulated genes
(Figure 9). In species of the protozoan parasite Leishmania, which also delays
phagosomal maturation and replicates in an acidified phagolysosome, metabolic
pathways involved in carbohydrate metabolism are important for intracellular
survival; studies with metabolic mutants of Leishmania have suggested that the
phagolysosome contains a variety of carbon sources and essential nutrients, but
is lacking in carbohydrates (337). Some of the most strongly induced genes are
involved in amino acid transport (Table 5); many pathogens upregulate amino
acid transport during intracellular growth, including L. pneumophila (148), S.
Typhi (149), and Y. pestis (166), suggesting amino acid acquisition from the host
may be a general carbon and nitrogen acquisition strategy.
B. cenocepacia is able to occupy a diverse array of niches, and more than onethird of B. cenocepacia's 7261 genes are involved in metabolism (195). Thus, it is
possible that there are redundant nutrient uptake systems to function under
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different conditions and exploit multiple forms of the same metabolite. The
changes seen in expression of metabolic genes (Figure 9) may demonstrate the
ability of B. cenocepacia to utilize phagosomal resources. Production of
cholesterol-like hopanoids is catalyzed by squalene-hopene cyclase Shc; B.
cenocepacia encodes two shc genes. Of these, BCAS0167 is found alone on the
third chromosome and, although contributing little to in vitro hopanoid production
(423), was strongly upregulated by intracellular bacteria. However, the theme of
genetic redundancy and niche specialization carries beyond metabolism. One of
the most strongly repressed genes was cciR, the transcriptional regulator for the
B. cenocepacia-specific second quorum sensing system. A deletion mutant in
cciR has lower protease activity than the parental isolate (297), suggesting that
production or secretion of proteases is regulated by CciR, and is thus repressed
by intracellular bacteria. Interestingly, a number of genes involved in protein
export are also strongly repressed, including the first gene of the Tat system,
several genes in the Sec system, and the signal recognition particle RNA.
Poorly characterized genes account for one-third of the B. cenocepacia genome.
This trend holds true when examining differential regulation of genes by
intracellular bacteria, where at least one-third of identified genes are poorly
characterized.

5.1.4

The BcCV at 24 hours post-infection

During late-stage infection, B. cenocepacia appears to reside within acidic
vacuoles (Figure 18) that remain associated with the endocytic pathway (Figure
19), suggestive of acidified phagolysosomes. Lysosomes loaded with TMRdextran pre-infection showed only a weak signal in infected macrophages 24 h
p.i. (Figure 19), suggesting that B. cenocepacia can alter the dextran in some
way. Molecular Probes dextran conjugates are hydrophilic polysaccharides with
an -1,6-poly-glucose linkage; of the three polysaccharides produced as EPS by
B. cenocepacia, one is a dextran consisting of -1,6-glucans (66). Since B.
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cenocepacia can produce dextran, it may also possess mechanisms to degrade
or alter dextran; thus, long-term co-infections of B. cenocepacia and fluorescent
dextran are not feasible.
During the delay of phagosomal maturation, B. cenocepacia alters transcription of
many metabolic genes. The low pH of the phagolysosome can be used to drive
high-affinity uptake of metabolite:proton symporters to bring nutrients into the cell
(62). Such a mechanism could account for the labeling of intraphagosomal
bacteria by the acidotropic dye Lysotracker red during late-stage infection (Figure
18); as the bacteria take up nutrients from the phagosome, the corresponding
increase in intracellular proton concentration would cause the bacteria to be more
acidic than the surrounding vacuole, leading to Lysotracker labeling of the
bacteria rather than the vacuole. The SCOTS microarrays show intracellular
upregulation of a putative sodium:solute symporter and a putative Na+/H+
antiporter. This suggests a cyclic system whereby the low vacuolar pH drives
sodium out of the cell through the antiporter, which returns with a metabolite
through the symporter.

5.1.5

Bacterial cytotoxicity towards murine macrophages

Previous studies have demonstrated B. cenocepacia cytotoxicity in epithelial cells
(78, 107); however, this study is the first to demonstrate B. cenocepacia
cytotoxicity towards macrophages. B. cenocepacia infection of macrophages
results in secretion of proinflammatory cytokines IL-1β (242), IL-6, IL-8, and TNFα, (104). Elevated levels of the inflammatory mediators IL-6, TNF-α, macrophage
inflammatory protein MIP-2, and IL-8 homolog KC are also found in the
bronchoalveolar lavage of mice infected with B. cenocepacia (487, 500).
Production of proinflammatory cytokines, in particular TNF-α, can lead to both
apoptosis and necrosis (4). Pilin-mediated apoptosis of B. cenocepacia-infected
epithelial cells depends on the bacterial load (78). Similarly, macrophage cell
death can be induced by M. tuberculosis when the intracellular bacillary load
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exceeds a certain threshold (258); this atypical cell death freely releases viable
bacteria to the extracellular space (259). Non-apoptotic cell death in monocytes
is associated with higher bacterial burden for infections with both E. coli and
Klebsiella pneumoniae; in both instances, cell death results in membrane
permeabilization (515). The capacity of B. cenocepacia to spread in an
unchecked infection suggests either pyroptosis or necrosis, both non-apoptotic
forms of host cell death in which the macrophage membrane is permeabilized.
Production of IL-1β by infected cells is indicative of inflammasome and caspase-1
activation; excessive caspase-1 activation can lead to pyroptosis. The
inflammasome is activated by NLR-detection of bacterial ligands in the cytosol,
and many bacterial elements – putative NLR-ligands – are dispersed throughout
the macrophage by late stages of infection (Figure 39). Pyroptosis also induces
lysosome exocytosis, whereby any bacteria residing within a lysosome are freely
delivered to the extracellular milieu as the lysosome fuses with the macrophage
plasma membrane. Thus, further investigation into bacterially-induced pyroptosis
as the putative mechanism of macrophage cell death is warranted. Where the
mutant strain appeared to prevent cytotoxicity (Figure 15), it is possible that
infected macrophages instead underwent non-membrane-permeabilizing
apoptosis, which would not be detected with 7-AAD.

5.2 Secretion systems and B. cenocepacia
The objective of this study was to determine the role played by classical multigene secretion systems in the interaction of B. cenocepacia with phagocytic cells.
Because B. cenocepacia is a significant pathogen within cystic fibrosis patients,
leading to chronic infection, and increased morbidity and mortality, an
understanding of pathogenesis is critical. Survival and replication within host
cells may contribute to the establishment and persistence of chronic infection,
while induction of host cell death and stimulation of a strong inflammatory
response may lead to deterioration of the lung. Studies have shown that B.
cenocepacia is able to modulate the endocytic pathway of phagocytic cells,
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delaying phagosomal maturation (210, 252). Furthermore, the transcriptomic
studies above suggest that B. cenocepacia utilizes the delay to metabolically
adapt to the phagosomal environment for persistence and replication in the
phagolysosome; differential regulation of a number of secretion-associated genes
by intracellular bacteria emphasizes the involvement of bacterial secretion in
interactions with macrophages.
Classical multi-gene secretion systems have been shown to have many differing
roles in the interaction of intracellular bacteria with host cells, ranging from
inhibition of phagocytosis to alteration of phagosomal maturation, to induction of
host cell death. Thus, secretion systems may play a role in the internalization,
intracellular replication, and host-directed cytotoxicity of B. cenocepacia. The
ability of B. cenocepacia to inactivate Rab7 (210), located on the cytosolic face of
the phagosome, suggests that the bacterium must be able to secrete one or more
effectors into the host cell cytosol. Though direct translocation remains to be
shown, a functional T6SS is required for intracellular B. cenocepacia to alter the
actin cytoskeleton of macrophages (25); in Vibrio cholerae (369) and Aeromonas
hydrophila (467), a T6SS has been shown to secrete effectors into the host cell
capable of affecting actin. Thus, it is likely that intra-vacuolar B. cenocepacia is
able to secrete effectors from the phagosome into the host cell.

5.2.1

Type II secretion

B. cenocepacia employs a T2SS for secretion of a variety of enzymes, including
protease, lipase, and phospholipase C (Figure 21). Deletion of the major
structural components of the T2SS did not affect internalization of B.
cenocepacia, but increased intracellular replication. This phenotype could be
complemented in a single-gene deletion (Figure 24). Deletion of the T2SS also
decreased host-directed cytotoxicity (Figure 26), and marginally increased
bacterial spread (Figure 28); the latter is likely accounted for by higher
intracellular replication yielding an increased number of bacteria available to re-
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infect. It is also possible that less host-directed cytotoxicity could account for, at
least in part, the increase seen in intracellular replication, as preservation of intact
host cells protects intracellular bacteria from the antibiotic-containing cell culture
media. Lower host-directed cytotoxicity in ∆T2SS could indicate a role for type IIsecreted enzymes in interactions with eukaryotic cells. Inactivation of the T2SSessential gene gspD in B. pseudomallei caused a small increase in LD 50 in a
hamster model of infection (126), but had no effect on nematode killing (350). A
B. cenocepacia AU1054 transposon mutant in gspJ, a pseudopilin of the T2SS,
was less pathogenic in a nematode model of infection (451), whereas four
different transposon mutants in the T2SS apparatus of B. cenocepacia H111 had
no effect on nematode killing (241). In B. vietnamiensis, the T2SS is not involved
in the intracellular survival in Acanthamoeba polyphaga (150). Thus, it seems
probable that the membrane-compromising induction of cell death by the T2SS
and T2-secreted effectors is specific to macrophages.

5.2.2

Type III secretion

Many intracellular pathogens utilize a T3SS in diverse interactions with eukaryotic
cells. In Yersinia spp., effectors secreted by the T3SS are able to prevent
phagocytosis (144). In Edwardsiella tarda, lack of a functional T3SS allows
acidification of the bacteria-containing vacuole, which precludes intracellular
replication (352). Salmonella enterica also utilizes T3SS-secreted proteins to
alter intracellular trafficking, directing the BCV away from the endosomal pathway
to a compartment more suitable for replication (191). An effector secreted
through the T3SS of Shigella flexneri induces IL-8 secretion in epithelial cells
(147). In contrast, the T3SS of Y. pseudotuberculosis is responsible for
restricting the intracellular survival of the bacterium while inducing apoptosis in
host macrophages (539). The gentamicin protection assay showed no real
contribution of the B. cenocepacia T3SS to bacterial entry or intracellular
replication (Figure 23), with 1.6- and 1.5-fold increases respectively, nor does it
appear to contribute significantly to host-directed cytotoxicity. However, deletion
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of the T3SS significantly increases spread of B. cenocepacia in an unchecked
infection, while maintaining a parental strain rate of host cell death, suggesting
that a functional T3SS is necessary to restrict B. cenocepacia to the phagosome.
Previous studies regarding the role of the T3SS in B. cenocepacia have had
mixed results. A polar insertion in the T3SS cluster did not impair intracellular
trafficking of B. cenocepacia in macrophages (252). Insertional inactivation of
T3SS gene bcscN resulted in reduced lung tissue inflammation and more rapid
bacterial clearance from the lung in a mouse model of lung infection, but did not
affect invasion of epithelial cells (480). Mutations in the T3SS also affect the rate
of killing in C. elegans in a strain-dependent manner only seen at certain time
points (306).

5.2.3

Type IV secretion

T4SSs are able to translocate both DNA and protein substrates, usually in a cellcontact dependent manner [reviewed in (188)]. Together with the T3SS, T4SSs
are the most common secretion systems involved in the interplay between
prokaryotes and eukaryote hosts. Many intracellular pathogens shown to delay
or alter phagosomal maturation utilize T4SS to translocate effectors into the host.
Legionella pneumophila requires a functional Dot/Icm T4SS for intracellular
replication and evasion of BCV fusion with lysosomes (472). Brucella spp. also
utilize a T4SS to subvert the endosomal pathway (95), with recent work showing
translocation of a Rab2-interacting effector into the host cytosol through the VirBtype T4SS (117). Coxiella burnetii, which is able to delay phagolysosomal fusion
and subsequently replicate within an acidified compartment (317), possesses a
functional T4SS capable of secreting effectors containing eukaryotic-like domains
into the cytosol of the host cell (76). Some bacteria utilize T4SSs to induce
inflammation, including L. pneumophila (172), which, along with C. burnetii, also
produces a T4-secreted effector capable of preventing host cell apoptosis (36,
281); in Bartonella spp., T4SSs lead to host adaptability (400).
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Previous research in B. cenocepacia has identified two T4SS which contain
different subunits and carry out different functions (141, 538). T4SS-1 consists of
a combination of VirB/D4 and F-specific subunits, the genes for which are spread
across half of the 92 kb plasmid of B. cenocepacia; also referred to as the Ptw
T4SS, it secretes a cytotoxic effector protein responsible for plant tissue water
soaking, thought to provide the bacteria with nutrients through the leakage of
plant cell cytosol during soft rot (141). T4SS-2, located on chromosome 2, is
homologous to the VirB/D4 T4SS of Agrobacterium tumefaciens (141), and is
involved in plasmid mobilization (538). A single study linked T4SS-1 with
intracellular survival in epithelial cells and macrophages, showing reduced
intracellular replication and more rapid maturation through the endosomal
pathway in the absence of a functional T4SS coupling protein (403). We found
that absence of the complete T4SS-1 cluster halved the number of total
internalized bacteria in the gentamicin protection assay, but doubled the number
of total infected cells with flow cytometry, suggesting internalization of fewer
bacteria per cell. The intracellular replication of ∆T4SS-1 was increased relative
to the parental strain, though correction for cytotoxicity lowered replication to
parental strain levels (Figure 27). This apparent contradiction with the previous
study may be explained by differences in calculation method. While we related
intracellular replication to bacterial entry, the former study reported total numbers
of intracellular bacteria at each time point; since the mutant bacteria are not
internalized as well, there are less initial bacteria present to replicate, lowering
the final CFU counts. Additionally, it is possible that other genes present within
the 42 kbp deletion contribute to virulence. Deletion of the plasmid-encoded
T4SS required deletion of almost half of the entire plasmid; in other intracellular
pathogens with a large plasmid, including Salmonella enterica (527), R. equi
(202), and Y. pestis (130), the plasmid contributes to intracellular survival and
virulence.
Deletion of the complete T4SS-2 cluster resulted in an increase in both
internalized bacteria and infected cells, but a decrease in intracellular replication,
when corrected for cytotoxicity. Deletion of a single gene in the T4SS-2 operon
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had no effect on bacterial entry or replication, while deletion of the homologous
gene in T4SS-1 increased bacterial entry and replication, both of which could be
complemented by restoration of the gene on a complementation plasmid (Figure
25). It is possible that subunits of each T4SS are able to cross-complement,
explaining the lack of phenotype seen for JST184. L. pneumophila contains two
separate T4SSs; the dot/icm T4SS is required for intracellular growth in
macrophages, and is involved in conjugation, while the lvh T4SS is involved in
plasmid mobilization; elements of the lvh system are able to substitute for
homologous components of the dot/icm system (432).
The significant increase in bacterial internalization in the absence of T4SS-2
suggests some involvement of the secretion system with the inhibition of
phagocytosis. Bartonella henselae translocates effector BepG through a VirB/D4
T4SS to inhibit endocytosis by human endothelial cells (382). Yersinia spp.
(144), P. aeruginosa (170), and enteropathogenic E. coli (EPEC) (176) are all
able to inhibit phagocytosis by macrophages dependent on the action of a T3SS.
Interestingly, the plant water soaking phenotype linked to T4SS-1 in B.
cenocepacia is also found in Erwinia spp. and Pantoea stewartii subsp. stewartii,
where it is caused by T3SS-mediated secretion of effectors DspE/A (197), and
WtsE/F (184), respectively. Thus, it is conceivable that an antiphagocytic
effector delivered by a T3SS in other bacteria may be delivered by T4SS-2 in B.
cenocepacia. Of note, B. cenocepacia J2315, which belongs to the ET12
epidemic clone of B. cenocepacia along with strain K56-2, is internalized by
macrophages at an increased rate and in increased numbers per cell (411), and
contains a frameshift mutation in VirD4 of the T4SS-2 cluster (195).
In flow cytometry assays, neither T4SS deletion affected cell spread, but ∆T4SS2 was less cytotoxic. We determined cytotoxicity by means of 7-AAD, a
fluorescent compound that binds to DNA but cannot readily cross cell
membranes, thus technically measuring membrane permeability. Legionella spp.
require the dot/icm T4SS to permeabilize macrophage membranes, leading to
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pyroptosis (522), thus is it possible that inactivation of T4SS-2 in B. cenocepacia
prevents release of a membrane-permeabilizing effector.

5.2.4

Type VI secretion

The recently identified T6SS, the most common of the gram-negative large
specialized secretion systems, plays a diverse role in interbacterial interactions;
however, it is also linked with host interactions in certain pathogens [reviewed in
(426)]. In a previous study, three separate transposon mutants in the T6SS
cluster of B. cenocepacia were attenuated for virulence in a rat model of chronic
lung infection (207), showing a definite role in pathogenesis. B. cenocepacia
upregulates expression of T6SS genes during macrophage infection. Deletion of
the T6SS in B. cenocepacia did not alter the number of bacteria internalized by
macrophages (Figure 23), nor the number of eukaryotic cells infected (Figure 26),
but significantly increased intracellular survival of the bacteria, a phenotype
clearly complemented in a single gene deletion model (Figure 25B). An increase
in observed intracellular replication could be due to the fact that cytotoxicity was
significantly decreased in ∆T6SS infected-macrophages. As with the T2SS,
maintaining the integrity of the macrophage membrane protects intracellular
bacteria from the antibiotic-laden culture media, thus leading to an increase in
viable bacteria at 24 h post-infection. However, the unchecked spread of the
mutant at a rate similar to the parental strain suggests either a true increase in
intracellular replication - with less macrophages dying, more bacteria must be
released per macrophage to maintain the rate of spread – or a non-membrane
damaging method of bacterial release. Comparison with ∆BCAL0340 –
examined during the transcriptomic study above – lends credence to the former
hypothesis. BCAL0340, a putative lipoprotein, is the first gene in the second
transcriptional unit of the T6SS (24); macrophages infected with ∆BCAL0340 still
show evidence of an altered actin cytoskeleton (data not shown), while
macrophages infected with deletions in BCAL0342, BCAL0343, or the entire
T6SS cluster do not (24, 25). ∆BCAL0340 does not show decreased
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macrophage-directed cytotoxicity (Figure 15), but does show increased
intracellular replication (Figure 11), suggesting that ∆T6SS truly replicates faster
than the parental strain bacteria within the phagosome. The ability of the T6SS
to limit intracellular replication is also seen in Y. pestis, although the
corresponding promotion of phagocytosis in Y. pestis was not seen in B.
cenocepacia (386). In B. pseudomallei, inactivation of T6SS-1 resulted in
decreased cytotoxicity in macrophages, as well as decreased virulence in a
hamster model of melioidosis (65). The role of the T6SS in macrophage-directed
cytotoxicity has also been demonstrated in A. hydrophila; expression of T6essential gene hcp resulted in epithelial cell apoptosis (468). Thus, there is a
clear role for the T6SS of B. cenocepacia in interactions with macrophages,
especially in limiting intracellular replication and promoting host-cell directed
cytotoxicity.

5.2.5

The contribution of secretion systems as a whole

B. cenocepacia is somewhat unusual in that it encodes at least one of every
known gram-negative multi-gene secretion system, including both T3SS and
T4SS (195). Among pathogenic Burkholderia spp., however, it lacks the large
redundancy of secretion systems seen with B. pseudomallei and B. mallei, which
have three and two T3SSs, and six and four T6SSs, respectively (196, 344).
Deletion of each secretion system, entailing deletion of large segments of DNA,
does not affect the growth of the bacterium in rich media; indeed, deletion of all
secretion systems in a single strain – accounting for a total of 109 kbp – does not
cause any growth defect (Figure 20). In gentamicin protection assays, JST112
behaved as the parental isolate with regards to bacterial entry and intracellular
replication (Figure 23). However, flow cytometry revealed a four-fold reduction in
infection for JST112, suggesting internalization of a greater number of bacteria
per cell by a decreased number of cells. Interestingly, though T4SS-2 is absent,
there is no increase in bacterial internalization, suggesting that bacterial uptake
by macrophages may be more complex than simple phagocytosis. In B.
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cenocepacia J2315, the internalization of more bacteria per cell has been linked
to the absence of a complete lipopolysaccharide (LPS) O antigen (411),
demonstrating a role in for surface structures in the interactions between bacteria
and macrophage. However, J2315 also infects a greater number of cells, which
is not seen for JST112. The means by which B. cenocepacia enters
macrophages is unknown; it is possible that there is a threshold level of
stimulation for phagocytosis which is more difficult to reach in the absence of the
large outer membrane structures unique to specialized secretion systems, thus
requiring the presence of increased numbers of JST112 for a single event.
Flow cytometry also showed a decrease in host-directed cytotoxicity by a mutant
lacking large secretion systems; though JST112 spreads rapidly in an unchecked
infection, it remains much less cytotoxic than the parental strain (Figure 28). The
cause of such bacterial spread – 40-fold in 24 hours – in the absence of
increased intracellular replication or increased host cell death is source for
speculation. Lack of large specialized secretion systems does not preclude all
secretion from the cell – at the minimum, types I and V remain possibilities (195)
– but it does prevent expression, or at least translocation, of a vast array of
effectors. Effectors of the T2SS, T4SS-2, and T6SS all contribute to hostdirected cytotoxicity (Figure 26). It is possible that JST112, likely unable to
secrete effectors to the host cytosol, avoids activating a strong proinflammatory
response or permeabilizing the cell membrane, and simply resides within the
phagosome. In the absence of a functional T6SS, the host cytoskeleton is
unaffected, allowing normal motility and replication of the macrophage. Infected
macrophages typically show multiple BcCVs, especially at later time points postinfection (Figure 18); the rapid spread of the bacteria could be due to normal
proliferation of infected macrophages. Of note, though the ratio of dead to
infected host cells is lower in a JST112-infection, the total number of dead host
cells is actually increased due to the rapid spread. Thus, secretion systems may
function as an infection-limiting factor in B. cenocepacia, enabling bacterial
persistence. Such a strategy is exemplified by Brucella spp., which utilize a
T4SS to stimulate an inflammatory response carefully balanced between
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checking uncontrolled intracellular replication and preventing host cell death, thus
allowing the bacteria to establish a chronic infection within a granuloma (118).
Similarly, B. cenocepacia-infected macrophages attract other non-infected cells in
zebrafish embryos, forming cellular aggregates within which local bacterial
spreading occurs 15 to 20 h post-infection (502). Aggregate formation and
kinetics of embryo death differ between B. cenocepacia J2315 and K56-2.
B. cenocepacia strains K56-2 and J2315 are clonal isolates belonging to the
highly transmissible lineage known as ET12; J2315, first isolated from a CF
patient in Scotland, was the index strain for epidemic spread, while the more
genetically-tractable K56-2 was isolated from a CF patient in Canada (290).
Though closely related, K56-2 and J2315 have accumulated different genetic
mutations. Apart from the aforementioned frameshift mutation in T4SS-2, B.
cenocepacia J2315 also contains a 110-bp deletion in gspL, an essential
component of the T2SS, and a frameshift mutation in BCAM2043, located in the
T3SS cluster (195), putatively inactivating three of the five large, specialized
secretion systems. Though there are undoubtedly other genetic differences
between K56-2 and J2315, it is interesting to link the presence of functional
secretion systems with pathology. In our study, absence of the T3SS allowed the
bacteria to spread more widely, while absence of T4SS-2 was linked with
increased bacterial uptake, and both the T2SS and T4SS-2 were associated with
host-directed cytotoxicity. Thus, in the absence of these three secretion systems,
one could expect to see increased bacterial uptake, widespread bacterial
spreading, and slower host killing. As mentioned previously, J2315 infects a
greater number of macrophages with a greater number of bacteria than an
equivalent infection with K56-2 (411). As an aside, this would tend to suggest a
role for T4SS-1 in balancing the anti-phagocytic activity of T4SS-2, as this
increase is not seen in JST112. In a C. elegans nematode model, though K56-2
killed rapidly, J2315 was also pathogenic at a slower rate, a phenotype not
dependent on the LPS O antigen (69). Differences in virulence may also be seen
in a zebrafish embryo model, where killing by K56-2 occurred within 48h, but
J2315 required an additional 24h to induce significant host death; microscopic
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examination revealed widespread dissemination of J2315 bacterial aggregates
throughout the vasculature of the embryo prior to death, a phenotype not seen in
K56-2 infection (502). Thus, anecdotal evidence would tend to support the role of
secretion systems in the pathogenicity of B. cenocepacia.

5.3 Proposed future experiments
There are many interesting avenues to pursue, beginning with further
investigation into genes upregulated by intracellular B. cenocepacia during
phagosomal adaptation 4 h p.i.. Transcriptomic analysis of B. cenocepacia and
further characterization of the BcCV during late stage infection would contribute
to a greater understanding of the bacteria-macrophage interaction. The role of
bacterial secretion systems should be investigated in models more relevant to
human infection, and an attempt made to identify effectors contributing to
interactions with eukaryotic cells.

5.3.1

Further investigation of genes regulated by intracellular
bacteria

One area for further study is the role of iron in the intracellular life of B.
cenocepacia. Intracellular bacteria may limit siderophore-mediated iron
acquisition, as the receptor for ornibactin is downregulated 10-fold, as is the
transcriptional activator for the pyochelin receptor; the putative pyochelin
biosynthetic protein is also repressed. However, three transport proteins
predicted to be involved in TonB-dependent ferric iron uptake are upregulated.
Another aspect of future studies is further characterization of metabolic
adaptation to the phagosome, including the upregulation of amino acid
transporters, and the role of cobalamin in the intracellular life of B. cenocepacia.
Other avenues to pursue include quorum sensing - B. cenocepacia-specific
regulator cciR is downregulated 46-fold by intracellular bacteria - and changes to
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the membrane and surface structures; a squalene-hopene cyclase necessary for
hopanoid biosynthesis is strongly upregulated, as are genes found in the clusters
of both the Flp type pilus and type IVa pilus, while a number of adhesins,
including the 22 kDa adhesin encoded by BCAM2143 and several BuHA family
proteins, are differentially regulated. Lipase has proven important to infection in
epithelial cells (336), suggesting that strongly upregulated lipase BCAM0949 may
play a role in the interactions between B. cenocepacia and macrophages. Other
specific genes meriting further characterization include CheYC protein
BCAM2837 and conserved hypothetical protein BCAM0314, both among the
most strongly upregulated by intracellular bacteria; BCAM2837 displays a strong
phenotype in macrophages, but little is known regarding its true function, while
BCAM0314 is homologous to a putative cell wall-associated hydrolase.

5.3.2

The transcriptional response of macrophage-adapted B.
cenocepacia

With the development of gentamicin-sensitive B. cenocepacia MH1K, the
transcriptional response of B. cenocepacia at later stages of infection can now be
analyzed with SCOTS and microarrays or next-generation sequencing. Many of
the genes upregulated at 4h p.i. are involved in signal transduction and
transcription, suggesting adaptation is only beginning; as the phagosomal
environment continues to evolve, B. cenocepacia must continue to adapt. In L.
pneumophila, the number of upregulated genes increases with time post-infection
(148). Following adaptation to the phagosome, B. cenocepacia is capable of
replicating, inducing host cell death, and escaping the macrophage. Thus,
transcriptome analysis of B. cenocepacia throughout a time-course of infection
could significantly contribute to a more complete understanding of the interaction
between B. cenocepacia and murine macrophages.
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5.3.3

The role of secretion systems in CF infection

Large, specialized, multigene secretion systems play a clear role in the
interaction of B. cenocepacia with murine macrophages; however, there are
many steps between relevance in murine macrophages and relevance to human
infection. The panel of secretion system mutants should be examined in more
relevant cell culture models, including CFTR-/- macrophages and primary cells,
and in higher organisms, including zebrafish and murine models. In addition,
because it is strongly upregulated by intracellular bacteria, a deletion mutant in
the T1SS should be added to the panel of secretion system mutants.
Furthermore, analysis of the secretome for each of the mutants may prove useful
in identifying effectors important in interactions with macrophages.
The contribution of secretion systems to the dispersal of bacterial elements
throughout the macrophage could be investigated by B. cenocepacia Ab labelling
of macrophages infected with JST112; should the dispersed bacterial elements
be absent in JST112 infection, further experiments with the entire panel of
secretion system mutants could identify the specific system responsible.
Identification of the bacterial components would require isolation of macrophage
membranes during late-stage infection. If the bacterial component is a protein, it
could be detected in a Western blot using B. cenocepacia Ab and identified by
mass spectrometry; likewise, bacterial LPS could be detected by Western blot.
Effectors translocated in the host cell cytosol by other bacteria have been
identified by fusing genomic fragments to adenylate cyclase and assaying for an
increase in host cell cAMP levels (70). Once identified, putative effectors would
be screened through the panel of secretion system mutants to determine which
system is responsible for translocation.

5.3.4

Further characterization of late stage macrophage infection
by B. cenocepacia

Preliminary characterization suggests that the BcCV is an acidified
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phagolysosome 24h p.i., but further studies are necessary. Immunolabelling with
compartment-specific markers such as LAMP-1 and cathepsin D, and
colocalization with Lysosensor dextran would contribute to confirmation; the
possibility of autophagy should also be investigated. Because experiments with
Lysotracker red suggest that intracellular bacteria themselves become acidified,
measurement of intraphagosomal pH over time would show whether B.
cenocepacia is able to decrease the pH of the vacuole.
While we have shown that B. cenocepacia can induce host cell death, the mode
of cell death is unclear. Apoptosis could be investigated via flow cytometry
analysis of infected cells labelled with specific markers. The ability of B.
cenocepacia to affect host cell signalling, including caspase activation, should
also be examined.
It would also be interesting to isolate and characterize phagosomally-adapted B.
cenocepacia. It has been shown that E. coli is capable of transcriptional
adaptation in anticipation of natural environmental change (329); such bacterial
“learning” suggests that bacteria which escape the macrophage may be better
suited to re-infect neighbouring cells. It would be interesting to investigate the
infection rate, intracellular trafficking, and replication rate of B. cenocepacia
isolated from late-stage macrophage infection. Perhaps B. cenocepacia would
not need to delay phagosomal maturation, being already adapted to the
phagosomal environment. It could be hypothesized that previously intracellular
B. cenocepacia would display increased infection and intracellular replication,
and more rapid host cell-directed cytotoxicity.

5.4 Significance and concluding remarks
Altogether, it appears that there are many elements contributing to the
intracellular survival and behaviour of B. cenocepacia; if there is a single gene or
gene cluster that is absolutely essential for intracellular survival, it has yet to be
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discovered. B. cenocepacia has an extremely large genome and broad
metabolic range, potentially explaining the ability of the bacteria to survive in a
wide variety of niches, including the hostile environment of the phagolysosome.
Indeed, the intracellular survival of B. cenocepacia in macrophages is associated
with profound changes in metabolic activity and motility rather than the presence
of more specific traditional "virulence" genes. Delay of phagosomal maturation
provides time for the bacteria to alter gene expression conferring a survival
advantage for persistence and replication in a phagolysosomal compartment.
The role of secretion systems in the intracellular behaviour of B. cenocepacia is
complex. Large, specialized secretion systems - predominantly the T4SSs - are
involved in bacterial entry into macrophages, in terms of both numbers of host
cells infected and numbers of bacteria per host cell. Secretion systems,
particularly the T2SS and T6SS, also play a role in intracellular replication, and
host-directed cytotoxicity, though it is likely that the latter two are intertwined, as
preservation of the host protects intracellular bacteria. Together, secretion
systems function to limit the spread of B. cenocepacia and increase pathogenicity
during cell culture infection.
B. cenocepacia is an opportunistic pathogen, not an obligate intracellular
pathogen, and as such, simply adapts to survive in the niche in which it finds
itself until it can be released back into the extracellular milieu by dying
macrophages. The mechanism by which B. cenocepacia is internalized and
induces host cell death, whether purposeful or incidental, and the role of the
varied secretion systems in this interaction, is a subject for further study as it
relates to the establishment and maintenance of a chronic infection in host cells
of cystic fibrosis patients.
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Appendix 1

1

The role of outer membrane vesicles in the intracellular
behaviour of B. cenocepacia

1.1 Introduction
Vesiculation is a nearly ubiquitous process in Gram-negative bacteria.
Vesiculation may allow bacteria to interact with and alter surrounding prokaryotic
and eukaryotic cells (11, 16). Indeed, vesiculation has been referred to as a
secretion mechanism, allowing delivery of potentially large and complex mixtures
of proteins and lipids to the extracellular milieu (11). Although the actual
mechanism of vesiculation is elusive, it is thought that periplasmic cargo is
encapsulated within an outer membrane (OM) bleb (20, 23) when the OM bulges
and pinches off at sites where cross-links between peptidoglycan and the OM are
decreased (9); vesiculation is not indicative of membrane instability (17), but
appears to be directed, as specific proteins, lipids, and sugars may be enriched
or excluded in these vesicles (11). As such, vesicles have the capacity to act as
potent virulence factors for pathogenic bacteria, delivering toxins, enzymes, and
immunomodulatory compounds to a host or neighbouring cell; indeed, vesicles
from B. cepacia have been found to possess LPS, proteases, lipases, PLC, and
peptidoglycan hydrolases, all putative virulence factors which could have a role in
intracellular survival (1). Vesicles have been observed within the context of
infection: Borrelia burgdorferi, the causative agent of Lyme disease, produces
vesicles following invasion of the dermis (3), vesiculating Neisseria meningitidis
has been identified in the cerebrospinal fluid and blood of meningitis patients
(21), and, Helicobacter pylori vesicles containing vacuolating cytotoxin have been
detected in gastric epithelium biopsies (7). Vesiculation has been suggested as a
response to stress, which would certainly be present in an intracellular setting. P.
aeruginosa alters LPS and increases production of membrane vesicles under
conditions of oxidative stress (22), and Escherichia coli appears to vesiculate in
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response to envelope stress (18). L. pneumophila releases natural membrane
vesicles which are capable of delaying phagosome-lysosome fusion
independently of the T4SS (5). Thus, for pathogenic bacteria, including B.
cenocepacia, vesicles may be important tools in establishing and maintaining
infection.

1.2 Materials and Methods

1.2.1

Bacterial strains and growth conditions

Bacterial strains and plasmids used in this study are listed in Table 8. Bacteria
were grown at 37oC in Luria-Bertani (LB; Difco) broth with agitation or on LB
plates with 1.6% Bacto agar. For vesicle isolation, large scale broth cultures of
bacteria were grown in either trypticase soy broth (TSB) or 3-(N-morpholino)
propanesulfonic acid (MOPS) – minimal salts – tryptose (MMST) medium [3 mM
KCl, 12 mM (NH 4 ) 2 SO 4 , 3.2 mM MgSO 4 , 0.02 mM FeSO 4 , 3 mM NaCl, 20 mM
glucose, 0.1% w/v tryptose (Difco)]. Escherichia coli cultures were supplemented
as required with 20 g/ml tetracycline, 50 g/ml trimethoprim, and 40 g/ml
kanamycin; B. cenocepacia cultures were supplemented as required with 100
g/ml tetracycline and 100 g/ml trimethoprim. Plasmids were conjugated into B.
cenocepacia by triparental mating at 37oC using E. coli DH5α carrying helper
plasmid pRK2013 (6). E. coli donor and helper strains were selected against with
50 g/ml gentamicin.

1.2.2

Vesicle isolation

Outer membrane vesicles were isolated as in Allan et al. (1). Briefly, one litre of
B. cenocepacia C5424 was grown to an OD 600 of 1.0-1.5. Cells were removed by
centrifugation at 6000 x g, and the cell-free supernatant was filtered
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Table 8: Bacterial strains and plasmids
Strain or
Relevant characteristics
plasmid
Escherichia coli
F-, f80 lacZ DM15 D(lacZYA-argF) U169 endA1
DH5α
recA1 hsdR17 (r K - m K +) supE44 thi-1 DgyrA96 relA1

Laboratory
stock

Burkholderia cenocepacia
J2315
epidemic strain ET12 clone, CF clinical isolate
K56-2
epidemic strain ET12 clone, CF clinical isolate
C5424
epidemic strain ET12 clone, CF clinical isolate

P.A. Sokol
BCRRCa
BCRRCa

Plasmid
pRK2013
pDA17
pRF132
pJRL1
a

RK2 derivative, KanR, mob+, tra+, ori colE1
ori pBBR1 , TetR, mob+, P dhfr , FLAG epitope
pDA17, BCAL2829 HtrA
ori pBBR1 , TpR, mob+, P dhfr , mRFP1

Source or
reference

(6)
(8)
(8)
(12)

B. cepacia complex Research and Referral Repository for Canadian CF Clinics
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sequentially through 0.45 m and 0.2 m polyethersulfone (PES) membranes.
OMVs were collected by centrifugation at 150 000 x g for 3h at 5oC, resuspended
in 50 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) pH 6.8,
and retained at -20oC. OMVs were purified through a 30% - 60% sucrose
gradient in 50 mM HEPES pH 6.8. Gradients were centrifuged at 183 000 x g for
18h; no brake was applied to slow the centrifuge. Fractions were removed and
protein concentration determined via absorbance at 280 nm.
OMV were also isolated as in McBroom et al. (17). Bacteria were pelleted from
250 mL overnight broth cultures by centrifugation at 10 000 x g for 10 min at 4oC.
The supernatant was filtered twice through a 0.45 m cellulose ester filter and
centrifuged at 38 400 x g for 1h at 4oC. Pelleted vesicles were resuspended in
Dulbecco’s PBS with 0.2 M NaCl and retained at -20oC.

1.2.3

Outer membrane and periplasmic protein isolation

Outer membrane proteins were isolated via a modified version of the Sarkosyl
insolubility protocol of Carlone et al. (4). Bacterial cells were resuspended in 10
mM Tris/HCl pH 8.0 and disrupted by sonication until clear. The lysate was
pelleted, and the supernatant centrifuged at 31 191 x g for 30 min at 4oC. The
pellet was resuspended in 1.5% w/v Sarkosyl in 20 mM Tris/HCl pH 8.0 and
incubated at RT for 20 min. Samples were centrifuged as above, and the OMcontaining pellet resuspended in sterile water.
Periplasmic proteins were isolated as described previously (10). Bacterial cells
were pelleted at 9000 x g for 10 min and resuspended in lysis buffer (20% w/v
sucrose, 30 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0, 3.5 mg/mL lysozyme). Cell
suspensions were incubated at 37oC for 3h, and spheroplast formation confirmed
by light microscopy. Spheroplast preparations were centrifuged as above, and
supernatants containing periplasmic proteins were retained at -20oC.
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1.2.4

Protein analysis

Protein concentration was determined using the Bradford assay (Bio-Rad). For a
slot blot (BioRad), protein adherence to a nitrocellulose membrane was mediated
by vacuum according to the manufacturer’s instructions. Both SDS-14% PAGE
and protein transfer to nitrocellulose membranes were performed as described
previously (2). Gels were stained with Coomassie [0.1% (w/v) Coomassie blue,
10% (v/v) acetic acid, and 50% (v/v) methanol] or with silver. Silver staining
required gel fixation [40% (v/v) 95% ethanol, 10% (v/v) acetic acid] and
sensitization [0.02% (w/v) Na 2 S 2 O 3 .5H 2 O] prior to staining [0.1% (w/v) AgNO 3 ]
and developing [0.04% (v/v) CH 2 O, 2% (w/v) Na 2 CO 3 ]. Membranes for slot blot
and Western blot were incubated with our own rabbit-raised B. cenocepacia
J2315 antibodies or FLAG M2 monoclonal antibodies (Sigma) and AlexaFluor
IRDye800 CW affinity-purified anti-rabbit IgG (Rockland) or AlexaFluor 680 goat
anti-mouse IgG (Molecular Probes) secondary antibodies, respectively; reacting
bands were fluorescently detected with the Odyssey infrared imaging system
(Licor Biosciences).

1.2.5

Lipopolysaccharide analysis

LPS was extracted as described previously (14, 15). Briefly, bacteria or OMV
were resuspended in PBS, and boiled for 10 min in lysis buffer [2% sodium
dodecyl sulfate (SDS), 4% -mercaptoethanol, 10% glycerol, and 1M Tris (pH
6.8)]. The lysate was treated with proteinase K at 60oC for 12h, and stored at 20oC. LPS was separated on a 14% polyacrylamide gel using Tricine-SDS buffer
and silver-stained as described previously (15). LPS was quantified using the
Purpald assay (13).
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1.2.6

Lipid quantitation

OMVs were incubated with 3.3 g/mL FM4-64 (Molecular Probes) in PBS at 37oC
for 10 min. Following excitation at 506 nm, emission at 750 nm was measured
with a Cary Eclipse spectrofluorometer (Varian). Vesicle production was
calculated as fluorescence units (FU) relative to the CFU of the initial culture.

1.2.7

Electron microscopy

OMV preparations and B. cenocepacia C5424 grown overnight in TSB were
negatively stained with 1% uranyl acetate and imaged on a Phillips EM300
electron microscope; imaging was done in the Transmission Electron Microscope
(TEM) facility in the Department of Microbiology and Immunology at the
University of Western Ontario.

1.2.8

Cell culture and infection

RAW 267.4 macrophages (ATCC) were maintained in DMEM (Wisent)
supplemented with 10% FBS (Wisent) at 37oC in a 95% humidified atmosphere
with 5% CO 2 . For macrophage infection, cells were seeded in a 6-well plate at 5
x 105 cells per well and grown 15 h. Bacterial cultures grown at 37oC for 16 h
were washed twice and resuspended in DMEM-10% FBS. Macrophage
monolayers were washed with PBS (Wisent). Bacteria were added at a
multiplicity of infection (MOI) of 50:1 in 2 ml DMEM-10% FBS. Plates were
centrifuged 1 min at 300 x g and incubated at 37oC, 95% humidity and 5% CO 2 .

1.2.9

Gentamicin protection assay

RAW267.4 macrophages were infected as above with E. coli DH5 at an MOI of
30. E. coli was infected alone, with HEPES buffer, or with B. cenocepacia OMV.
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30 min post-infection, macrophage monolayers were washed three times with
PBS and DMEM-50 μg/ml gentamicin was added to kill extracellular bacteria.
Infected monolayers were washed with PBS, and lysed with cold sterile water at
30, 60, and 90 min p.i.. Surviving bacteria were enumerated by bacterial plate
count for CFU.

1.2.10

Bead labelling and infection

Protein A Dynabeads (Invitrogen) were coated with B. cenocepacia J2315 Ab
according to the manufacturer’s instructions; 40 L of antibody was added to 10
L of 0.5 M NaPO 4 buffer pH 8.1, and incubated with 50 L of Dynabeads for 10
min. 75 L of B. cenocepacia or 500 L of B. cenocepacia OMV were captured
by the Ab-coated beads. Macrophages were infected as above at an MOI of 10
beads/macrophage.

1.2.11

Immunolabelling and confocal microscopy

Immunolabelling was performed as in Lamothe et al. (12). Briefly, coverslipgrown infected macrophage monolayers were fixed in 4% (v/v) paraformaldehyde
for 30 min at RT, followed by a 10 min incubation with 100 mM glycine. Cells
were permeabilized with 0.1% (v/v) Triton X-100 and blocked with 5% (w/v) skim
milk powder for 1h at RT. Cells were sequentially labelled with 1:500 rabbit antiB. cenocepacia J2315 and 1:1000 AlexaFluor 488 goat anti-rabbit (Molecular
Probes) antibodies, each for 1h at RT in 5% milk. Rat anti-mouse LAMP-1 (ID4B;
Developmental Studies Hybridoma Bank) was used at a dilution of 1:50, with
1:1000 secondary antibody AlexaFluor 488 chicken anti-rat (Molecular Probes).
Coverslips were mounted onto glass slides using fluorescent mounting medium
(Dako Cytomation). Images were acquired on a Zeiss LSM 510 laser scanning
confocal microscope with a 100x oil immersion objective.
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1.3 Results

1.3.1

Vesicle isolation and characterization

OMVs were isolated from late-exponential phase rich medium cultures of B.
cenocepacia using the protocol of Allan et al. (1). The presence of bacterial
components in the vesicle fraction was confirmed by a slot blot with B.
cenocepacia J2315 antibodies (Figure 29), which revealed higher putative vesicle
production by B. cenocepacia C5424 than by J2315. B. cenocepacia C5424 is
effectively labelled with J2315 Ab, but not with K56-2 Ab, and delays phagosomal
maturation similar to J2315. Neither the Bradford assay for protein nor the
purpald assay for LPS were able to accurately quantify OMV production, despite
the presence of LPS core and several major proteins in OMV preparations
(Figure 30).
TEM imaging of B. cenocepacia C5424 showed vesiculation by TSB-grown
bacteria (Figure 31A); imaging of isolated OMVs (Figure 31B) demonstrated the
efficacy of vesicle isolation, but also showed significant contamination by flagella
and pili. OMV purification through a sucrose gradient showed protein content
only in the final fractions (Figure 32), of which most contained only a single 45kDa protein suggestive of flagellin. Consequently, the OMV isolation protocol of
McBroom et al. (17) was adopted, as lower centrifugation speeds would be less
prone to pelleting contaminating structures.
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Figure 29. Bacterial components are detectable in outer membrane vesicle
fractions.
Samples were adsorbed to a nitrocellulose membrane via vacuum. Rows
contain 50 L (A) or 200 L (B) of indicated sample. Membranes were
blotted with anti-B. cenocepacia J2315.
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Figure 30. Vesicle fractions contain proteins and lipopolysaccharide.
Native or boiled OMV fractions and whole cell lysates were separated on
a 14% polyacrylamide gel by SDS-PAGE and stained with Coomassie
blue (A) or transferred to a nitrocellulose membrane and blotted with antiB. cenocepacia J2315 (B). Molecular weight marker (M) masses in kDa.
LPS extracted from isolated OMV or B. cenocepacia C5424 was
separated on a 16% Tricine-SDS-PAGE gel and stained with silver nitrate.
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Figure 31. B. cenocepacia produces vesicles.
(A) Negative-stained B. cenocepacia C5424 grown in TSB.

Arrow

indicates vesicle. Bar = 500 nm. (B) Negative-stained OMV preparations
without sucrose gradient purification. Contaminating flagella and pili are
present. Arrow indicates OMV. Bar = 100 nm.
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Figure 32. OMV purification through sucrose gradient ultracentrifugation.
Protein concentration in each fraction of the sucrose gradient was
quantified at a 1 in 5 dilution via absorbance at 280 nm (A). Later fractions
were separated on a 14% polyacrylamide gel by SDS-PAGE and stained
with silver nitrate (B) or transferred to a nitrocellulose membrane and
blotted with anti-B. cenocepacia J2315 (C). Molecular weight marker (M)
masses in kDa.
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1.3.2

Increasing vesiculation in vitro

Bacteria increase vesiculation under conditions of stress, including oxidative (22)
and envelope stress (18). We overexpressed the periplasmic protein HtrA from
constitutively active plasmid pRF132 in B. cenocepacia C5424. OMV produced
by B. cenocepacia C5424 pRF132 are enriched in protein relative to OMV
produced by wild type bacteria (Figure 33). While the FLAG-tagged protein is
present in isolated periplasmic protein, a lesser amount is also present in the OM;
though this may be due to the high level of overexpression, the FLAG signal in
isolated OMV cannot be conclusively linked to the packaging of periplasmic
proteins (Figure 34).
Nutrient limitation and growth rate have been linked to the regulation of virulence
factor production in “B. cepacia” (19); previous studies have shown an
enrichment in OMV-packaging of enzymes during growth in minimal media (1).
Bacterial growth in minimal medium MMST significantly increased relative
vesiculation compared to growth in rich medium TSB (Figure 35); the protein
composition of MMST-OMV was different from TSB-OMV (Figure 36). TEM
imaging of MMST-grown C5424 revealed smaller bacteria, many of which were
associated with OMV (Figure 37); TEM imaging of isolated OMV showed a
decrease in contaminating protein.

1.3.3

Intramacrophage vesiculation

An antibody against whole formalin-fixed B. cenocepacia J2315 was raised in
rabbits; this antibody could be used for effective (Figure 38A), and specific
(Figure 38B) immunolabelling of B. cenocepacia. In infected macrophages, the
B. cenocepacia-specific Ab labels elements unassociated with intact mRFP1labelled bacteria; over the course of an infection, these bacterially-derived
elements increase in number and in distance from intracellular bacteria (Figure
39).
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Figure 33.

Overexpression of a periplasmic protein results in a greater

concentration of protein and LPS in isolated OMV fractions.
Equivalent volumes of OMV isolated from B. cenocepacia C5424 and B.
cenocepacia C5424 pRF132 were separated on a 14% polyacrylamide gel
by SDS-PAGE and stained with silver nitrate (A) or transferred to a
nitrocellulose membrane and blotted with anti-B. cenocepacia J2315 (B).
Molecular weight marker (M) sizes are listed in kDa. LPS prepared from
equivalent volumes of OMV isolated from B. cenocepacia C5424 and B.
cenocepacia C5424 pRF132 were separated by 16% Tricine-SDS-PAGE
and stained with silver nitrate (C).
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Figure 34. Periplasmic protein can be detected in isolated OMV.
Outer membrane (OM), periplasmic protein (P), and isolated OMV (V)
were separated on a 14% polyacrylamide gel by SDS-PAGE, transferred
to a nitrocellulose membrane and blotted with anti-B. cenocepacia J2315
(A) or anti-FLAG (B). Molecular weight marker (M) masses in kDa.
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Figure 35. Nutrient stress increases relative vesiculation.
B. cenocepacia growth is slowed in minimal media MMST when compared
to growth in rich media TSB, but vesiculation is increased.

(A) Bacterial

concentration of overnight cultures from which OMV were isolated. (B)
Total OMV obtained in an equivalent isolation procedure, as measured in
fluorescence units. Fluorescence units quantify the lipid content of OMV
fractions via lipophilic probe FM4-64. (C) Relative vesiculation, defined as
fluorescence units in isolated OMV fractions per CFU of culture. Standard
error of 2 (TSB) and 4 (MMST) independent experiments is indicated.
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Figure 36. OMV isolated from nutrient-stressed bacteria display an altered
protein profile.
OMV isolated from E. coli DH5, B. cenocepacia C5424 grown in rich
media TSB, and B. cenocepacia C5424 grown in minimal media MMST
were separated on a 14% polyacrylamide gel by SDS-PAGE and stained
with Coomassie blue. Molecular weight marker (M) masses in kDa.
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Figure 37. Growth in minimal media alters the size, shape, and vesiculation
of B. cenocepacia.
(A) Negative-stained B. cenocepacia C5424 grown in MMST.

Arrow

indicates vesicle. Bar = 500 nm. (B) Negative-stained OMV preparations
isolated with slower centrifugation. Arrow indicates vesicle. Bar = 100 nm.
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Figure 38. B. cenocepacia antibodies effectively label the bacteria (A), but
do not bind to uninfected macrophages (B).
RAW264.7 macrophages were infected with B. cenocepacia J2315
expressing mRFP1, immunolabelled with anti-B. cenocepacia J2315, and
observed with confocal (A) or fluorescence light (B) microscopy. Arrow
indicates an uninfected cell.
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Figure 39. Anti-B. cenocepacia-reacting particles dispersed throughout
infected macrophages increase in number and in distance from intact
bacteria over time.
RAW264.7 macrophages were infected with B. cenocepacia J2315
expressing mRFP1, immunolabelled with anti-B. cenocepacia J2315, and
observed with confocal microscopy.

From left to right, panels show

merged green anti-J2315 and red mRFP1-expressing J2315 fluorescence,
and fluorescence merged with the DIC image at 30 min (A), 2h (B), 4h (C),
and 6h (D) post-infection. Arrows indicate anti-B. cenocepacia-reacting
particles that are unassociated with intact bacteria.
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1.3.4

The effect of B. cenocepacia OMV on the intracellular
trafficking of inert particles

If the OMV shed by B. cenocepacia are the mechanism by which phagosomal
maturation is delayed, then the OMV alone should be able to delay delivery of an
inert particle to the lysosome. Protein A Dynabeads are magnetic particles to
which IgG will strongly bind; thus, B. cenocepacia bacteria or OMV can be linked
to the particle via B. cenocepacia J2315 Ab. In theory, such a protocol would
allow magnetic purification of the BcCV. However, the beads are poorly
internalized in the absence of bacterial components (Figure 40), immunolabelling
antibodies bind directly to the beads, antibody binding is inconsistent, and linked
bacteria can be sheared from the beads (Figure 41).

1.3.5

The effect of B. cenocepacia OMV on the intracellular
survival of E. coli

If the OMV shed by B. cenocepacia are the mechanism by which phagosomal
maturation is delayed, then co-infection of E. coli with B. cenocepacia OMV
should prolong the intracellular survival of E. coli by delaying delivery to the
lysosome. Macrophages were infected with E. coli alone, in the presence of
buffer, or in the presence of B. cenocepacia OMV. In the presence of HEPES
buffer, macrophages took up more E. coli, a phenotype abrogated by the
presence of B. cenocepacia OMV in HEPES (Figure 42). However, in
macrophages infected with E. coli alone or with buffer, the population of
intracellular bacteria decreased over time to less than 40% of the initial
population by 90 min p.i.. In contrast, following an initial decrease, in the
presence of B. cenocepacia OMV, intracellular E. coli began to increase in
number, suggesting intracellular replication by living bacteria. Thus, it appears
that B. cenocepacia OMV are able to affect the intracellular fate of E. coli.
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Figure 40. Dynabeads are poorly internalized by macrophages in the
absence of bacteria.
RAW264.7 macrophages were infected with Dynabeads alone or in the
presence of B. cenocepacia J2315. 1 h p.i., a total of 1575 macrophages
were examined for the presence of internal Dynabeads in a single
experiment.
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Figure 41. Substrate binding to Dynabeads is inconsistent and incomplete.
RAW264.7 macrophages were infected with Dynabeads coated with B.
cenocepacia OMV (A) or whole bacteria (B). 4 h p.i., macrophages were
labeled with anti-LAMP1 (green) and anti-J2315 (red) and observed with
confocal microscopy. Arrows in (A) indicate an extracellular bead with
bound antibody for endosomal marker LAMP1, and an intracellular OMVcoated bead unlabelled with anti-J2315. Arrows in (B) indicate intracellular
bacteria distinct from any bead.
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Figure 42. B. cenocepacia OMV affect the intracellular fate of E. coli.
RAW264.7 macrophages were infected with E. coli DH5 alone, in the
presence of buffer, or in the presence of B. cenocepacia OMV. Viable
intracellular bacteria were quantified 30, 60, and 90 min p.i.. The survival
index was calculated relative to bacteria present 30 min p.i., set as 100%.
Data represents the mean of two independent experiments. Standard
error bars are indicated.
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1.4 Summary
B. cenocepacia produces natural outer membrane vesicles than can be pelleted
from cell-free supernatants. Strain C5424 appears to produce more OMV than
J2315. Biochemical characterization demonstrates LPS and protein components
in isolated OMV. Growth in minimal media – nutrient limitation and slowed
growth rate – greatly increases relative vesiculation, as quantified by lipophilic
dye, and alters the protein composition of the OMV. Bacterial components are
shed into macrophages during infection; further study is necessary to
characterize both the bacterial elements and the mechanism of dispersal.
Preliminary experiments show that B. cenocepacia OMV are able to increase the
intracellular survival of E. coli during co-infection, suggesting that further
investigation into the relevance of OMV to intracellular trafficking is warranted.
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Appendix 2

2

Selective capture of transcribed sequences for B.
cenocepacia

2.1 rDNA blocking plasmid isolation
 Grow E. coli DH5 pJT25 8h in 5 mL LB Ap100
 Add 25 L of O/N culture to 100 mL LB Ap100
 Grow to 3-4 x 109 cells/mL (12-16 hours – OD 600 = 35)
 Extract pJT25 with Qiagen midi-plasmid kit (re-use column with 2 batches)
 Spin 6000 x g 15 min 4oC
 Resuspend in 4 mL Buffer P1
 Add 4 mL Buffer P2, mix by vigorous inversion 4-6 times
 5 min at RT
 Add 4 mL chilled Buffer P3, mix by immediate vigorous inversion 4-6 times
 15 min on ice
 Spin > 20 000 x g for 30 min at 4oC
 Remove supernatant containing plasmid promptly (to glass bottles)
 Apply 4 mL buffer QBT to Qiagen-tip 100 column & empty by gravity flow
 Filter supernatant through glass wool (in pasteur pipet) into column
 Wash column with 2 x 10 mL Buffer QC
 Elute DNA with 5 mL Buffer QF
 It may be stored O/N at 4oC
 Add 3.5 mL RT isopropanol
 Mix & centrifuge immediately at 15 000 x g for 30 min at 4oC
 Carefully decant supernatant
 Resuspend pellet in 200 L water & transfer to eppendorf
 Add 20 L 3M Na acetate pH 5.2
 Add 1 mL 100% EtOH
 Leave at -20oC for > 45 min (O/N)
 Spin 10-15 min 13.2 krpm
 Wash pellet in 1 mL of RT 70% ethanol
 Spin 1 min
 Air dry pellet 5-10 min
 Resuspend plasmid in appropriate volume of 10mM EPPS – 1mM EDTA
(EE)
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 Quantify with NanoDrop spectrophotometer

2.2 Chromosomal library preparation
 Grow B. cenocepacia K56-2 to mid-log phase (OD 600 0.4-0.6)
 Extract DNA
 Pellet 1.5 mL of O/N culture
 Resuspend pellet in 560 L TE buffer, 30 L 10% SDS, 10 L Proteinase
K (20 mg/mL)
 Incubate at 37oC at least 1 h (until mix is clear)
 Add 300 L chloroform:isoamyl alcohol (24:1)
 Mix well & spin 10 min at 13.2 krpm
 Transfer ~ 400 L of upper phase to new tube
 Add 0.1 volume (= 40 L) 3M sodium acetate & 2.5 volumes (=1.2 mL)
100% EtOH
 Mix & spin 15 min at 13.2 krpm
 Discard supernatant & wash twice with 500 L 70% EtOH
 Dry pellet at 45oC (~ 10 min)
 Resuspend in 50 L water by vortexing vigorously
 Add 1 L RnaseA (10 mg/mL)
 Incubate at 37oC 30 min
 Check A 260 (NanoDrop)
 Aliquot 15 L with 0.5 – 1.0 g/mL DNA into clear 0.6 mL thin-walled PCR
tube
 photobiotinylate
 Add 15 L of 1g/mL photobiotin acetate in sterile distilled water
 Incubate on ice 2-3 cm below 250W incandescent bulb for 30 min
 Switch ice buckets & rotate tube every 5 minutes
 Add 15 L fresh photobiotin acetate solution
 photoactivate on ice an additional 30 min
 Switch ice buckets & rotate tube every 5 minutes
 Dilute to 50 L with water
 Add 50 L 0.1x TE buffer [pH 9.0] (10 mM Tris-1mM EDTA)
 Butanol extract DNA (removes unbound biotin – repeat 2x or as required)
 Add 100 L isobutanol & mix well
 Centrifuge 2 min
 Remove & discard organic (upper) layer
 Evaporate any residual isobutanol
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 Add 1/10 volume 3M sodium acetate pH 5.2
 Add 1 L glycogen
 Precipitate with 2 volumes 100% EtOH >3h
 Spin at 4oC 15-30 min
 Resuspend DNA in EE
 For each chromosomal library, include 0.3 g of biotinylated chromosome and
5 g of pJT25 (1 chromosome: 17 rDNA) – typical SCOTS-CE requires 30
aliquots
 Use microtip and sonicate in minimal volume
 Sonicate 150 g pJT25 with 2-2s pulses at 10% amplitude
 Add 9 g biotinylated chromosome
 Sonicate 2s at 10% amplitude
 Check fragments on gel, determine final volume & quantitate
- Divide into 30 aliquots of 4 L containing 5.4 g of DNA

2.3 RNA extraction














Prepare RNA from 2-6 well plates per condition
 Resuspend & collect bacteria from non-macrophage-exposed condition
 Lyse macrophages in 1mL cold water / well
 Spin 8 min at 8000 rpm in a 50mL Falcon tube
Resuspend in 100 L lysozyme (1 mg/mL in TE buffer)
 5 min at room temperature (RT)
Add 1 mL TRIzol
 Vortex until homogeneous (~ 1 min)
 5 min on ice
Add 200 L chloroform
 Mix ~ 1 min
 5 min on ice
Spin 15 min at 4oC & 12 000xg
Recover ~ 600 L RNA-containing supernatant
Add 500 L isopropanol & mix
 30-40 min on ice
Spin 10 min at 4oC & 12 000xg
 Discard supernatant
Wash with 500 L cold 75% EtOH
 Vortex
Spin 5 min at 4oC & 7500xg
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Discard EtOH
 respin ~ 30 s & draw out residual EtOH
air-dry pellet
o
 5-10 min at 45 C
Resuspend gently in 10 L RNase-free water
 5 min at RT
add 5 L DNase
o
 60 min at 37 C
o
 15 min at 75 C
check DNA removal by PCR with RNA as template:
21.2 L water
8 L Q solution
4 L 5x PCR buffer
0.8 L dNTPs
0.8 L / primer (3550+3551: cblB, 3743+3744: -actin)
0.8 L Taq polymerase
- divide into 3 x 9 L aliquots
- add 1 L of template (two RNA samples + water control)
3 min at 95 oC
28 cycles of:
45s at 95oC
30s at 55oC
30s at 72oC
5 min at 72oC
check by agarose gel
quantify clean RNA with NanoDrop










2.4 cDNA synthesis

2.4.1




First strand cDNA synthesis

heat RNA & primer 75oC 5 min
1 μL random primer (I-3025; NME-3017)
x μL DNase-trasted RNA (5 μg)
(11-x) μL RNase-free water
set up RT reactions:
8 μL RT buffer
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1 μL RNase inhibitor
4 μL dNTPs
1 μL DMSO
1 μL Q Solution
 divide into 2 x 7.5 μL
 add RNA mixture
0.75 μL RT enzyme
15 min at 25oC
40 min at 55oC
5 min at 85oC
immediately on ice

2.4.2





to 20 uL RT rxn add (for 50 uL Klenow rxn):
 5 uL 10x Klenow buffer (random priming)
 1.25 uL dNTP
 4 uL Klenow fragment
 19.75 uL water
45 min at 37oC
clean with PCR product purification kit
 elute in 62 μL water

2.4.3








Second strand cDNA synthesis

cDNA amplification

100 uL cDNA PCR:
 4 μL primer (I-3032; NME-3033)
 2 μL dNTP
 10 μL 10x buffer
 20 μL Q solution
 2 μL Taq
 62 uL template
95oC for 5 min
25 cycles of:
o
 95 C for 30 s
o
 49 C for 90 s
o
 72 C for 50 s
o
72 C for 5 min
4oC for 10 min
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purify cDNA & elute in 42 μL EE
quantify with NanoDrop
divide into 10 x 4 μL aliquots of 750 ng/μL

2.5 Selective capture of transcribed sequences
















heat 1 chromosomal DNA aliquot (5.3 μg in 4 μL) to 98oC (boiling) under
mineral oil for 3 min
 add 1 μL 1M NaCl
o
 incubate at 68 C 30 min
boil cDNA (3 μg) 3 min in 4 μL hybridization buffer (10 mM EPPS – 1 mM
EDTA)
 add 1 μL 1M NaCl
o
 incubate at 68 C 30 min (if desiring to enrich for low abundance
transcripts)
mix chromosomal DNA with cDNA
o
 continue hybridization at 68 C for 20-24 h with oil overlay
wash Dynabeads-streptavidin (10 mg/mL)
 shake vial to resuspend beads
 transfer 60 μg (6 μL) of beads to eppendorf
 place on magnet 1-2 min
 remove supernatant with pipette while tube remains on magnet
 remove tube from magnet
 resuspend in equal volume capture buffer
 repeat wash
 resuspend in 1 mL capture buffer
add cDNA to capture buffer with beads
o
 incubate at 43 C 30 min
 place tube on magnet 1-2 min
 remove supernatant with pipette
3 washes in wash buffer (20mM NaCl-0.5% SDS)
o
 > 5 minutes at 65 C
elute with 100 μL elution buffer (0.25M NaOH-0.1M NaCl)
o
 15 minutes at 65 C
 place tube on magnet 1-2 min
 remove supernatant to fresh eppendorf with pipette
neutralize with 20 μL neutralization buffer (1M Tris pH 7.4)
ethanol precipitate in the presence of 10 μg (0.5 μL) glycogen
PCR amplify with linker primers
 resuspend pellet in 124 μL water
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8 μL primer (I-3032; NME-3033)
 4 μL dNTP
 20 μL 10x buffer
 40 μL Q solution
 4 μL Taq
 divide into 2 x 100 μL PCR reactions
o
 95 C for 5 min
 25 cycles of:
o
 95 C for 30 s
o
 49 C for 90 s
o
 72 C for 50 s
o
 72 C for 5 min
o
 4 C for 10 min
clean PCRs
 elute both together in hybridization buffer
10 parallel first round captures of each cDNA mixture
 combine amplified cDNAs for second round
at least 3 rounds of SCOTS with cDNA mixtures from each condition






Hybridization Buffer:
Capture Buffer:
Wash Buffer:
Elution Buffer:
Neutralization Buffer:

10 mM EPPS – 1 mM EDTA
1 M NaCl – 5 mM EPPS – 0.5 mM EDTA
20 mM NaCl – 0.5% SDS
0.25 M NaOH – 0.1 M NaCl
1 M Tris pH 7.4

2.6 Competitive enrichment







prehybridize chromosomal DNA with both rDNA & SCOTS-treated NME
cDNA
 use 10 μg NME-cDNA / chromosomal aliquot
24 hour hybridization with 0.5 μg I-cDNA at 68oC
recover by binding to streptavidin-coated beads as above
PCR amplify with I-3032 linker primer
Repeat twice for a total of 3 rounds of competitive enrichment

2.7 Screening


prepare 50 μL pUC19 using Qiagen MiniPrep kit
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digest vector & cDNA with XbaI
 10 μL vector / cDNA
 1.5 μL Buffer H
 1.5 μL XbaI
 2 μL water
incubate at 37oC O/N
clean digested cDNA with MinElute kit
 elute in 15 μL water
treat vector with alkaline phosphatase
 35 μL digested pUC19
 4 μL 10x AP buffer
 1 μL Antarctic alkaline phosphatase
incubate at 37oC at least 1 h
clean vector with Qiagen kit
ligate O/N
 15 μL vector/cDNA
 2 μL 10x ligation buffer
 1 μL T4 DNA ligase
 2 μL water
incubate at 16oC O/N
transform plasmid into E. coli DH5
 heat shock or electroporation
screen colonies using linker primers (I-3032) or vector primers (3035+3037)
 with vector primers, negative results will have ~100 bp product
 with linker primers, multiple inserts of different sizes will be obvious
screen clones using parallel Southern blot hybridization with DIG-labelled
cDNA libraries
 dilute PCRs 1/20 to run on gel
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